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Abstract 
The size of the prenylated indole alkaloid family sharing the unique bicyclo[2.2.2]diazaoctane core 
ring system has grown steadily over the last decades. Due to the complex structures, and in some cases 
the potent biological activity, these molecules have been adopted as challenging targets for several 
synthetic groups. Chapter One gives an introduction to these alkaloids, their origin, biological activity 
and biosynthetic studies. 
Our strategies to deliver 5,6- and 6,6-fused diketopiperazines (DKPs) and monoketopiperazines 
(MKPs) are discussed in Chapter Two. Radical cyclisation of a phenylselenyl DKP 108 (Scheme 2.10) 
and a bromo MKP 140 (Scheme 2.22) gave mixtures of exo and endo products. An alternatizve thio-
mediated radical approach allowed access to exo products (Table 2.2 and Scheme 2.28) 
Previous experiments on the established cationic cyclisation showed that the pyran ring present in the 
stephacidins is particularly sensitive to the presence of acid. These results prompted us to explore 
alternative approaches in which the formation of the pyran ring occurs after the key-step (Scheme 3.19 
and 3.20). Our progress towards stephacidin A and previous syntheses are discussed in Chapter Three.  
Synthesis of a sulfide DKP 218 (Scheme 4.22) allowed access to indoline products via radical 
approach (Scheme 4.27). An oxidative radical approach as well as a cationic approach is also 
discussed in Chapter Four. In comparison with our new strategy there is also a review of all previously 
described approaches to assemble the bicyclo[2.2.2]diazaoctane framework.  
Among the different approaches to access the core structure of these natural products the radical 
cyclisation approach appeared to be the most efficient. Based on this strategy, synthesis of indolines 
348/349 which is structural related to avrainvillamide is discussed in Chapter Five (Scheme 5.10). Our 
rapid radical methodology allows synthesis of these indolines in 6 steps and 28% overall yield. 
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Chapter 1 
Introduction 
 
1.1 Diketopiperazines 
Diketopiperazines (DKPs) are cyclic dipeptides, commonly biosynthesised from amino acids by 
different organisms including mammals, marine microorganisms, sponges, sea stars, tunicates and red 
algae. They are considered as secondary functional metabolites or undesired by-products and in some 
cases degradation products in the synthesis of oligopeptides. Similarly to peptides, DKPs display 
favourable pharmacodynamic and pharmacokinetic properties due to reduced susceptibility to 
metabolic amide bond reactions and the conformational mobility. The above characteristics confer 
drug-like properties whereas the presence of mimicking peptidic pharmacophoric groups enhances 
favourable interactions with macromolecules. The potent biological activities of DKPs have increased 
the interest in the synthesis of these compounds.
1
 Inhibitors of plasminogen activator inhibitor-1 (PAI-
1)
2
, alteration of the cardiovascular and blood-clotting functions are some examples of the important 
biological activities showed by the DKPs.
3
 They also display activities such as antitumour,
4
 antiviral,
5
 
antifungal,
6
 antibacterial,
7
 and antihyperglycaemic activity,
8
 and have been shown to display affinities 
for calcium channels and opioid,
9
 GABAergic,
10
 serotoninergie 5-HT1A,
11
 and oxytocin
12
 receptors.    
There are three DKP regioisomers 1-3 sharing this particular heterocyclic core system (Figure 1.1). 
Our synthetic investigations have been focused exclusively on the 2,5-diketopiperazine systems (2).  
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Figure 1.1 Structure of DKP regioisomers  
2,5-DKPs, head-to-tail dipeptides, represent a common naturally occurring structural unit.
13
 According 
to recent literature reviews, there have been reported more than 124 DKPs from bacteria, fungi and 
several marine organisms.
14
 Figure 1.2 shows the distribution of the DKP sources, reported from 
marine-derived microorganism. It is interesting that, even though the number of isolated DKPs has 
significantly increased during the last decades, the biosynthesis of many of these natural products still 
remains largely unexplored.       
 
Figure 1.2 Distribution of the DKPs, reported from marine-derived microorganism 
14
    
1.2 Prenylated indole alkaloid family 
The size of the prenylated indole alkaloids family has grown steadily over the last decades. Nowadays 
more than 69 alkaloids have been isolated from a wide selection of fungi of the genera Aspergillus and 
Sea cucumbers 
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9% 
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Penicillium. The unique bicyclo[2.2.2]diazaoctane framework of these alkaloids is present in the form 
of a DKP or a partially reduced derivative incorporating different structural features (Figure 1.3). The 
DKP core of these alkaloids is often linked with five- or six-membered rings and additionally with 
indole, spiro-oxindole or spiro-indoxyl motifs. Pyrrolidine and piperidine derivatives are also common 
in many natural products of this family. Two distinct stereochemistries have been observed with 
respect to the relative configuration at the C4 stereogenic centre.
15
 The anti-configuration or a syn-
configuration refers to the relative relationship between the C4–C3 bond and the C6–N bond of the 
cyclic amino acid residue (pyrrolidine, piperidine). To date within the family of prenylated indole 
alkaloids only brevianamides
16
 and versicolamide B
15a
 possess the anti-configuration.  
 
Figure 1.3 General structure of the bicyclo[2.2.2]diazaoctane ring system      
 
Members of the brevianamide family were the first isolated alkaloids within this interesting family of 
alkaloids sharing the bicyclo[2.2.2]diazaoctane core. Brevianamide A (4) was isolated as a major 
fluorescent metabolite from Penicillium brevicompactum in 1969 (Figure 1.4).16 The absolute 
stereochemistry was determined by X-ray crystallography of a semisynthetic derivative.
17
 It was also 
reisolated from the culture extracts of Penicillium viridicatum and Penicillium ochraceum18 while the 
rest members of this family were isolated
19
 from the same fungus afterwards. It was reported that 
brevianamide C (6) and D (7) were photochemically delivered artifacts during the isolation process.
15c
 
This was proved by growing a culture of P. brevicompactum in the absence of light where neither 
brevianamide C (6) or D (7) were not detected after the analysis of the crude extraction. Brevianamide 
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A (4) and B (5) share a bicyclo[2.2.2]diazaoctane framework which is equipped with a proline residue 
and a spiro-indoxyl unit. The most important structural characteristic of the brevianamide family is the 
anti-configuration at C4. 
 
 
 
 
 
 
 
Figure 1.4 Structure of the brevianamides 
Another important subclass of the prenylated indole alkaloid family includes paraherquamides. 
Paraherquamide A (10) was isolated from cultures of Penicillium paraherquei in 1980 and displays 
the highest biological activity among the group of paraherquamides (Table 1.1).
20
 Since then, the 
family of paraherquamides has grown steadily with the most of the recent members paraherquamide 
B–G (11–14, 19–21),21 VM55595 (22), VM55596 (15) and VM55597 (16),22 SB203105 (17) and 
SB200437 (18),
23
 and sclerotiamide (23),
24
 being isolated from various Penicillium Aspergillus 
species. Moya and co-workers isolated paraherquamide H (19) and I (24) along with other structurally 
related alkaloids from cultures of Penicillium clueniae. Structurally similar but more complex than the 
brevianamides is the paraherquamide family which shares tryptophan and variously substituted proline 
motifs (Table 1.1). Unlike the brevianamides, they possess a partially reduced DKP core which is 
linked with a spiro-oxindole rather than the spiro-indoxyl ring system. Finally, they further 
characterised by either a dioxygenated 7-membered ring or pyran ring on the tryptophan unit. 
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Paraherquamides as well as the majority of alkaloids in the prenylated indolic family possess the syn-
configuration.  
 
 R1 R2 X   R1 R2 R3 R4 
paraherquamide A (10) OH Me N  VM55597 (16) OH Me O H 
paraherquamide B (11) H H N  SB203105 (17) H Me 2H OH 
paraherquamide C (12) =CH2 =CH2 N  SB200437 (18) H H 2H H 
paraherquamide D (13) -OCH2- N  paraherquamide 
H (19) 
H Me O H 
paraherquamide E 
(VM54159) (14) 
H  Me N       
VM55596 (15) OH  Me N
+
-O
-   
     
 
 R1 R2 R3 R4 
paraherquamide F 
(VM55594) (20) 
H Me Me H2 
paraherquamide G 
(VM54158) (21) 
OH Me Me H2 
VM55595 (22) H Me H H2 
sclerotiamide (23) H H H OH 
Table 1.1 Structures of the paraherquamides 
      
6 
 
Marcfortines A–C (25–27), isolated from Penicillium roqueforti, are compounds closely related to 
paraherquamides but they are equipped with a piperidine unit in the place of pyrrolidine moiety 
(Figure 1.5).25 Unlike with marcfortines A–B (25–26), marcfortine C (27) possesses a pyran ring in the 
place of the dioxepin ring. 
 
Figure 1.5 Structures of the marcfortines 
Notoamide A (28), B (29) and N (31) are also important members of prenylated alkaloid family. In 
2002, notoamides A–D were isolated from Aspergillus sp. by the Qian-Cutrone’s group (Table 1.2).26 
More recently, notoamide F–K were also detected from Aspergillus sp.27 
 
 
Table 1.2 Structures of the notoamides 
Asperparalines are a reduced bicyclo[2.2.2]diazaoctane DKP derivatives (monoketopiperazines - 
MKPs), sharing a spiro-succinimide unit in place of the spiro-oxindole or indole (Table 1.3). 
Asperparaline A (32) was isolated
23,28
 in 1997 from the fungus Aspergillus japonicus JV-23 and later 
on in the same group of fungi were also detected asperparaline B (33) and C (34).
29
     
 R1 R2 R3   
notoamide A (28) OH H H   
notoamide B (29) OH H H   
notoamide H (30) OH OH H   
notoamide N (31) H H Cl   
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Table 1.3 Structures of the asperparalines 
Avrainvillamide (36) and the stephacidins are a recently isolated group of natural products which 
attracted the attention of the synthetic chemical community due to their complex architectures as well 
as their potent biological activity (Figure 1.6). Avrainvillamide (36) was first isolated from the marine-
delivered fungus Aspergillus sp. by Fenical and co-workers30 and a year after from Aspergillus 
ochraceus by Sugie et al. who described it as CJ-17,665.7c In 2001, Qian-Cutrone and co-workers 
reported isolation of stephacidin A (35) and B (39) from the fungal species Aspergillus ochraceus 
WC76466.
31-34
 Isolation of the antipodal stephacidin A (35) by Williams et al. sparked further interest 
into biogenesis pathways of these compounds.
32
 It was originally suggested that these compounds 
were closely related natural products to the aspergamides A (38) and B (37) (isolated from Aspergillus 
ochraceus by Fuchser and co-workers)33 in a different oxidation state. The dimer of avrainvillamide 
(36), stephacidin B (39), possessing 15 rings and 9 stereogenic centres represents one of the most 
complex alkaloids in Nature. Another fascinating architectural feature of avrainvillamide (36) and 
aspergamide A (38) is the unsaturated nitrone function, which plays an important role in the 
dimerization process and the observed potent activity.  
 
 
 
 
 
   R1 R2 
asperparaline A, 
aspergillimide, (32) 
(VM55598) 
Me Me 
asperparaline B (33) Me H 
asperparaline C (34) H OMe 
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Figure 1.6 Structures of the stephacidins, aspergamides and avrainvillamide 
 
Mata and co-workers increased the number of reported prenylated indole alkaloids by isolating 
malbrancheamides from Malbranchea aurantiaca fungus (Figure 1.7).34 Unique features of 
malbrancheamide (40) and malbrancheamide B (41) are the chlorinated indole ring and the lack of a 
tertiary amide in the bicyclo[2.2.2]diazaoctane core ring system. 
 
 
 
Figure 1.7 Structures of the malbrancheamides 
1.3 Origin of the bicyclo[2.2.2]diazaoctane framework 
A year after the original isolation of brevianamide A (4) by Birch and Wright,
16
 Sammes and Porter 
proposed that the bicyclo[2.2.2]diazaoctane core arises through a hetero-Diels-Alder reaction (Figure 
1.8).
35
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Figure 1.8 Proposed Diels-Alder reaction 
 
In order to support the possibility of this scenario Sammes and Porter tested pyrazine derivative 43 
with a selection of dienophiles to effect a Diels-Alder reaction (Scheme 1.1). One of the most relevant 
examples was cycloaddition reaction of pyrazine 43 with an unactivated dienophile to give 45 in 18% 
yield.
35a
   
 
 
Scheme 1.1 
 
Birch et al. proposed a biosynthetic pathway of brevianamide B (5) as shown in Scheme 1.2.35b The 
proposed biosynthesis was based on feeding experiments with 
14
C and 
3
H-labelled compounds and 
previous reports by Steyn et al.36  
 
 
 
 
 
 
 
Scheme 1.2 
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In similar fashion, Williams et al. proposed a biosynthetic pathway towards brevianamide A (4) and B 
(5) (Scheme 1.3).
37
 This proposal involves a reverse prenylation of brevianamide F (9), followed by 
oxidation and enolisation to furnish azadiene 50. Cycloaddition of the achiral 50 would lead to 
formation of racemic 51 which could undergo an oxidation by an (R)-selective indole reduction to give 
two optically pure, diastereomeric hydroxyindolenines 52. Finally, stereospecific pinacol-type ring 
construction would provide the optically pure brevianamides.    
 
 
 
 
 
 
 
 
 
Scheme 1.3 
In order to explore this proposed biosynthetic pathway, Williams and co-workers synthesised a 
racemic mixture of 
13
C-labeled cycloadducts 51 (Scheme 1.4).
38
 Feeding cultures of Penicillium 
brevicompactum with 51 and further analysis of the extracts by NMR and MS showed 0% 
incorporation into the natural brevianamides A (4) and B (5).  
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Scheme 1.4 
After these results Williams and co-workers envisioned an alternative biosynthetic pathway which 
involved a tritium-labelled deoxybrevianamide E (48) derivative as the initial precursor (Scheme 
1.5).
38
 When cultures of Penicillium brevicompactum were fed with 48 incorporation was observed 
into 4, 5 and 8 with the most efficient incorporation into brevianamide E. The cultures were then re-
fed with brevianamide E (8) but in that case they did not observe significant incorporation into 
brevianamide A (4) and B (5). This observation suggests that brevianamide E (8) is a dead-end, shunt 
metabolite in this biogenetic pathway.     
 
 
 
 
 
 
Scheme 1.5 
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With these results in hand, a new biosynthetic pathway was suggested (Scheme 1.6). As previously 
described, brevianamide F (9) could give deoxybrevianamide E (48) via a reverse prenylation. (R)-
selective oxidation at the 3-position of the indole gives an (R)-hydroxyindolenine 53 which undergoes 
either irreversible nucleophilic addition of the tryptophyl amide nitrogen, generating brevianamide E 
(8), or a stereospecific pinacol-type rearrangement to 54. Intermediate 54 could undergo two-electron 
oxidation of the tryptophyl α-carbon, followed by enolisation and intramolecular hetero Diels-Alder 
reaction to give brevianamide A (4) and B (5).   
 
 
 
 
 
 
 
 
Scheme 1.6 
Ab initio calculations were then carried out in order to find further support and explain the outcome of 
these results (Scheme 1.7). Analysis of calculations showed that the conformers which lead to 
formation of the natural product had the lowest energy transition-state TSA and TSB. Moreover, TSA 
was even lower than TSB due to the hydrogen bonding. The fact that 55 and 56 were not detected in 
the crude extracts from fungus could be due to the high transition-state energy of TSA’ and TSB’.  
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Scheme 1.7 
1.4 Stephacidins – The biosynthetic studies  
The fascinating molecular architecture of stephacidin B (39) provided a new level of complexity 
within the family of prenylated indole alkaloids. In many cases in biogenesis of prenylated indole 
alkaloids, Nature can assemble libraries of natural products from only limited panels of starting 
materials such as tryptophan, proline and isoprene units. Considering the structural similarities, it was 
initially suggested that stephacidins, avrainvillamide, notoamides, and sclerotiamide consist of natural 
products with common biosynthetic origins. Williams was also interested to investigate the biogenesis 
of this family of prenylated indole alkaloids. In recent biosynthetic research, he proposed that 
oxidative ring closure of notoamide S (57) followed by oxidation - tautomerization could generate key 
achiral azadiene species 59 (Scheme 1.8).39 It is known that azadiene species can undergo 
cycloaddition reactions and presumably 59 could lead to stephacidin A (35) in the respective 
producing organism such as metabolite Aspergillus sp. MF297-2
40
 and NRRL 35600.
41
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Scheme 1.8 
It was also proposed that a face-selective oxidative rearrangement of the 2,3-disubstituted indole (35) 
would possibly generate notoamide B (29). As Scheme 1.9 shows, notoamide B (29) could undergo a 
second face-selective oxidation at C10 position to give sclerotiamide (23).
42
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.9 
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In order to provide new evidence for the biogenesis of notoamide B (29) and sclerotiamide (23), 
Williams and co-workers synthesised a 
13
C labelled analogue of racemic stephacidin A (35) (Scheme 
1.10).
42
 The racemic mixture was added to cultures of A. versicolor NRRL 35600 and the fungal’s 
extracts were then investigated further. Analysis of the samples showed 2.7% intact-incorporation of 
the labelled (-)-stephacidin A (35) into (+)-notoamide B (29) and 5.0% incorporation into the 
metabolite (+)-sclerotiamide (23). Unreacted (+)-stephacidin A (35) was also isolated. In a similar way 
racemic stephacidin A (35) was also added to the marine-delivered Aspergillus sp. MF297-2. The 13C-
incorporation into (-)-notoamide B (29) was 8.1% and 6.8% into the known metabolite (-)-
sclerotiamide (23). Similarly with the previous experiment, unreacted (-)-stephacidin A (35) was also 
isolated. 
 
 
 
 
 
 
 
Scheme 1.10 
Feeding experiments of Aspergillus versicolor NRRL 35600 with synthetic 13C-labeled notoamide E 
(58) showed 
13
C incorporation into three minor metabolites, 60, 61, and 62 (Scheme 1.11).
43
 In 
contrast with previous studies,
44
 traces of unlabelled (-)-stephacidin A (35) and (+)-notoamide B (29) 
were also detected. It was also reported that the amount of notoamide E (58) in Aspergillus versicolor 
affected the ratio of minor and major metabolites. For example, normal feeding conditions of 
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Aspergillus versicolor with notoamide E (58), resulted in production of 60, 61, and 62 in trace 
amounts with stephacidin A (35) and notoamide B (29) being the major metabolites. When an excess 
of notoamide E (58) was added 60, 61, and 62 were the major metabolites. This suggests that addition 
of notoamide E (58) inhibits or diverts the enzymatic machinery which is responsible for the 
biosynthesis of bicyclo[2.2.2]diazaoctane metabolites.   
 
 
 
 
 
 
 
 
Scheme 1.11 
 
1.5 Avrainvillamide, stephacidin B – The dimerization step 
Qian–Cutrone et al. from Bristol-Myers Squibb pointed out that Stephacidin B (39) probably 
represents a dimer of avrainvillamide (36) (Scheme 1.12).
26
 They suggested that a protonation at O62 
in the monomeric unit could promote a nucleophilic attack at C51 from the C20–C21 double bond of 
another avrainvillamide unit. Finally N55 could then attack at C21 to form the central 5-membered 
ring of stephacidin B (39).  
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Scheme 1.12 
It is also more likely, that the dimerization pathway occurred via a double Michael addition rather than 
the generation of secondary carbocation as an intermediate as previously reported (Scheme 1.13).
45
 
Nucleophilic attack of the amidic N55 at the nitrone Michael acceptor followed by a subsequent attack 
of the upper donor to the lower nitrone Michael acceptor were the key step to furnish the spiro-system 
at C20. 
   
 
 
 
 
 
 
Scheme 1.13 
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Based on previous studies,
45b
 Myers and co-workers described the interconversion between the 
monomer avrainvillamide (36) and stephacidin B (39) in solution as a reversible process. Myers 
reported that avrainvillamide (36) could be transformed into stephacidin B (39) in the presence of 
triethylamine. The same observation was also reported when a solution of avrainvillamide (36) in 
DMSO-d6-CD3CN was concentrated in vacuo. The dimerization reaction could also occur during the 
purification process using a preparative TLC method. When pure synthetic stephacidin B (39) in 
MeCN-water was concentrated, a 2:1 mixture of avrainvillamide (36) and stephacidin B (39) was 
observed. Moreover, it was also shown that stephacidin B (39) was stable in a solution of DMSO-d6-
CD3CN, but when powdered 3 Å molecular sieves were added then a retrodimerisation occurred to 
give a mixture of 36 and 39.
46
 Comparison of samples of avrainvillamide (36) in solid state and 
solution showed that the natural product was stable only in solid form and this implies that 
dimerization could only occur in solution.
47
 The above observations could also be supported by other 
reports in the literature which describe the ability of saturated indolic nitrones to dimerize.
48
 Further 
studies by Myers el at. showed that 63 in methanol-d4 could undergo a reversible 1,5-addition of 
solvent to the α,β-unsaturated nitrone group (Scheme 1.14).45b It was also reported that the equilibrium 
between 63 and 64 exhibited a significant temperature dependence. 
 
 
 
Scheme 1.14 
Analysis by HPLC shown a half-life 10 minute at 37 
o
C of stephacidin B (39) to avrainvillamide (36) 
which supported that a retrodimerisation process could also occur in cell culture media.
49
 Considering 
the experimental observations of the equilibrium, Myers and Herzon cast some doubt over which of 
the alkaloids is responsible for the potent biological activity.  
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1.6 Avrainvillamide, stephacidin B – Biological activity 
The initial biological studies on stephacidins by Qian-Cutrone and co-workers showed that both 
natural products display potent in vitro cytotoxicity against a panel of tumor cell lines (Table 1.4).26 
Stephacidin B (39) shows significant ability to inhibit the growth of the testosterone-dependent 
prostate cancer cell line LNCaP at nanomolar concentration. Due to the fact that both compounds were 
not mediated by p53, mdr, bcl2, tubulin or topoisomerase II-mediated it was suggested that cytotoxic 
activity arose by a novel mechanism of action.   
Table 1.4 In Vitro Cytotoxicity of (+)-stephacidin A (35) and (-)-stephacidin B (39), IC50 in μM 
Myers and co-workers investigated further the biological activity of both enantiomers of stephacidin B 
(39) and avrainvillamide (36) against four different cancer cell lines (Table 1.5).
49
 It was shown that 
stephacidin B (39) exhibits similar activity with its monomer (36) when corrected for stoichiometry 
(i.e., solutions of 39 were twice as potent as equimolar solutions of 36). It was also reported that both 
of the enantiomeric series were similarly active against the specific cell lines. 
Cell-line Histotype Characteristic IC50 (35) IC50(39) 
PC3 prostate Testosterone-independent 2.10 0.37 
LNCaP prostate Testosterone-sensitive 1.00 0.06 
A2780 ovarian Parental 4.00 0.33 
A2780/DDP ovarian Mutp53/bcl2+ 6.80 0.43 
A2780/Tax ovarian Taxol-resistant 3.60 0.26 
HCT116 colon Parental 2.10 0.46 
HCT116/mdr colon Overexpress mdr 6.70 0.46 
HCT116/topo colon Resistance to etoposide 13.10 0.42 
MCF-7 breast Estradiol-sencitive 4.20 0.27 
SKBR3 breast Estradiol- independent 2.15 0.32 
LX-1 lung Sencitive 4.22 0.38 
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 Natural enantiomers Unnatural enantiomers 
Cell line steph. B (39) avrainvillamide (36) ent-steph. B (39) ent-avrainvil. (36) 
LNCaP 135 nM 
(40-231) 
241 nM 
(159-323) 
952 nM 
(638-1266) 
1514 nM 
(1243-1786) 
βΤ-549 346 nM 
(321-372) 
621 nM 
(548-694) 
550 nM 
(488-611) 
786 nM 
(717-855) 
T-47D 91 nM 
(30-152) 
205 nM 
(110-299) 
942 nM 
(583-1301) 
1485 nM 
(1305-1655) 
MALME-3M 289 nM 
(108-469) 
406 nM 
(206-607) 
987 nM 
(727-1247) 
1854 nM 
(1750-1957) 
Table 1.5 Measured IC50 values for (±)-stephacidin B (39) and (±)-avrainvillamide (36) 
Further evidence supporting  that the biological activity of stephacidin B (39) arises from the nitrone 
moiety of avrainvillamide (36) were also reported by Myers et al. (Figure 1.9).49 Synthetic analogues 
63 and 65 share the structural features of stephacidin B (39) and avrainvillamide (36) but are incapable 
of dimerization. Both nitrone derivatives 63 and 65 exhibit potent cytotoxicity on LNCaP and T-47D 
cancer cell lines. These results strongly suggested that avrainvillamide (36) was responsible for the 
biological activity in vivo. 
 
 
Figure 1.9 Structures of synthetic analogues of avrainvillamide 
In their studies Myers and co-workers also examined the possible biological binding targets of the 
corresponding cancer cell lines. This part was investigated by affinity-isolation experiments with cell 
lysates from LNCaP cancer cells.
49-50
 Thus, lysates were treated with activity-based probe 65 and 
streptavidin-agarose, followed by subsequent purification to isolate several cysteine-containing 
proteins as possible targets (heat-shock protein 60 -HSP60-, exportin 1 -XPO1, glutathione reductase -
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GR-, peroxiredoxin 1 -PRX1-). Compounds 66 and 67 sharing a bicyclo[2.2.2]diazaoctane core were 
also tested in similar experiments, acting as molecular probes (Figure 1.10). Both compounds showed 
growth-inhibition potencies against T-47D and LNCaP cancer cell lines. Compound 67 proved to be a 
more efficient binder to the phosphoprotein nucleophosmin which is an overexpressed protein in many 
human tumors with an important role in cancer progression.
51
 The ability of 67 to bind in a more 
efficient way than 66 was also proved by the results of competition experiments between 66, 67 and 
nucleophosmin. Fluorescence microscopy experiments of dansyl-substituted probe 68 demonstrate that 
the probe partially localized in the nucleoli of T-47D cells. Compound 67 was also used in order to 
provide new evidence about the source of binding in nucleophosmin. Studies showed that, when 
cysteine residues (cys
275
) were exchanged with mutant alanine, the nucleophosmin binding to 67 was 
significantly reduced. 
 
 
 
 
 
 
 
 
Figure 1.10 Structures of synthetic analogues of avrainvillamide 
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Finally, it was demonstrated that changes in the chromene moiety could affect the biological activity.
50
 
Examination of the synthetic analogues 70, 71 and 72 showed lower activities compare with 67 and 68 
(Figure 1.11). The only case where the biphenyl moiety did not affect the inhibition of the molecule 
was observed with compound 69.    
 
 
 
 
 
 
Figure 1.11 Structures of synthetic analogues of avrainvillamide 
The unusual structures and in some cases potent biological activity have made the prenylated alkaloid 
family important and challenging targets for synthetic and biosynthetic studies. Since the first isolation 
of brevianamide A (4), there has been significant progress towards giving access to these synthetically 
complex structures. However, much work is left to be done before we have a full understanding of the 
biosynthetic pathways. 
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 Chapter 2  
Synthesis of fused DKP and MKP 
2.1 Marcfortines, paraherquamides and asperparalines  
Marcfortines A–C (25–27), paraherquamides A (10), C (12), E (14), F (20) and asperparalines A (32) 
and B (33) constitute part of an interesting class of structurally related prenylated alkaloids, sharing a 
bicyclo[2.2.2]diazaoctane core system equipped with spiro-oxindole or spiro-succinimide units 
(Figure 2.1). 
Figure 2.1 Structures of the paraherquamides, marcfortines and asperparalines 
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Another common structural feature of paraherquamides and asperparalines includes an interesting β-
methylproline motif which can be delivered biosynthetically from isoleucine. Unlike with 
paraherquamides and asperparalines, marcfortine A (25) and B (26) possess an unsubstituted six-
membered ring instead of proline, which initially can be delivered from pipecolic acid. 
 
2.2 Synthesis of the pipecolate moiety 
Trost and co-workers became interested in this subclass of prenylated indolic alkaloids as their 
previous research on trimethylenemethane (TMM) [3+2]-cycloadditions was able to assemble the 
common structural features of these natural products.
52
 In the first total synthesis of (±)-marcfortine B 
(26), the core ring system was delivered by an alkylation of 2-hydroxypipecolic amide (82) and 
oxindole (81), followed by an intramolecular Michael-Addition and a radical ring closure (Scheme 
2.2).
53
 Thus, 2,3-dimethoxybenzoic acid 74 was converted to aniline 75 via a Yamada modification of 
the Curtius rearrangement
 
followed by hydrolysis of the resulting urethane (Scheme 2.1).
54
 In the 
presence of sulfuryl chloride, aniline 75 was chlorinated and then reacted with ethyl 
(methylthio)acetate. The heterocyclic ring of 76 was formed after rearrangement in the presence of 
triethylamine followed by acetic acid. Desulfurization of oxindole 76 followed by condensation and 
Boc protection led to formation of the TMM-acceptor 78. Similarly with previous studies
55
 by Trost et 
al. a spirocyclic carboxyl acid was generated by carboxylative cycloaddition of 78 and 79. The 
corresponding acid was then converted to the corresponding methyl ester 80. Epoxidation of the exo-
methylene double bond of 80 followed by subsequent exposure to DBU yielded an allylic alcohol 
which was then transformed to mesylate 81.  
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Scheme 2.1 
N-Alkylation of 82 with 81 followed by elimination of the secondary alcohol of the piperidine ring 
yielded the α,β-unsaturated amide 83 in 84% overall yield (Scheme 2.2). It was shown that N-Boc 
deprotection of the spiro-oxindole 83 prior to Michael-addition was necessary in order to avoid 
decomposition during the cyclisation step. Michael-addition of the free oxindole resulted in formation 
of only one diastereomer of 85 due to the efficient shielding of the re-face by the aromatic portion of 
the Michael acceptor. The corresponding enolate 84 was protonated by the amide hydrogen atom to 
deliver the trans relationship into the ester 85. The validity of their explanation for the observed 
stereocontrol was supported when the reaction was repeated on the N-methylated amide derivative of 
83 and they obtained exclusively the other epimeric ester.  
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Scheme 2.2 
In order to improve the solubility of compound 85, oxindole unit was protected with p-methoxy 
benzylbromide (Scheme 2.3). Chemoselective reduction of ester 86 with DIBAL, followed by 
conversion of the corresponding alcohol to its xanthate ester gave 87. The key step for the synthesis of 
marcfortine B (26) involved a radical cyclisation and is being discussed in detail in Chapter 4.
53
    
 
Scheme 2.3 
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In the synthesis of (±)-marcfortine C (27), Williams and co-workers chose a DKP (91) equipped with 
a fused pipecolate unit as a key intermediate to access the natural product (Scheme 2.4).
56
 In order to 
prepare intermediate 91, peptide coupling was applied to tryptophan derivative 88 and pipecolic acid 
ethyl ester 89. The resulting diastereomeric mixture of amides 90 was then treated with a solution of 
morpholine in THF to promote N-Foc deprotection and an intramolecular cyclisation between the free 
amine and the ester group occurred to give the desired DKP 91 as a mixture of diastereoisomers.  
 
 
 
 
 
 
 
 
Scheme 2.4 
2.3 Synthesis of β-methylproline moiety  
The methyl group in the β-methylproline moiety of VM55599 (73) is disposed syn to the bridging unit. 
In all the other isolated prenylated alkaloids the observed stereochemistry in the β-methylproline 
moiety is anti. In extensive investigation on the biosynthetic proposal of VM55599 (73) and 
paraherquamide A (10), Williams established the unknown absolute configuration of VM55599 (73).
57
 
For the asymmetric total synthesis of 73, Williams and co-workers envisioned installing the β-
methylproline ring in such a manner that the stereogenic centre at β-position would not be perturbed. 
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Enantiopure β-methylproline 93 was delivered in five steps using the Hoffman – Loeffler – Freytag 
sequence,
58
 starting from (S)-isoleucine (L-Ile) (92) (Scheme 2.5). Hydrolysis of proline 93 with LiOH 
gave acid 94 which was then coupled with glycine methyl ester hydrochloride to furnish the 
corresponding peptide. Treatment with TFA effected removal of Boc group and the crude material was 
heated in toluene to afford the desired DKP 96.  
        
 
Scheme 2.5 
 
Williams and co-workers also synthesised a deuterium-labelled derivative to investigate biosynthesis 
of paraherquamides. DKP 100 was synthesised starting from enantiopure proline derivative 98 
(Scheme 2.6). Peptide coupling of 98 with a modified tryptophan 97 furnished peptide 99. Selective 
removal of Boc group followed by thermal cyclisation of the corresponding amine gave 100 as a 2:1 
(syn:anti) mixture of diastereomers.    
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Scheme 2.6 
 
2.4 Retrosynthetic plan 
Our interest to deliver new approaches for the synthesis of prenylated indole alkaloids prompted us to 
investigate the possibility of assembling the bicyclic fused system of these natural products via a 
radical approach. Thus, our retrosynthetic plan for the fused bicyclic DKPs or partially reduced 
derivatives (MKPs) 102 and 103 involved a key disconnection of the C–C bond as Scheme 2.7 shows. 
According to disconnection A the desired products 102 and 103 could be delivered via an 
intramolecular radical cyclisation of a precursor equipped with a leaving group at the α-amidic 
position (105). Alternatively, the same C–C bond could be formed by radical translocation and 
cyclisation of 104. 
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Scheme 2.7 Retrosynthetic plan of the radical key step 
Firstly, we were interested in investigating the regioselectivity of the radical cyclisation reaction on 
simple DKP and MKP substrates. The aim of this project included the application of this methodology 
to enantiopure substrates such as 106 and 107 and further investigation of the stereoselectivity of the 
outcome (Figure 2.2). This strategy in combination with established work
59
 from our lab on 
construction of the bicyclo[2.2.2]diazaoctane framework would allow access to other important 
members of this alkaloid family.      
 
Figure 2.2 Radical cyclisation of enantiopure DKP and MKP substrates 
2.5 Radical cyclisation of DKP and MKP substrates 
The first example investigated involved DKP 108, which contains a phenylselenyl group (Scheme 
2.8). In the presence of tributyltin hydride and AIBN, captodative radical 109 would formed by 
homolytic cleavage of the phenylselenyl group. The corresponding radical species could then react 
with the double bond in the N-substituent via a 6-endo-trig or 5-exo-trig cyclisation to give 112 and 
113.  
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Scheme 2.8 
The radical precursor 108 was easily synthesised in two steps via a double N-alkylation of glycine 
anhydride 114 followed by introduction of the phenylselenyl group (Scheme 2.9).  
 
Scheme 2.9 
Compound 108 in toluene was treated with tributyltin hydride and AIBN over 8 hours (Scheme 2.10). 
After purification of the crude material we were able to obtain DKPs 116 and 117 in 2:1 ratio and 70% 
overall yield. We were pleased to confirm by nOe studies that the β-methyl on the proline unit was 
placed with the same stereochemistry as that most of reported prenylated indole alkaloids. Surprisingly 
the major product of this reaction was the thermodynamic product 116 from 6-endo-trig cyclisation 
rather than the kinetic product 117 from 5-exo-trig cyclisation as Baldwin rules suggest.60 
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Scheme 2.10 
Frontier orbital theory can explain much of the selectivity in radical reactions.
61
 Beckwith has pointed 
out the stereoelectronic effects which can contribute to the regioselectivity of radical cyclisation.
62
 It is 
known that radical centres attack at an obtuse Bürgi-Dunitz-like angle
63
 the carbon atom with the 
largest LUMO coefficient. The intramolecular radical cyclisation of 118 proceeds via an 
unsymmetrical 6-membered chair-like transition state (Scheme 2.11). The most preferable approach 
occurs via TSA (5-exo-trig) where the angle α is similar to the value of the Bürgi-Dunitz angle. Thus, 
due to better LUMO-SOMO orbital overlap, 5-exo-trig product (119) forms faster than the 
thermodynamically more stable 6-endo-trig product (120).60-61,62a,64 The 6-endo-trig pathway is not 
explicitly disfavoured but it is usually more strained than the corresponding 5-exo-trig. 
Scheme 2.11          
There are number of cases where the 6-endo-trig product is favoured.
64b,65
 One example involves 
substrates with Z-substituents
64b,66
 (electron-withdrawing groups), such as 121 (Scheme 2.12).
67
 The 5-
exo-trig cyclisation of the stabilised radical 121 occurs faster than the 6-endo-trig and gives primary 
radical 122. Under the reaction conditions the 5-exo-trig process could be reversible and the latter of 
122 could open again to give the thermodynamically preferred secondary radical 124.  
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Scheme 2.12                     
Radicals adjacent to Z-substituents (121, Scheme 2.12) (carbonyl, cyano, nitro, carboxyl, metals and 
metalloids such as silyl groups) are electrophilic radicals with low-energy SOMO orbital (Figure 2.3). 
In that case, SOMO orbital will interact with HOMO orbital of alkene. Alternatively, when radicals 
adjacent with X-substituents (methoxy, amino, alkyl) or hydrogen atoms (118) (Scheme 2.11), the π-
bond will interact more with LUMO orbital of the alkene (Figure 2.3). Finally, when the radical centre 
is substituted by an aryl group then the substituents to the aromatic ring are able to influence the 
interaction between the SOMO and HOMO or LUMO of alkene.
68
 
     
Figure 2.3 Frontier orbital interaction of an electrophilic and nucleophilic radical with alkene 
Radical cyclisation of 1,1 disubstituted terminal olefins such as 126 could also lead to 6-endo-trig 
products (Scheme 2.13) due to steric effects. Addition of radical 126 occurs faster via 6-endo-trig 
pathway by a factor of 1.6 (krel-endo/krel-exo) to give the more stabilized radical 128.
69
 When substituents 
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are placed on the terminal carbon (C6) of the double bond, the 5-exo-trig cyclisation is favoured 
compared to the 6-endo-trig process.70  
Scheme 2.13              
Another category in which 6-endo-trig is favoured, involves silicon-containing radicals such as 129,71 
131
70b,70c,71
 and 133
71
 (Scheme 2.14). The regioselective outcome in that case could arise by the 
presence of Si–C bond. The relatively long length of the Si–C bond reduces the strain of the 6-endo-
trig transition state and allows better orbital overlapping. Moreover, the silicon group in radical 129 
consists of a Z-substituent which will promote a 6-endo-trig addition.    
Scheme 2.14                         
In a similar manner, radical cyclisation of substrates, such as 135, containing amido groups also leads 
to formation also of the endo products 137 (Scheme 2.15).72 These examples are important for 
comparison with our substrate, DKP 108 (Scheme 2.10), in which we were also observed formation of 
6-endo product. 
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Scheme 2.15         
We believed that regioselectivity in cyclisation of 108 (Scheme 2.10) was mainly affected by the 
geometrical restriction of the DKP ring which has four sp
2
 and two sp
3
 centres. The nature of the sp
2 
nitrogen centre increases the planarity of the N-substituent while the presence of carbonyl groups also 
contributes to the ring’s low flexibility. Careful examination of molecular models showed that the 
terminal double bond is disposed at a disfavoured distance from the radical centre which would 
probably contribute to an inefficient SOMO-HOMO overlapping.   
In order to examine the contribution of steric effects of the DKP core on the regioselectivity for this 
reaction we decided to synthesise the MKP analogue 139 (Scheme 2.16). Compound 139 possesses 
only one carbonyl group which would enable a more flexible transition state and would possibly allow 
a more efficient overlapping between the orbitals. Double N-alkylation of 138 with 4-bromo-1-butene 
gave the corresponding N-alkylated MKP in 52% yield but unfortunately the following substitution 
step with phenylselenyl chloride or diphenyl disulfide was not successful.  
 
Scheme 2.16 
Another possible synthetic way to generate radical centres at positions where the introduction of a 
group such as a halogen atom or SPh or SePh is restricted, involves intramolecular hydrogen–atom 
translocation (HAT). Position five from the radical centre is usually favoured for H-atom transfer due 
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to favoured distance and angle of X – H – C (180o) which allows such a process (Scheme 2.17).73 
When 1,5-H abstraction could not occur then 1,6 or 1,7 abstractions maybe be observed. 
Scheme 2.17                                
Given the failure of the preparation of 139, an alternative precursor compound 140 was prepared 
(Scheme 2.18). Unlike DKP 139, the mechanism for radical cyclisation of 140 would involve 
generation of an alkenyl radical centre (141) which would translocate to generate a new radical centre 
(142) and/or, (144). We expected that the abstraction of the hydrogen atom would occur on C5 
position from the alkenyl radical and exclusively α-position to the amide, to give a more stable 
captodative radical 142. 
 
Scheme 2.18 
 
Parsons
74
 (Scheme 2.19) and Curran
73
 (Scheme 2.20) thoroughly investigated the process of vinyl 
radical translocation initiated using vinyl halides. For example, iodine atom abstraction from 146 
generated radical species 147 which subsequently translocated via 1,5-H atom abstraction to give 148 
(Scheme 2.19). The new radical centre then reacted with the double bond to furnish compound 149 via 
a 5-exo-trig cyclisation. 
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Scheme 2.19 
 
In similar fashion, Curran and co-workers obtained spiro-system 151 through a straightforward route 
from the precursor 150 (Scheme 2.20). This process involved formation of a vinyl radical followed by 
1,5-hydrogen abstraction and finally 5-exo-trig cyclisation.73b  
Scheme 2.20         
Synthesis of the desired compound 140 started with N-alkylation of the commercially available 
oxopiperazine (138) to furnish compound 154 (Scheme 2.21). Protection of the amide 154 with a Boc 
group led to formation of the radical precursor 140.   
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Scheme 2.21 
Radical cyclisation of 140 under the standard conditions gave a 10:1 mixture of endo (155) and exo 
(156) products (Scheme 2.22). The unexpected by high regioselectivity in favour of the endo product 
presumably arises from a combination of steric and electronic factors. Although due to the structural 
and mechanistic differences between DKP 108 and MKP 140, it is difficult to identify the contribution 
of the individual effects on the selectivity outcome.  
 
 
 
Scheme 2.22 
After this unexpected highly regioselective synthesis of a 6,6-fused MPK (155) we wanted to 
investigate the possibility of a radical cyclisation with 5-exo cyclisation selectivity. We thought that 
this might be possible by using an alternative way to generate the intermediate alkenyl radical by 
radical addition of sulfanyl radical onto a terminal alkyne group. 
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2.6 Radical cyclisation –The thiophenol mediated approach 
Intermolecular addition of radicals onto terminal alkynes offers an efficient method to generate 
alkenyl radical centres suitable for 1,5-hydrogen translocation. To date, a wide selection of radical 
species (tin, thiol and phosphate radicals) have been used, with the recent attention of tin-free 
procedures which involve thiophenol-mediated hydrogen transfer-cyclisations (Scheme 2.23).
75
 
Addition of sulfanyl radical, generates an alkenyl radical (158) which subsequently translocates, 
usually through a 1,5-hydrogen atom translocation (159), followed by radical cyclisation to give the 
final products (160).  
 
Scheme 2.23 
Extensive research carried out by Renaud and co-workers revealed further synthetic application of this 
method.
75l-o
 In many cases it had been shown that the thiophenol-mediated abstraction-cyclisation 
process was an efficient method to minimize the amount of directly reduced products (Table 2.1).
75m
 
 
 
 
      
 
40 
 
 
Substrates 161 or 162 Y,Z PhSH 163/164 (% yield) Bu3SnH 165/166 (% yield) 
OCH2CH2O 100:0 (90%) 58:42 (81%) 
OTBS, H 100:0 (89%) 88:12 (87%) 
PhS, H 100:0 (88%) – 
Ph, H 100:0 (85%) 78:22 (76%) 
CO2Et, H 100:0 (57%) 76:24 (83%) 
Me, Me, 100:0 (83%) 87:13 (65%) 
Table 2.1 Comparison of thiophenol-mediated with tin-initiated approach 
After examination of the literature, we were pleased to find a structurally related example described by 
Renaud.
75n
 According this report, piperidinone 167 was reacted under the typical conditions to give 
168 in 92% yield and 78:22 diastereoselectivity (Scheme 2.24).  
Scheme 2.24            
With this in mind and considering the possible steric effects between thiophenyl and carbonyl group 
we were confident that radical cyclisation of DKP 169 would lead selectively to the 5-exo product 170 
(Scheme 2.25). Thus, DKP 169 was chosen as the first target compound to test the proposed plan.   
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Scheme 2.25 
Preparation of the precursor 169 involved N-alkylation of the commercially available glycine ethyl 
ester 172, followed by peptide coupling with Boc protected glycine to furnish the corresponding amide 
175 (Scheme 2.26). Deprotection of the Boc group under acidic conditions followed by treatment with 
potassium carbonate gave the non-symmetrical DKP 177. Finally the desired radical precursor was 
synthesised after protection of the amide function with a Boc group. With DKP 169 in hand, we were 
now ready to set about the radical cyclisation following Renaud’s protocol. 
Scheme 2.26 
Addition of 2.0 equivalents PhSH and 2.0 equivalents AIBN over 20 hours to a toluene solution of 169 
at 80 
o
C led to the formation of fused bis-cyclic DKP 170 as well as the reduced product 178 in 1:2 
ratio (Table 2.2 entry 1). The fact that we were not able to isolate the 6-endo product (171) confirmed 
our expectations for the regioselectivity of the reaction. Unlike Renaud’s reports,75m we obtained a 
high yield of the reduced product 178 (65% yield). Further investigation was then carried out in order 
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to minimize formation of 178, which involved attempts at lower concentration or with faster addition 
of the reagents. It was shown that the reaction was complete with less than 2.0 equivalents of AIBN 
and 2.0 equivalents PhSH. The optimum conditions involved, addition of 1.3 equivalents of AIBN and 
1.3 equivalents of PhSH over 3 hours at reflux to furnish the final products as a 1.0:1.6 mixture of 170 
and 178 (Table 2.2 entry 2). The rate of the reduction process appeared to be higher than the 
cyclisation step, something which could arise from the additional steric effect by the presence of the 
thiophenyl group. 
 
 
 
 
 
 
Table 2.2 Thiophenol-mediated cyclisation reaction of 169 
Since we were able to obtain only the 5-exo product 170 we were also interested to investigate how the 
MKP analogue would react and what the regioselectivity would be under the same conditions. Thus, 
compound 180 was chosen as the final substrate on which to apply the thiol-mediated radical 
cyclisation (Scheme 2.27). Precursor 180 was successfully prepared through N-alkylation of 
commercially available 2-oxopiperazine 138 with tosylate 173 followed by Boc protection of the 
resulting ketopiperazine 179. 
 
 PhSH (eq) AIBN (eq) addition of 
PhSH/AIBN 
Yield 170 / 178 
entry 1 2.0 2.0 20 h 65% 1:2 
entry 2 1.3 1.3 3 h 70% 1.0:1.6 
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Scheme 2.27  
When cyclisation of ketopiperazine 180 was attempted in t-BuOH/toluene at reflux we did not observe 
formation of cyclisation products but we only recovered the starting material. Another attempt of the 
reaction in toluene under reflux, showed formation of compound 181 in 20% yield within a complex 
mixture of unidentified products (Scheme 2.28). nOe studies showed correlation between the methyl 
groups and H5 which has anti stereochemistry to the thiophenyl group. This proves that addition of the 
cyanopropyl radical occurred anti to thiophenyl group due to the steric hindrance on the opposite face.   
 
 
 
Scheme 2.28 
It is possible that the major product 181 of this reaction was generated through an additional hydrogen 
atom abstraction of the cyclised products. As Scheme 2.29 shows, a second sulfanyl radical could 
abstract the α-hydrogen atom of the amide 182 to generate a captodative radical centre 183. Addition 
of the cyanopropyl radical generated by the excess of AIBN would give the observed bicyclic product 
181. In many examples in the literature it has been reported that sulfanyl radical can directly abstract 
α-amidical hydrogen atoms, which supports our explanation.75n,76  
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Scheme 2.29 
Thus, all of our work with thiophenol-mediated hydrogen transfer-cyclisation both for DKPs and 
MKPs led to the formation of the 5-exo products in low yields. Due to the low yield of these reactions 
we would not be in a position to apply this reaction in more complex systems. However the highly 6-
endo regioselective radical cyclisation of MKP 140 (Scheme 2.21) could possibly give more 
interesting results under further investigation of radical cyclisation employing enantiopure precursors 
such as 184 (Scheme 2.30). 
Scheme 2.30                  
Unfortunately, preparation of MKP 184 would involve a more complex synthetic approach thus, we 
diverted our interest to the exploration of different methodologies within the area of prenylated indole 
alkaloids. Our next targets involved formal synthesis of stephacidin A (35) and new methods to access 
the hexacyclic bicyclo[2.2.2]diazaoctane framework.     
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Chapter 3 
Towards stephacidin A 
3.1 Previous syntheses 
Stephacidins (35), (39) and avrainvillamide (36) are important representative members of prenylated 
indole alkaloids which have been a vibrant source of inspiration for the synthetic chemist over the last 
few decades (Figure 3.1). Stephacidin A (35) and B (39) were isolated from fugal strain Aspergillus 
ochraceus WC76466 in 2001 and were shown to exhibit a potent in vitro cytoxicity against various 
human tumor cell lines.
26,31
 The absolute configuration of stephacidin A (35) was not reported in the 
original isolation. Due to the intriguing structural architecture, the biological activity and the need to 
determine the absolute stereochemistry of stephacidin A (35), these molecules have been adopted as 
challenging targets for several synthetic groups. To date three synthetic approaches towards 
stephacidin A (35) have been reported, first by Baran et al.47,77 and later from Williams et al.78  
 
 
 
 
 
 
 
 
 
Figure 3.1 Structures of the stephacidins and avrainvillamide 
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First enantioselective total synthesis of unnatural (-)-stephacidin A  
Baran and co-workers in 2005 were the first to demonstrate an enantioselective total synthesis of        
(-)-stephacidin A (35) via a novel bis-oxidative enolate coupling reaction.77 As shown in Figure 3.2 the 
core skeleton of the bridged DKP was generated by a metal-mediated enolate coupling of a DKP 
precursor followed by a formal ene reaction and 1,2-rearrangement.  
 
Figure 3.2 Key disconnections of stephacidin A (35)       
                 
In their synthetic approach the racemic tryptophan derivative 185 was chosen as the starting material 
and it was coupled with an enantiomerically pure L-proline derivative 186 to give a mixture of 
diastereomeric amides 187 in 62% yield (Scheme 3.1). Chemoselective N-Cbz deprotection followed 
by thermal cyclisation led to DKP 188. Amide 188 was protected with a MOM group followed by 
TBS removal to give the corresponding alcohol which was then oxidised to furnish ester 189.  
 
 
 
 
 
 
 
 
 
Scheme 3.1 
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The key step for the synthesis of the bridged DKP core structure involved an intramolecular oxidative 
heterocoupling of two carbonyl enolates. After extensive investigation on model systems, Baran and 
co-workers reported the first example of this type of intramolecular coupling. Among all the oxidants 
which were investigated, Fe(acac)3 and Cu(II) salts furnished the highest yields of 19-39% and 41% 
respectively. The optimum conditions involved the addition of 2.2 eq of LDA to a solution of 189 
followed by addition of 2.2 eq solid Fe(acac)3 to give 190 in 41% as a single diastereoisomer (Scheme 
3.2).
79
 
 
 
Scheme 3.2 
The authors suggest that the key reaction occurred in high yield possibly due to unique selectivity of 
the iron oxidant. Four possible scenarios are suggested for the bond formation in which the iron 
oxidant could selectively oxidise one of the enolate species (Figure 3.3).
79
 The remaining enolate 
could then be combined with the new radical centre and generate a ketyl-type radical anion which 
could be further oxidised to give the final product.  
 
 
 
 
 
 
 
 
 
Figure 3.3 Possible scenarios for bond formation  
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The selectivity outcome was rationalised by a chelated transition state between the enolate and the 
oxidant (Figure 3.4). Williams in his research had also related the stereoselectivity on similar reactions 
to the presence or absence of metal chelation (tight ion pairing).
80
  
 
 
 
 
Figure 3.4 Metal chelation 
 
Removal of the N-MOM group of 190 with B–bromocatecholborane (191) followed by Grignard 
reaction with methylmagnesium bromide and dehydration of the corresponding tertiary alcohol gave 
192 in 55% overall yield (Scheme 3.3).  
 
 
 
Scheme 3.3 
The final step of the synthesis involved formation of the last six-membered ring which would lead to 
the desired heptacyclic core. Although acid treatment proved to be ineffective for this step as the pyran 
ring is sensitive under acidic conditions, when neat 192 was heated at 200 
o
C for 1 h the favoured 
product 35 was formed in 45% yield (Scheme 3.4). It was suggested that the last cyclisation firstly 
involved a thermal Boc removal to give 193 followed by a formal ene reaction to afford spirocyclic 
compound 194 and finally 1,2-alkyl shift to furnish 35. In comparison with the isolation reports it was 
confirmed that synthetic 35 had identical spectral properties with the natural product. However only 
the relative configuration of 35 could be confirmed at that time as the optical rotation of the natural 
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product was not reported. A few years later in 2009, Baran’s research group reported an improved 
synthesis of α,β-unsaturated nitrones relevant to the stephacidins.81 
 
 
 
 
 
 
 
 
Scheme 3.4 
 
First enantioselective total synthesis of the natural (+)-stephacidin A – 
Determination of the absolute configuration  
 
In 2005, Baran, in collaboration with Fenical et al. re-isolated natural stephacidin A (35) and measured 
the optical rotation of the natural product.
47
 It was proved that natural stephacidin A (35) exhibit the 
opposite CD data to that exhibited by synthetic 35 (Figure 3.5).                        
 
Figure 3.5 CD measurements of natural and synthetic stephacidins A  
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As a consequence, Baran repeated the synthesis starting with D-proline to give the enantiopure natural 
product (+)-stephacidin A (35) in 18 steps and overall synthetic yield of 0.5% from commercially 
available material (Scheme 3.5). Having the correct enantiomer in hand they also proceeded toward 
the enantioselective total synthesis of avrainvillamide (36) and stephacidin B (39).     
 
 
 
Scheme 3.5 
Biomimetic total synthesis of (±)-stephacidin A: the Diels-Alder approach 
The most extensive work in the area of synthesis and biosynthesis of prenylated indole alkaloids has 
been carried out by Williams. Williams and co-workers have achieved several total syntheses of these 
natural products and also verified the biosynthetic proposal of a Diels-Alder reaction, originally 
described by Birch and Sammes.
16,35
 Even though this elegant biomimetic Diels–Alder approach has 
proved to be difficult for enantioselective synthesis of these compounds, Williams and co-workers 
applied this approach to the total synthesis of (±)-stephacidin A (35).
78a
  
 
Figure 3.6 Key disconnections of bridged lactim ether 195 
           
L-Proline derivative 196 was coupled with compound 88 to give amide 197 as a mixture of 
diastereomers in 54% yield and 1:1 ratio (Scheme 3.6). Treatment of 197 with morpholine resulted in 
removal of the Fmoc protective group and the resulting amine underwent an intermolecular cyclisation 
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to form DKP 198 as 1:1 mixture of diastereomers. Mitsunobu-type elimination of water followed by 
treatment with Me3O
+
BF4
-
 and Cs2CO3 generated Diels-Alder precursor 199.  
 
 
 
 
 
 
 
Scheme 3.6 
A Diels-Alder reaction under the optimum conditions which had previously been described was then 
attempted.
82
 Under basic conditions, 199 formed azadiene 200 which spontaneously underwent an 
intramolecular Diels-Alder reaction to give selectively compounds 195 and epi-195 in a 2.4:1.0 ratio 
(syn/anti) and 86% yield (Scheme 3.7).  
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Scheme 3.7 
Lactim ether 195 was hydrolysed in the presence of HCl in THF to afford a ring-opened amino ester 
201 which then cyclised on the treatment with NaHCO3 to give the corresponding (±)-stephacidin A 
(35) in 96% yield (Scheme 3.8).  
 
 
 
 
 
Scheme 3.8 
Intermediate 203 was generated by a stereoselective oxidation of 35 using an excess of oxaziridine 
202 followed by epoxide opening (Scheme 3.9). This oxidation step involves an epoxidation of a 2,3- 
disubstituted indole from the less hindered α-face. A pinacol [1,5]-sigmatropic rearrangement then 
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takes place to form another biologically active natural product notoamide B (29) in 73% yield.  
Williams’ synthesis of stephacidin A (35) was achieved in 17 synthetic steps and 5.0% overall yield. 
 
 
 
 
 
 
 
 
Scheme 3.9 
 
Asymmetric, stereocontrolled total Synthesis of (-)-stephacidin A: the SN2’ 
alkylation approach 
Williams published an asymmetric total synthesis of (-)-stephacidin A (35), (+)-stephacidin B (39) and 
(+)-notoamide B (29).
78b
 The advantage of this approach was the high selectivity of the SN2
’
 key step 
cyclisation reaction in the formation of the bridged DKP skeleton (Figure 3.7). The heptacyclic core 
was generated by a Pd-mediated coupling reaction between the isoprene functional group and the 
indole moiety of a DKP derivative.  
 
Figure 3.7 Key disconnections of stephacidin A (35)      
                                            
      
 
54 
 
Proline derivative 205 was coupled with tryptophan 204 to afford peptide 206 and then the crude 
mixture was heated in a microwave to remove the Boc group and form DKP 207 in 70% overall yield 
(Scheme 3.10). Over the next three steps, the amide functional group was protected as lactim ether and 
the nitrogen of the indole moiety with a Boc group, before cross-metathesis with Hoveyda-Grubbs 2
nd
 
generation catalyst was carried out to give formyl DKP 210. 
 
 
 
 
              
 
 
 
 
 
 
Scheme 3.10 
Formyl DKP 210 was reduced to the allylic alcohol which was then transformed into the desired 
allylic chloride 211 in 71% yield over two steps (Scheme 3.11). As previously described,
83
 a 
cyclisation with syn selectivity could occur when NaH was added to a solution of this type of 
substrates in benzene. Repeating the standard conditions, Williams and co-workers were pleased to 
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isolate the bridged product 212 as a single diastereoisomer in 60% yield. As described earlier, the 
diastereoselective outcome arises through a tight ion-pair-driven closed transition state.  To perform 
the second cyclisation it was necessary to develop a different methodology in the absence of acids as 
the pyran ring is sensitive to these conditions. After extensive investigation they found that the 
optimum conditions involved addition of 5.0 equivalents of Pd(TFA)2 to a solution of 212 in MeCN. 
The resulting alkyl-palladium intermediate was then reduced using NaBH4 and the double cyclised 
product was obtained after treatment with aqueous HCl at low concentration (0.1 N). Finally, the Boc 
group was removed under thermal conditions and (-)-stephacidin A (35) was isolated in 60%. Thus     
(-)- stephacidin A (35) was prepared in 6% overall yield from commercially available materials and in 
17 total steps.  
 
 
 
 
 
 
 
 
Scheme 3.11 
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Improved total synthesis of (±)-stephacidin A: Mitsunobou conditions for 
intermolecular Diels-Alder reaction   
Williams in 2007 also published an improved biomimetic total synthesis of (±)-stephacidin A (35) in 
14 steps and overall yield of 11%.
78c
 It was observed that a Diels-Alder reaction occurred during 
elimination of the hydroxyl group DKP 198 when the reaction was left longer (Scheme 3.12). After 
purification (±)-stephacidin A (35) and its epimer in a 2.4:1.0 ratio were isolated in 64% yield. The 
new general protocol lacked the need for amide protection and deprotection steps and it is closer to the 
biosynthetic pathway that Nature chooses in order to make these natural products.  
 
 
 
 
Scheme 3.12 
Isolation of the antipodal (-)-stephacidin A 
In 2008 Williams reported for the first time the isolation of the antipode (-)-stephacidin A from 
Aspergillus versicolor NRRL 35600.32 This report was published seven years after the original paper 
for the isolation of (+)-stephacidin A (35) and 3 years after Baran’s group reported the synthesis of the 
unnatural product. The isolation of the both antipodal natural products such as stephacidins and 
notoamides supports the proposal that the biosynthetic path for these natural products involves a Diels-
Alder reaction. 
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3.2 Previous work by Simpkins’ group - Studies towards complex bridged 
alkaloids 
Previous work in our group carried out by M. Pichowicz,
84
 showed a promising cyclisation of a highly 
substituted DKP substrate to access the bridged DKP core present in the prenylated alkaloid natural 
products. Synthesis of the unsymmetrical DKP 213 (Scheme 3.13) was achieved in 5 steps and 
involved peptide coupling of two amino acid derivatives and several protection/deprotection 
modifications.
84b
 Enolisation of the DKP 213 proved to be problematic as various bases such as LDA, 
LiHMDS, KHMDS, n-BuLi did not give successful results and only bis-amine 214 gave reasonable 
yields. Treatment of 213 with 1.1 equivalents of base 214 at -78 
o
C followed by addition of diphenyl 
sulfide after 1 h gave DKP 215 as a single diastereoisomer in 64% yield (Scheme 3.13). The 
stereochemical assignment was secured by X-ray crystallography and the SPh substituent was found to 
be anti to the prenyl group and on the more concave face of the bicyclic system. The stereoselective 
outcome was been explained by hindrance of the convex face which is shielded by the prenyl group. 
Thus the electrophile approaches anti to the prenyl group. Since DKP substrates are known for their 
ability to generate cationic intermediates, compound 215 was treated with AgOTf in an attempt at a 
cationic cyclisation. The resulting carbocation was trapped by the double bond of the prenyl group to 
give bridged DKP 216 as a single diastereoisomer in 65% yield. A direct cyclisation was also effected 
by enolisation of 213 followed by electrophilic fluorination and then treatment with TMSOTf to afford 
216 in 43% in a one pot process. After the successful cyclisation of the model system it was attempted 
to extend this approach towards brevianamide F. 
Scheme 3.13 
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It was proposed that the indole moiety might trap the intermediate isoprenyl carbocation involved in 
these cyclisation, leading to another cyclisation. DKP 217 was straightforwardly synthesised following 
a similar approach to that for compound 213.
84b
 Unfortunately enolisation of 217 using the previous 
reported conditions was unsuccessful and the cationic cyclisation methodology could not be applied to 
this system (Scheme 3.14). At this point an alternative approach needed to be investigated.  
Scheme 3.14   
The modified synthetic plan, which was carried out by F. Frebault, involved introduction of a different 
functional group to trigger the cationic cyclisation.
59a
 A hydroxyl group seemed to be a suitable 
candidate for this proposal and so hydroxyl-DKP 219 was chosen as the ideal precursor (Scheme 
3.15). DKP 219 was easily synthesised and when it was treated with TMSOTf at 0 
o
C it gave 
compound 216 in 30% yield. 
Scheme 3.15                       
Having shown that a cationic cyclisation could occur, starting with a hydroxy-DKP, the next step was 
to synthesise DKP 220.
59a
 The presence of the indole was crucial in order to undergo a cationic 
cascade and afford the hexacyclic bridged DKP in a single step. DKP 220 was synthesised in 4 steps 
and when it was treated with TMSOTf, 221 and epi-221 in a 4:1 ratio were isolated in 82% combined 
yield (Scheme 3.16).  
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Scheme 3.16 
 
In comparison to previous reported approaches to access the bicyclo[2.2.2]diazaoctanecore ring 
system, only the Diels-Alder approach leads to the formation of two new C–C bonds in a single step 
(Scheme 3.7). However the Diels-Alder methodology does not enable enantiomeric control and leads 
to racemic mixtures. On the other hand Williams’ SN2’ cyclization reaction and Baran’s oxidative 
enolate coupling undergo reactions with higher stereoselectivity, however in these approaches there is 
a stepwise formation of the final products. Simpkins’ cationic cyclisation occur a double cyclisation of 
the hydroxy-DKP leading to the final products in one pot and with reasonable stereocontrol. Ent-
malbrancheamide B (41) and ent-brevianamide B (5) were synthesised by applying this new 
methodology to some modified precursors.
59
 Unfortunately, this reaction could not be used for the 
synthesis of stephacidin A (35) due to the high acid sensitivity of the pyran ring of compound 222 and 
223 (Scheme 3.17). The triflic acid generated during the reaction promotes decomposition of the 
starting material and the products. Several Lewis and Brønsted acids were also tested (TFA, HCl, 
TiCl4) but with no success. Unfortunately F. Frebault was not able to isolate the monocyclised 
products and complete the synthesis via a stepwise cyclisation process. 
 
 
 
Scheme 3.17 
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Previous studies have shown that the presence of an electron donating oxygen atom on the indole 
made the molecule sensitive to acidic conditions. Williams had also reported
78b
 the sensitivity of the 
pyran ring in a similar substrate during acidic work-up of 224 (Scheme 3.18).  
 
Scheme 3.18 
As we were not able to synthesise the heptacyclic core structure via a cationic cascade cyclisation it 
was necessary to devise an alternative route in order to complete the synthesis of stephacidin A (35). 
 
3.3 Investigating the new strategy 
In order to overcome the acid sensitivity of the pyran-containing intermediates it was decided to 
develop a new synthetic route which involved introduction of the pyran ring at a late stage of the 
synthesis. The feasibility of two new approaches was initially explored by choosing compound 227 
(Scheme 3.19) and 230 (Scheme 3.20) as potential precursors. For the first approach, O-
benzyloxyindole bridged DKP 227 would be synthesised via a cationic cascade reaction of 228 as 
previously described by our group (Scheme 3.19). Deprotection of the OBn protecting group followed 
by formation of the ether via a copper-mediated coupling would lead to compound 226. Finally, 
intermediate 226 could undergo an aromatic Claisen rearrangement
78b
 according to previous reports to 
furnish the final target of the synthesis 35.  
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Scheme 3.19 Retrosynthetic analysis of 35 
 
Alternatively, synthesis of compound 226 could also be achieved from 230 as the primary precursor, 
which could also be prepared by cationic cyclisation of a bromo modified DKP derivative (Scheme 
3.20). Furthermore, there are two district pathways by which 230 can be converted via the phenolic 
derivative 229 (path-B) or directly to 226 (path-A). Path-A involves a Pd-coupling reaction of 
bromoindole analogue 230, whereas path-B would involve a copper catalysed aryl hydroxylation of 
230 followed by another metal-catalysed coupling to furnish 226. 
 
 
 
 
 
 
 
 
 
Scheme 3.20 Retrosynthetic analysis of 226 
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3.4 Synthesis of 6-benzyloxy-hydroxy-DKP precursor 
Vilsmeier formylation of the commercially available 6-benzyloxyindole 231 with POCl3 in DMF 
followed by N-Boc protection gave formyl indole 232 (Scheme 3.21).85 Aldol condensation of 232 
gave alcohol 234 in a ratio of 1.2:1.0 and 94% yield.
59b
 The mixture of alcohols were then dehydrated 
after treatment with MsCl, TEA and DBU to obtain α,β-unsaturated esters 235 as a 1.4:1.0 mixture of 
stereoisomers. The variation of diastereoselectivity in these reactions confirms the results of previous 
studies within our research group of structurally similar substrates.
59b
   
 
Scheme 3.21 
Ester 235 was treated with 5.0 eq of LiOH in THF/H2O this allowed the formation of 1:1 mixture of 
237 (in a range of 50 - 66% yield) with the minimum formation of amine 236 (Scheme 3.22) and 
recovery of starting material. It was important to avoid formation of the 236 derivative due to 
difficulties during the purification process. Previous work in our laboratory had shown that hydrolysis 
of esters similar to 235 has proved problematic.
59b
 In order to improve the yield of this step several 
modifications of the experimental process were attempted but with no success. Finally, following the 
procedure originally described by Boger,
86
 ester 235 was treated with 3.0 N LiOH in THF/MeOH/H2O 
(3/2/1). In this case loss of the Boc group during the first 2 h of the reaction was observed.  
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Scheme 3.22    
Acid 237 was coupled with enantiopure proline derivative 238 in the presence of HATU and DIPEA 
to afford a 2.8:1.0 mixture of amide 239 and 76% yield (Scheme 3.23). We were also able to observed 
changes in the diastereoselectity during the peptide coupling as previously studies reports.
59b
 
Preparation of hydroxy-DKP 228 involved OSEM deprotection of the enol followed by an 
intramolecular cyclization. The deprotection was facilitated by treatment of 239 with CBr4 in dry i-
PrOH at 50 
o
C. After 24 h DKP derivative 228 was obtained as a single diastereoisomer in 45% yield. 
 
Scheme 3.23 
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3.5 Cationic cyclisation of 6-benzyloxy-hydroxy-DKP   
With DKP 228 in hand we were now ready to investigate the cationic cascade cyclization (Scheme 
3.24).Treatment of 228 with 2.0 eq of TMSOTf at 0 
o
C followed by quenching with Et3N after 30 min 
a new, more polar product, showed by TLC analysis. Upon purification of the reaction mixture we 
were able to obtain a 32% yield of the monocyclised product 240.  
 
Scheme 3.24 
Unfortunately, when the reaction was left for longer in the presence of TMSOTf we were able to 
obtain only 15-25% of the double cyclised product 227 (Scheme 3.25). The cyclisation attempt was 
followed by degradation of the starting material and/or products.  
 
Scheme 3.25 
During our investigations for the optimal conditions we observed that concentration of the reaction 
mixture had critical effect on the reaction rate. Surprisingly, concentration of the reaction mixture was 
also affecting the rate for the intramolecular cyclisation step, from intermediate 242 towards 227 
(Scheme 3.26). Considering this, it is possible that the presence of another equivalent of acid (triflic 
acid) could initiate the second cyclisation and furnish 227.  
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Scheme 3.26 
Having evidence that the presence of acid could be vital for the completion of the reaction we were 
keen to repeat the reaction using directly triflic acid instead of TMSOTf. Unfortunately, treatment of 
228 with 1.0-2.5 equivalents of triflic acid at 0 
o
C
 
led to partial formation of the desired products as 
well as degradation (Scheme 3.27). In order to avoid degradation of the product, the reaction was then 
repeated at lower temperature (8 h at -50
 o
C to -40
 o
C for the first cyclisation, then 10 h at rt) but also 
in this case the yield was low. 
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Scheme 3.27 
Finally, when DKP 228 was allowed to stir in the presence of triflic acid for 20 min and then treated 
with triethylamine we were able to isolate the monocyclised product 240 in 42% (Scheme 3.28).  
 
Scheme 3.28 
With small quantities of 240 in hand, the second cyclisation in the absence of acid was then attempted. 
These types of isoprene bridged DKP are known to undergo an ene reaction followed by a 1,2-shift 
when they are heated.
77,87
 Unfortunately, when solution of 240 in toluene was heated in microwave, 
left the starting material unchanged, while heating neat 240 at 200 
o
C resulted in complete degradation 
of the starting material (Scheme 3.29).   
 
Scheme 3.29 
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3.6 Synthesis of DKP precursor of 6-bromoindole-hydroxy-DKP 
It is worth mentioning that similarly with preparation of 228 and other structurally related substrates 
the diastereoselectivity of the reactions towards 249 also varied.
59b
 The route towards DKP 249 began 
with formylation of 6-bromoindole (243) followed by N-Boc protection to afford indole 244 (Scheme 
3.30). Aldol condensation using the same procedure as before and then dehydration of the hydroxy 
esters gave SEM enol ester 246 as a mixture of stereoisomers (Z/E, 1.1:1.0) and 94% yield.  
 
Scheme 3.30 
Hydrolysis of ester 246 in the presence of LiOH followed by peptide coupling led to the formation of 
amide 248 as a single diastereoisomer (Scheme 3.31). Finally derivative 248 was then SEM-
deprotected to yield compound 249 which is the precursor for the key cationic cyclisation step. 
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Scheme 3.31 
3.7 Cationic cyclisation of 6-bromoindole-hydroxy-DKP 
A cationic cyclisation of 249 was then induced using 2.5 equivalents of triflic acid in dry DCM at 0
 o
C 
for 30 minutes and then the mixture was stirred at rt overnight to give compound 230 in a 2:1 ratio and 
40% yield. Hoping to improve the diastereoselectivity of the reaction, it was repeated at lower 
temperature for the first cyclisation. Treatment with 2.2 eq of acid at -50
 o
C to -40
 o
C for 8 h and then 
overnight at rt gave the 230/epi-230 as a 3:1 mixture of isomers in 68% yield (Scheme 3.32). 
 
Scheme 3.32 
After the successful key reaction we were ready to investigate the next manipulations in order to 
install the pyran ring. Due to the various possible synthetic approaches, we decided firstly to find the 
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optimum synthetic route and conditions by testing a cheap model system. Commercially available N-
Boc-6-bromoindole was considered a suitable substrate for our research. Firstly methoxylation of 6-
bromoindole was tested according literature reported examples.
88
 Copper-mediated coupling of N-
Boc-6-bromoindole 250 in dry DMF and excess of NaOMe/CuI after 48 h showed only Boc-
deprotection of the starting material (scheme 3.33). Deprotection of the indole nitrogen was also 
observed when the reaction was repeated in MeOH in the presence of TMEDA.  
 
Scheme 3.33  
Aryl bromides are known to give phenol products via copper-catalysed coupling.
89
 Despite the lack of 
examples of indole derivatives in the literature we were keen to investigate this possibility in our 
substrates. First a literature example was tested in order to verify the experimental procedure as it is 
shown in Scheme 3.34.
89a
 Treatment of 252 with copper iodide, sodium iodide and TMEDA in 1,4-
dioxane followed by addition of KOH in degassed H2O gave the desired phenol 253 in 65% yield. 
Unfortunately, when the same conditions were applied to N-Boc-6-bromoindole, only starting material 
was recovered.  
 
Scheme 3.34                                  
      
 
70 
 
We then turned our attention to Pd-catalysed C–O bond formation of aryl bromides with 
primary/secondary alcohols as developed by Buchwald et al.90 We were pleased to find that among the 
test substrates, bromoindoles were also reported to undergo this type of transformation (Scheme 3.35). 
 
Scheme 3.35 Literature examples of Pd-catalysed C–O bond formation indole substrates90 
Buchwald reports the use of non-commercial complex ligands for coupling reaction with indole 
substrates (Scheme 3.35).
90
 As we were not certain of the unique utility of these ligands we firstly 
decided to test the reaction with commercially available ligands. Test reactions of 6-bromoindole were 
then attempted with various palladium catalysts (Pd(OAc)2, Pd(dba)3·CHCl3,) and the in presence of 
ligands 259-262 (Figure 3.8). The Pd-mediated coupling reactions attempts were preceded with either 
commercially available alcohols (n-BuOH, 2-methyl-3-butyn-2-ol) under basic condition (Cs2CO3) or 
salts such as sodium 2-methyl-3-butyn-2-oxide.   
 
Figure 3.8 Structure of Pd-ligands 
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Unfortunately we were not able to obtain any of the desired products and as a consequence we turned 
our attention to the synthesis of the ligands that Buchwald reported (Scheme 3.36).
91
 The lack of 
experimental procedures and characterisation data
91
 for the intermediates made this synthesis very 
difficult to accomplish. We were only able to proceed to compound 266 in 45% overall yield from 
263, but despite our attempts we were not able to repeat the methylation step of this synthesis and 
synthesise 267.  
Scheme 3.36
91
 The Buchwald synthesis of ligand 
 
3.8 Progress toward stephacidin A 
Despite our efforts to develop a new strategy towards stephacidin A (35), our attempts were not 
successful at this stage. After examination of the literature, we found that Dala and co-workers have 
developed a highly efficient α-amino alkylation reaction of silicon-based nucleophiles by N-
acyliminum ion assisted by the catalytic system of HNTf2/Me3SiNTf2.
92
 The strong oxophilic Lewis 
acid Me3SiNTf2 was synthesised in situ by photodesilylation of the precatalyst HNTf2 with with silyl 
enol ether 269 (Scheme 3.37).  
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Scheme 3.37        
An intramolecular Friedel-Craft type cyclisation of hydroxylactam 271 in presence of 1 mol% of 
HNTf2 was also reported (Scheme 3.38).
93
 Considering the extremely poor nucleophilicity of HNTf2 
(which could provide long-lived cations) and its lower acidity than TfOH, this encouraged us to 
investigate the possibility of a cationic cyclisation initiated by catalytic acid. 
Scheme 3.38                    
We were hoping that the low concentration of this acid in solution would promote a cyclisation of the 
DKP precursor rather than the degradation reaction. Besides, it is known that advanced intermediates 
of stephacidin A (35) are stable to 0.1 N solution of HCl.
78b
 From an advanced intermediate (273), we 
prepared the desired hydroxy-DKP 222 (Scheme 3.39) and we were now poised to apply cyclisation 
under HNTf2 catalyst.  
Scheme 3.39 
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To a solution of 222 in dry DCM was added 5% mol of 0.5M solution of HNTf2 in DCM and the 
reaction mixture was stirred at rt (Scheme 3.40). TLC analysis of the reaction mixture after 2 h 
showed that the starting material was left unchanged, and it proved possible to drive the reaction to 
completion only by addition of 1 equivalent of HNTf2. After purification of the new polar spot by 
flash column chromatography followed by HPLC, we were pleased to confirm formation of the 
bridged DKP 274 by NMR analysis, albeit in very modest yield. 
 
Scheme 3.40  
With DKP 274 in hand, we were now in a position to set about the formal synthesis of (-)-stephacidin 
A (35). Deprotection of the DKP-amide by oxidative cleavage using freshly prepared SmI2
94
 would 
lead to compound 192 which is described by Baran and co-workers in the total synthesis of 
stephacidin A (35).
77
 When the optimum conditions were applied in solution of 274 in THF a new 
more polar spot was observed by TLC analysis (Scheme 3.41). Despite our efforts and due to the 
insufficient amount of product, we were not able to provide clean NMR data and compare them with 
literature.   
 
Scheme 3.41  
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Even though we were not able to complete the formal synthesis, it has been shown that a stepwise 
cyclisation was possible to give an advanced intermediate for stephacidin A (35). It was clear to us 
that the present cationic cyclisation key-step promoted by acids had limitations in the synthesis of 
complex and sensitive natural products belonging to this family. For these reasons we focused our 
efforts to developing a new radical-based methodology for construction of the core ring system which 
could be applied in the synthesis of various natural products including stephacidin A (35). 
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Chapter 4 
Studies of cyclisation reaction  
of prenylated DKP 
4.1 Synthetic approaches to the bicyclo[2.2.2]diazaoctane ring system. 
The bicyclo[2.2.2]diazaoctane core ring system is common to a number of biological highly active 
secondary metabolites isolated from various species of fungi. Over the last three decades intense 
research efforts have been made to prepare the basic skeleton for the diverse family of prenylated 
indole alkaloids. Major synthetic strategies employed intramolecular SN2’ cyclisation, biomimetic 
Diels-Alder reaction, radical cyclisation and a one-pot cationic approach. 
4.2 Biomimetic Diels-Alder approach 
An interesting by-product was reported by Fabre et al. during their studies on 1,3-dipolar 
cycloaddition of prolines.
95
 When proline 275 was treated with acetic anhydride, azadiene 276 was 
formed and spontaneously reacted with 2-chloroacrylonitrile to give cycloadducts 278 and 279 
(Scheme 4.1). 
 
 
 
 
Scheme 4.1 
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The first application of the biomimetic Diels-Alder reaction to this family of alkaloids was in the total 
synthesis of (±)-brevianamide B (5) by Williams (Scheme 4.2).82 Lactim ether 280 was tautomerized 
to the azadiene 281 under basic conditions followed by an intramolecular Diels-Alder reaction to give 
282 as a 2:1 ratio of diastereomers. Very similar synthetic approaches were also applied to the 
synthesis of racemic VM55599 (73),
96
 stephacidin A (35) and notoamide B (29).
78a
 
 
 
 
 
Scheme 4.2 
For the synthesis of malbrancheamide B (41), DKP 283 was prepared for use in the key intramolecular 
Diels-Alder reaction (Scheme 4.3).
97
 Addition of aqueous KOH to a solution of 283 followed by a 
selective reduction of tertiary amide using an excess of DIBAL gave the final heptacyclic product 41. 
 
 
 
 
 
Scheme 4.3 
This methodology was also applied to the synthesis of spiro-oxindole structures common to a number 
of highly biologically active natural products.
15a
 As Scheme 4.4 shows, oxindole 284 was chosen as a 
precursor for the key step towards (-)-versicolamide B. Under basic conditions DKP 284 undergoes an 
intramolecular Diels-Alder reaction to give spiro-oxindole 285 and its diastereomeric cycloadduct in a 
1.4:1.0 ratio and 72% yield. 
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Scheme 4.4 
From ab initio calculations it has been shown that the Diels-Alder reaction of an oxindolic azadiene 
leads to anti-cycloadducts due to a particularly stable transition state.98 On the other hand, an indolic 
azadiene reacts though roughly equally stable syn- and anti-transition states. 
A Diels-Alder reaction under neutral conditions was introduced by Liebscher and co-workers,
99
 who 
developed a shorter synthesis to access precursor 286. The unsaturated compound 286 was treated 
with neat acetyl chloride for 20 days leading the formation of bridged DKP 51 as a single diastereomer 
(Scheme 4.5).  
 
 
 
 
 
 
 
 
Scheme 4.5 
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Liebscher’s protocol was also applied to the synthesis of Z-unsaturated DKP 289 in the first 
asymmetric total synthesis of (-)-VM55599 (73) by Williams (Scheme 4.6).
57
 Diels-Alder reaction of 
289 gave a mixture of diastereoisomers with 73 as the major cycloadduct. The authors suggest that the 
key intermediate 289 undergoes an intramolecular Diels-Alder reaction via three of the four possible 
transition states. Cycloadduct 73 was reduced by an excess of DIBAL-H to give enantiopure (-)-
VM55599 (73) in 68% yield and the absolute stereochemistry of the natural product was also 
determined. 
 
 
 
 
 
 
Scheme 4.6 
 
A highly anti-selective Diels-Alder was later introduced for the synthesis of racemic brevianamide B 
(5) (Scheme 4.7).
100
 Amide 292 and DKP 293 which were generated by dithiane group removal from 
291, were treated with excess of AlCl3 to give exclusively cycloadduct 294. Fischer indole synthesis of 
294 gave 51 in 58% yield. 
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Scheme 4.7 
Finally, Williams also reported that 198 undergoes a Mitsonobu-type elimination and Diels-Alder 
reaction to give the bicyclo[2.2.2]diazaoctane core.
56,78c
 As shown in Scheme 4.8 when DKP 198 was 
treated with an excess of PBu3 and DEAD it formed cycloadduct 35 and its epimer in 2.4:1.0 ratio and 
a total yield of 64%.  
 
 
 
 
Scheme 4.8 
 
4.3 Intramolecular SN2’ cyclisation approach 
Before Williams’ research group focused their efforts on the biomimetic Diels-Alder approved they 
developed an intramolecular SN2’ cyclization reaction. In their first attempt a 1:1 mixture of 
diastereoisomeric epoxides 295 were ring-opened by a nucleophilic attack of an enolate which was 
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produced by addition of LiHMDS (Scheme 4.9).
101
 The epoxide ring opening gave a 2.8:1.0 mixture 
of 296 and 297 in 61% combined yield.  
 
 
 
Scheme 4.9 
In the synthesis of brevianamide B (5), Williams and co-workers introduced a chloro-alkyl group in 
order to avoid formation of a seven-membered ring akin to product 297.
83
 In the key step, DKP 298 
(Table 4.1) underwent intramolecular SN2’ cyclisation to give 299 and its epimer in a 2:1 ratio and 
62% yield. Surprisingly when benzene was used as a solvent they obtained epi-299 as the major 
product (ratio 3:97, 82% yield). In contrast with the previous example, the reaction in the presence of 
18-crown-6 in benzene gave as a major product 299 in a 4:1 ratio and 56% yield.  
 
 
 
 
 
Table 4.1 Intramolecular SN2’ cyclisation of 298 
A possible reason for the different diastereoselectivities is the ability of DMF and 18-crown-6 to 
solvate the sodium cation of the enolate anion.
83
 Without a solvent effect there is a tight intramolecular 
interaction which promotes an ion pair-driven closed transition state which leads to the syn product (B 
in Figure 4.1). Alternatively, the presence of DMF or 18-crown-6 can break open this closed transition 
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state to affect the cyclisation from the other face of the allylic π-system and lead to the anti-product (A 
in Figure 4.1).  
 
Figure 4.1
83
 Transition states of enolate 298 
Using the same strategy, Williams and co-workers applied the selective intramolecular SN2’ 
cyclization reaction in order to synthesise the structurally similar natural products paraherquamide A 
(10)
102
 and B (11),
103
 stephacidin A (35) and B (39), and avrainvillamide (36).
78b
 
4.4 Radical cyclisation approach  
Free radical chemistry is one of the most powerful tools in organic synthesis and it can provide new 
cascade reactions towards moderately complex and densely functionalised natural products. Several 
groups working on the synthesis of the bicyclo[2.2.2]diazaoctane core have based their retrosynthetic 
plans around multiple key bond disconnections which could be formed using radical chemistry.  
In their synthetic approach towards avrainvillamide (36) and stephacidin B (39), Myers and co-worker 
proved that the bicyclo[2.2.2]diazaoctane core could arise via an aminoacyl radical cyclisation of 300 
(Scheme 4.10).
46
 When 300 was heated in presence of tert-amyl peroxybenzoate, amino acyl radical 
301 was generated and cyclisation occurred onto the more substituted carbon of the enamine double 
bond. After addition a thiophenyl radical was expelled to give 302.  
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Scheme 4.10 
One year later a concise synthesis of (±)-marcfortine B (26) was reported by Trost et al.53 The 
synthetic route involved a [3+2] cycloaddition (TMM) and a radical cyclisation reaction to form the 
core framework of the natural product. Having in hand the spiro-oxindole 87 (eleven steps), a radical 
cyclisation was then performed to give the more advanced hexacyclic intermediate 303 (Scheme 4.11).  
 
 
 
Scheme 4.11 
Baran’s group was also attracted to the complexity of these natural products and for several years 
focused their research in this area. In their efforts to synthesise of the stephacidins, they demonstrated 
an interesting oxidative enolate coupling of 189 to 190 (Scheme 4.12).
47,77,79
  
 
 
 
 
Scheme 4.12 
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Previous work in our group showed that a cationic cyclisation route could also be applied to the 
synthesis of these bridged DKP structures.
59,84
 DKP 215 underwent cationic cyclisation in the presence 
of AgOTf to give exclusively bridged DKP 216 (Scheme 4.13).   
 
 
 
Scheme 4.13 
With the first successful example of cationic cyclisation in hand, Simpkins and co-workers were now 
keen to explore a cationic cascade reaction. DKP 218 was then attempted to be synthesised but 
unfortunately installation of a thiophenyl group proved to be problematic
59a,84b,104
 (Scheme 4.14) and 
so an alternative approach was then applied.   
 
 
 
 
 
 
Scheme 4.14 
The new strategy proposed that a hydroxyl-DKP such as 219 (Scheme 4.15) could possibly undergo a 
cationic cyclisation in the same fashion as 215 (Scheme 4.13) and furnish the same products. Thus, 
treatment of 219 with TMSOTf led to formation of bridged product 216 in 30% yield (Scheme 4.15).    
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Scheme 4.15 
A new access to indole alkaloids could be possibly achieved by combination of cationic reaction of 
hydroxy-DKPs with the indole-capture step already described by Williams.
80,83
 O-benzyl proline 
hydroxamic acid 238 was coupled with indole puruvic acid 305 to give DKP 220 in 46% yield 
(Scheme 4.16). Treatment of 220 with TMSOTf gave a 4:1 mixture of heptacyclic product 221 and 
epi-C4-221. Based on this successful double cyclisation, total syntheses of ent-brevianamide B (5)59a 
and ent-malbrancheamide B59b (41) was also achieved.  
 
 
 
 
 
 
 
Scheme 4.16 
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4.5 Investigation of a new strategy towards stephacidins 
Unfortunately, the previously described cationic cascade cyclisation strategy (Scheme 4.16) could 
only be applied on acid-stable substrates such as 220. Thus, this methodology could not been used for 
the synthesis of stephacidins or other relevant natural products. For that reason, we decided to put 
effort into the synthesis of sulfenyl-DKP 218 (Scheme 4.17).
84b,85,108
 This strategy was combining a 
non-acidic cationic reaction of sulfenyl-DKP 215 (Scheme 4.13) and the indole-capture step of 
intermediate 306 to give 304 (Scheme 4.17).    
 
 
 
 
 
Scheme 4.17  
                                               
4.6 Synthesis of the DKP precursor – The sulfenylation reaction  
Previous studies of the sulfenylation step in our group involved an extensive screening of different 
bases (LDA, LiHMDS, KHMDS, n-BuLi, NaH) but there was no examination about the time which 
the enolate was forming.
84b
 All attempts involved treatment of 217 with 1.0 to 2.5 eq of base at -78 
o
C 
and stirring at this temperature for a further hour before the electrophile was added (Scheme 4.18). We 
believed that the long enolate formation could be one of the possible reasons we could not obtain the 
desired 218. In order to investigate this possibility we decided to re-synthesize DKP 217 and optimise 
the condition in order to obtain the desired precursor 218. 
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Scheme 4.18      
Commercially available L-tryptophan 46 was doubly N-protected and subsequently coupled with 
enantiopure L-proline methyl ester to afford amide 308 (Scheme 4.19). Deprotection of the Boc group 
under acidic conditions, thermally induced cyclisation of the crude material followed by N-Boc 
protection gave the desired DKP 309. 
 
Scheme 4.19 
DKP 309 was treated with 1.1 eq of LiHMDS and the reaction mixture was left to stir at -78 
o
C for 1 h 
followed by addition of prenyl bromide in dry THF to furnish the corresponding prenylated DKP 
derivative 217 (Scheme 4.20). This highly stereoselective enolate substitution with overall retention at 
the proline α-centre led smoothly to formation of only one diastereoisomer 217. The alkylation 
proceeded with a high level of facial selectivity due to the pseudo-axial group located at C12 as 
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conformation A in Scheme 4.20 shows.
84b,104-105
 In the case of small R groups such as methyl this 
argument is less convincing. In that case, the steric shielding afforded by a small substituent in a 1,4- 
arrangement is not reasonable to explain the high stereoselectivity. In this case, conformation B seems 
reasonable due to the weak 1,2-torsional strain and it is possible the alkylation to occur from the top 
face as well-established work for various lactams enolates tend to react anti to the pyramidilised 
nitrogen lone pair.
106
    
Scheme 4.20  
With 217 in hand, we were about to investigate the optimum conditions of the sulfenylation step. 
Firstly, we examined whether we would be able to form the enolate of 217 and then report the 
optimum conditions. It was crucial to know how fast we could have full conversion of the starting 
material to the enolate form in order to obtain the desired product. Thus, solution of 217 in dry THF 
was prepared and 1.7 eq of LDA (1.0 M in hexane/THF) was added slowly at -78 
o
C (Scheme 4.21). 
After 5 min, 1 mL of the reaction solution was transferred via syringe to a dry flask containing 2 mL 
of d4-MeOD. The same procedure was repeated at 30 min, 1 h and 2 h after the addition of the base. 
Monitoring the reaction by TLC we observed an additional more polar spot in all of these batches. By 
NMR studies we were delighted to find that we had full incorporation of deuterium at C12, 5 minutes 
after addition of base and that the new spot we observed was due to formation of the deuterated-(C12)-
epimer 311.  
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Scheme 4.21  
Simpkins and Pichowicz showed that the stereoselective outcome on enolisation of DKPs could arise 
by hindrance of the convex face which is shielded by the prenyl group.
84b
 The resulting steric effects 
promote an anti-electrophilic approach to the prenyl group. It is worth to note that we were able to 
monitor the enolate formation by TLC analysis due to different Rf of 311 and compound 217. Having 
defined the optimum conditions for the enolate formation we were now poised to investigate the 
sulfenylation step in the synthesis of the important sulfide 218. Repeating the reaction under the same  
conditions, DKP 217 was treated with 1.4 eq of LDA (0.8 M in THF/hex) at -78
 o
C and the reaction 
mixture was left to stir at this temperature (Scheme 4.22). Monitoring the progress of the reaction by 
TLC after 10 min we observed full conversion to the epi-217 and then a solution of Ph2S2 in dry THF 
was added. After 30 min TLC monitoring showed no remaining epi-217 but instead a new spot 
appeared. Examination of the crude 
1
H NMR spectrum showed no starting material or its 
corresponding epimer and the compound was the desired sulfide. After purification and assignment we 
were delighted to report that the crucial precursor sulfide 218 was formed in 92% as a single 
diastereoisomer.      
     
Scheme 4.22 
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nOe studies showed a correlation between H2 with H15 and H17 and as a result we were able to 
establish the complete stereochemistry relative to the unchanged α-centre of the proline. We were 
subsequently able to grow crystals from MeOH and secure the relative configuration by X-ray 
crystallography. The structure shows clearly that the substitution of the SPh unit is anti to the prenyl 
group and on the more concave face to the bicyclic system. The crystal system of this compound was 
orthorhombic and it contained one molecule of methanol per DKP unit which forms a hydrogen bond 
(Figure 4.2). 
 
Figure 4.2 Crystal structure of sulfide 218 
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4.7 A new stereospecific alkylation – Sulfenylation reaction 
Before we examined the possible synthetic applications of sulfide 218 we were keen to investigate an 
stereoselective double enolate substitution reaction. Our proposal involved a stereospecific 
introduction of a prenyl unit to the proline α-centre (C6) controlled by the presence of the indole 
substituent (Scheme 4.23). This prenyl substituent could now control the geometry of the newly 
formed stereogenic centre at C12 if a second equivalent of base was added followed by Ph2S2. Indeed, 
addition of 1.1 eq of LDA (0.8 M) to a solution of 309 in dry THF, stirring for 10 min at -78
 o
C 
followed by addition of 1.0 eq of prenyl bromide showed a new spot on the TLC plate. The reaction 
mixture was stirred for 30 min before another 1.1 eq of LDA was added at -78
 o
C. After 10 min 2.5 eq 
of Ph2S2 was added and the mixture quenched and purified to obtain 218 as a single diastereoisomer. 
This method proved to be effective for giving concise access to sulfide 218 in less steps with control 
of the stereochemistry of the centres at C12 and C6 without using the Seebach protocol
107
 in our 
synthesis. 
 
Scheme 4.23 
 
4.8 The cationic cyclisation  
With 218 in hand, we were now ready to explore the cationic cascade cyclisation which could be 
initiated by addition of AgOTf as previously described (Scheme 4.17). We were hoping that the 
carbocation formed from the isoprene could be trapped by the indole unit to form the desired 
bicyclo[2.2.2]diazaoctane core ring system. Sulfide 218 was diluted in dry THF and then 1.5 eq of 
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AgOTf was added at -10
 o
C for 1 hour before the reaction was quenched. Surprisingly after 
purification we only isolated bridged DKP 299 (Scheme 4.24). The reaction was repeated with 4.0 eq 
of AgOTf and overnight stirring but in that case we obtained the Boc-deprotected derivative of 299. 
Finally we also attempted to increase the nucleophilicity at the position 3 of the indole by removing 
the Boc group and therefore increasing the possibility of a trapping by the indole moiety of the tertiary 
carbocation intermediate. Thus, treatment of sulfide 218 with potassium carbonate in a mixture of 
methanol and water afforded the unprotected indole derivative but our attempts at cyclisation failed to 
give the desired product. 
Scheme 4.24           
These results provided additional evidence which suggests that in the absence of acid this type of 
cationic reaction undergoes only the first cyclisation and leads into products such as 299 (Scheme 
4.24). When the reaction occurs under acidic conditions another molecule of acid is possible to trigger 
the second cyclisation and lead to double cyclised products such as 227 in Scheme 3.26. 
Following these results we turned our attention to a different approach driven by that fact that an S–C 
bond is relatively weak and reactive under radical conditions. 
 
4.9 The radical cascade cyclisation 
It is well known that a carbonyl group has a remarkable influence on the stability of an α-radical 
centre.
108
 Moreover, thiophenyl groups along with halides are commonly used to initiate radical 
reaction by homolytic cleavage using a free radical source.
109
 As there is a lot prior art in respect of 
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radical addition to indole substrates,
110
 sulfide 218 was a suitable substrate to undergo a radical 
cascade cyclisation in a parallel fashion to the cationic proposal. As Scheme 4.25 shows, a homolytic 
cleavage of the SPh unit could generate a captodative α-amide radical 312 which could cyclise in 6-
exo-trig fashion to generate a new tertiary radical centre 313.  
 
Scheme 4.25   
The new radical centre could take part in a second cyclisation onto the indole appendage via an 5-exo-
trig process to give 314 or via an 6-endo-trig to generate 315 (Scheme 4.26). It is well known that 5-
exo products are usually favoured over the thermodynamically more stable 6-endo due to the fact that 
5-exo-trig cyclisations are faster than 6-endo-trig cyclisation.59-60,61a,63 Both 314 and 315 are well 
stabilised radical species but we believed that the regioselective outcome would be driven by the 
extended aromatic conjugation of intermediate of 315 and the steric effects from the gem-dimethyl 
group of 314 during the reduction step so that indoline 316 would be the final product. 
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Scheme 4.26              
If our proposal proved viable then we would be able to demonstrate a completely new approach to 
access the desired bicyclo[2.2.2]diazaoctane core ring system in the absence of acids. This would be 
the first double radical cyclisation towards this type of natural products. It is worth mentioning that 
only Myers
46
 and Trost
53
 was able to demonstrate a radical approach towards the 
bicyclo[2.2.2]diazaoctane framework, although these approaches did not involve a cascade radical 
cyclisation.
46
 Moreover, Baran also attempted to access similar structures via radical cyclisation with 
no success.
47,77,79
 
With 218 in hand, we were now poised to secure experimental support for such a radical approach. 
Bu3SnH and ACCN were added via syringe pump over 5 h to a solution of 218 in toluene under reflux 
(Scheme 4.27). After completion of the addition, the reaction mixture was purified using flash column 
chromatography and we were delighted to isolate indolines epi-C4-316 and 316 in 1.0:4.6 ratio and 
combined yield 86%.   
      
 
94 
 
 
Scheme 4.27 
NMR studies of the major product 316 showed a characteristic doublet at 4.06 ppm with J value of 8.2 
Hz which was assigned to H15 (Figure 4.3). H14 appeared in the spectra as a multiplet at 3.36 ppm 
and finally H4 appeared as a doublet of doublet (coupling with H5) at 1.89 ppm and with J values of 
10.6 and 5.4 Hz.  
 
Figure 4.3 
1
H-NMR spectrum of indoline 316 
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nOE studies also showed that the 
major component was the syn product 
with the H4 facing down and on the 
same side as PMB group (Figure 4.4). 
The correct stereochemistry at C4 is 
very important as most natural products of this family possess this specific configuration at this centre.  
In indoline 316 hydrogen atoms H15, H14 and H4 are facing up and are anti to the PMB group.  
 
Figure 4.4 nOe spectrum of 316. nOE correlations of H15 with H14/H4 and H27 with H4              
In addition it is worth mentioning that we did not observe any of the possible spiro-products 317 
(Scheme 4.26) which could be formed via 5-exo-trig cyclisation. Thus, our initial proposal proved to 
be correct and a new synthetic tool was now available to access the bicyclo[2.2.2]diazaoctane core 
structure. 
Indolines H15 H14 H4 PMB 
epi-C4- 316 H14 H15 - - 
316 H14, H4 H15 H15 H4 
Table 4.2 nOe correlations of indolines 316 and epi-316            
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We also tried to confirm our assignment by X-ray crystallography but with no success in growing 
crystals. We were hopeful though, that the N-deprotected material 318 might furnish good quality 
crystals. For that reason indoline 316 was stirred overnight in formic acid and after purification we 
obtained indoline 318 (Scheme 4.28). 
Scheme 4.28          
When indoline 318 was diluted in MeOH, crystals started to form spontaneously. After 2 weeks of 
slow evaporation we were pleased to observe sizable and good quality crystals of the product which 
confirmed our assignment. X-ray crystallography showed that hydrogen atoms H4, H14, H15 being all 
syn to the PMB group (Figure 4.5). The crystal system of 318 was monoclinic and possessed two 
MeOH units per molecule. 
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Figure 4.5 Crystal structure of indoline 318         
We also tried to cleave the PMB group using standard methods for this function but with no success. 
For example indoline 318 on treatment with PTSA in toluene
111
 at reflux resulted only in degradation 
of the starting material. The same result was observed when TFA was added to 318 in anisole,
112
 
whereas CAN left starting material untouched.
113
 
4.10 The oxidative radical cyclisation reaction 
At this stage, we decided to investigate further other possible synthetic applications towards bridged 
DKPs. Taking advantage of the acidic nature of H12 we were now interested to attempt a direct 
generation of a radical centre via an oxidation of the corresponding enolate. As Scheme 4.29 shows, 
intermediate 217 was chosen as the starting material to explore this proposal. Treatment of 217 with 
base should deprotonate C12 to form enolate 319. Oxidation of the corresponding enolate would 
generate radical intermediate 312 followed by radical cyclisation to give 316. Unlike the previous 
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approaches, this alternative way to access the bridged DKPs avoids the need for installation of an 
initiating group in order to trigger the cyclisation reaction. 
 
Scheme 4.29 
There are numerous examples of oxidative dimerization reactions of enolates using mild oxidants. 
Most commonly, lithium enolates have been combined with different oxidants such as FeCl3, Cu(II) 
salts or I2,
114
 while other metal ions such as Na,
115
 K,
114h,114i
 Si,
116
 Ti
117
 or Sn
118
 have been used less 
frequently.  
After an examination of the literature we were now ready to try an oxidative radical cyclisation on 
DKP 217. One of the inherent difficulties with this chemistry was the in-soluble nature of the 
oxidising reagents in common organic solvents. Considering the sensitivity of an enolate solution to 
moisture, we tried to address this problem by connecting an addition funnel pre-charged with the 
oxidant inside, prior to the addition of the base. Compound 217 was treated with 1.4 eq of LDA at       
-78 
o
C and stirred for 10 min before 8.0 eq of copper dichloride were added portion-wise over the 
period of 10 min (Scheme 4.30). After completion of the addition the reaction colour remained green-
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blue. TLC analysis showed full conversion of the starting material to a more polar spot which was 
different to the expected indoline 316 (Scheme 4.29). After purification of the crude material we 
obtained the monocyclised product 299. 
 
Scheme 4.30 
This unexpected result could be explained by a further oxidation step of the radical intermediate 313 
which could lead to 306 due to the excess of oxidant (Scheme 4.31). According to our previous results 
we showed that the cationic cyclisation when carried out in the absence of acid terminates after the 
first cyclisation. Notably, this reaction fails when using Fe(acac)3 and ferricinium hexafluorophosphate 
oxidants which are known to give radicals from enolates.
77
    
Scheme 4.31 
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In order to address this problem we repeated the reaction with 1.2 equivalents of oxidant but 
unfortunately we were only able to obtain a mixture of epi-C12-217 and the bridged DKP 299 with no 
observation of the desired indoline (Scheme 4.32).  
 
Scheme 4.32 
4.11 An inter/intra-molecular radical attempt  
As we abandoned our efforts to achieve cascade cyclisation on DKP 217, we turned our attention to a 
different approach in order to generate intermediate 312 (Scheme 4.33). This proposal involved an 
intermolecular radical addition of an indole radical source such as 320 onto an exo-methylene DKP 
321. The corresponding intermediate 312 would be identical with the intermediate generated via the 
radical cyclisation (Scheme 4.26) or via oxidative radical cyclisation (Scheme 4.31). As Scheme 4.33 
shows intermediate cyclisation of 312 could lead to indoline products 316 via a double radical 
cyclisation forming three new C–C bonds and two new rings in one pot. Since many of these natural 
products only differ in the substitution on the indole ring the application of such an approach would 
allow the rapid synthesis of a variety of these natural products in a highly convergent fashion.  
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Scheme 4.33  
In order to demonstrate the feasibility of this proposal, exo-methylene DKP was first synthesised 
starting from methylester 322 as the hydrochloride salt (Scheme 4.34).
119
 Compound 322 was acylated 
with bromoacetyl bromide to give 324. Addition of methylamine
120
 to a solution of 324 in methanol 
afforded DKP 325, which was then treated with n-BuLi and formaldehyde to give the radical precursor 
326. Iodination or bromination steps starting from cheap and commercially available tryptophan led to 
iodoindole derivative 329 and bromoindole substrate 328, respectively. Both of the halo-indole 
compounds were tested in these radical cyclisation attempts. 
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Scheme 4.34 
With gram quantities of 326, 328 and 329 in hand, we were now poised to engage them in the 
intermolecular radical procedure. In our first attempt (entry 1, Table 4.3), 326 and 328 were charged 
into a two neck round bottom flask in degassed toluene and a solution of ACCN and Bu3SnH was 
added over 8 h via syringe pump. After completion of the addition and examination of the crude 
1
H 
NMR spectrum only reduction of the halide was observed. The reaction was performed at a higher 
concentration with faster addition of the initiator and tin reagent but unfortunately this gave no result 
other than reduction of starting material (entry 2, Table 4.3). Finally 326 and 329 were treated with 
bis(tributyltin) and exposed to UV light at 80 oC for several hours while fresh tin reagent was added 
every 2 h (entry 3, Table 4.3). Unfortunately we were unable to obtain any of the desired products 
apart from reduction of 329.   
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Table 4.3 Radical cyclisation of 326 
Having already delivered a new synthetic tool for the synthesis of the complex 
bicyclo[2.2.2]diazaoctane core it was now envisaged to apply these methodologies towards a synthesis 
of the stephacidin B model system.  
 
 
 sm 1 sm2 concentration 
of reaction 
mixture 
reagents addition time 
of reagents 
product 
entry 1 326 
 
328 0.35 M Bu3SnH/ACCN 
in toluene  
8 h (110 
o
C) recovery of 326 
and 328 
entry 2 326 328 0.60 M Bu3SnH/ACCN 
in toluene 
3 h (110 
o
C) reduction of 328 
entry 3 326 329 0.35 M (Bu3)2Sn2 in 
toluene   
every 2 h, UV 
light (80
 o
C)  
reduction of 329 
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Chapter 5 
Synthesis of indolines via radical cyclisation 
approach 
5.1 Stephacidins, avrainvillamide and aspergamide A 
Stephacidins (35), (39), avrainvillamide (36) and aspergamide A (38) are structurally related 
prenylated indole alkaloids at different oxidation states. As Figure 5.1 shows, stephacidin A (35) has 
the lowest oxidative state among this group of natural products and can deliver through sequential 
oxidation steps aspergamide A (38) and avrainvillamide (36) respectively. In the presence of a weak 
base or acid, avrainvillamide (36) can be dimerised to furnish the most advanced and structurally 
complicated alkaloid, stephacidin B (39). The unprecedented structural architecture of stephacidin B 
(39) has been the subject of intense synthetic endeavours by several groups. Herein we present the 
previous syntheses by other groups and our recent progress towards a stephacidin B model system. 
 
Figure 5.1 Oxidation state of stephacidins, aspergamide A and avrainvillamide 
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5.2 Previous syntheses of stephacidin B and avrainvillamide  
Avrainvillamide (36) was first isolated in 2000 by Fenical and co-workers from the Aspergillus 
strains
30
 and a year after by Sugie et al. who described it as CJ-17,665.7c Qian-Cutrone and co-workers 
in 2001 reported the isolation
31
 of stephacidin B (39) from the fungal species Aspergillus ochraceus 
WC76466 and a year later they unambiguously elucidated its structure by a combination of NMR 
spectroscopy and X-ray crystallography studies.
26
 Nussbaum et al. proposed that the biosynthetic 
pathway of stephacidin B (39) could involve a formal double 1,5-Michael addition sequence between 
the nitrone moieties and nearby amide nitrogen of avrainvillamide (36).
45a
 This not only implies that 
the vinyl nitrones could serve as unusual Michael acceptors in this system, but also that the 
dimerization might be reversible. To date, three distinct approaches
46-47,121
 have been reported using 
various strategies and synthetic manipulations. Later on it was shown that avrainvillamide (36) was in 
equilibrium with stephacidin B (39) in the presence of either Et3N, silica or even on slow evaporation 
in DMSO. Likewise a retrodimerisation could also occur when molecular sieves were added to a 
solution of 39 in d6-DMSO/CD3CN.
47
    
   
 
 
 
 
 
 
 
 
 
 
 
Scheme 5.1 
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First enantioselective total synthesis of (+)-stephacidin B 
In a conceptually different approach among all the other strategies for assembling the 
bicyclo[2.2.2]diazaoctane core ring system, Myers and Herzon suggested that the key disconnection 
could be an intramolecular radical cyclisation of an aminoacyl derivative (Figure 5.2).
46
 A Pd-
mediated Ullman-like cross coupling, followed by reduction of the corresponding nitroarene would 
enable access to the heptacyclic (-)-avrainvillamide (36).  
 
Figure 5.2 Key disconnections of avrainvillamide (36)                           
Starting from cyclohexanone derivative 331 (Scheme 5.2),
122
 the trimethylsilyl enol ether was 
generated and was then transformed into the corresponding α,β-unsaturated ketone. The ketone was 
reduced enantioselectively using the Corey-Bakshi-Shibata (CBS) catalytic protocol to give (R)-allylic 
alcohol in 95% ee and 96% yield. The introduction of the new stereocentre of 332 was crucial because 
this centre was subsequently relayed to all others within stephacidin B (39). However due to the fact 
that the absolute configuration of stephacidin B (39) and avrainvillamide (36) were not known at that 
time, it was decided to use the (S)-CBS catalyst in this synthesis. The next manipulations included 
formation of a silyl ether and ketal hydrolysis to give ketone 332, which was then treated with 
KHMDS and the corresponding enolate was alkylated with 333, to form the trans coupling product 
334 as a single diastereoisomer. Compound 334 was subjected to a Strecker-like addition of hydrorgen 
cyanide, an epimerization in the presence of base and pivalic acid and finally a transformation of the 
corresponding nitrile group, to give primary amide 335. After treatment with thiophenol and Et3N, 335 
underwent a conjugate Michael-type addition of the thiophenol group as well as cyclic hemiaminal 
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formation to afford tricyclic product 336. Dehydration of the cyclic hemiaminal 336, Boc cleavage 
followed by acylation of the pyrrolidine ring with 1-methyl-2,5-cyclohexadiene-1-carbonyl chloride 
337 furnished intermediate 300 and this set the stage for a radical-mediated elaboration of the DKP 
ring. 
   
 
 
 
 
 
 
 
 
 
 
Scheme 5.2 
As the key step, heating a solution of 300 and tert-amyl peroxybenzoate in tert-butyl benzene 
generated bridged DKP 302 (Scheme 5.3). This is formed via an amino-acyl radical intermediate 
which proceeds to attack the more substituted carbon of the enamide C–C double bond. 
Transformation of 302 into vinyl iodide 338 followed by an Ulmann-type coupling gave 340. Finally 
340 was subjected to a zinc-mediated reductive coupling to furnish (+)-avrainvillamide (36) (4.2% 
overall yield, 17-steps), which spontaneously dimerised to 39 during the purification step.    
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Scheme 5.3 
Enantioselective total synthesis of avrainvillamide and (-)-stephacidin B 
As has been already described in Chapter 3 (Scheme 3.4), Baran and co-workers were the first group 
to  report the enantioselective total synthesis of (-)-stephacidin A (35).
77
 Later on, Myers reported the 
first synthesis of (+)-avrainvillamide (36) and (-)-stephacidin B (39) and a few months later Baran’s 
group also reported their approach towards (+)-avrainvillamide (36) and (-)-stephacidin B (39).
47
 
 
Figure 5.3 Key disconnections of stephacidin A (35) 
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Chemoselective Gribble reduction
123
 of the indole C2–C3 π-bond of stephacidin A (35) led to a 
mixture of indolines 341, which was then oxidised to deliver (+)-avrainvillamide (36) (Scheme 5.4).
47
  
 
 
 
 
 
 
 
Scheme 5.4 
Asymmetric, stereocontrolled total synthesis of the stephacidins. 
In 2007, having already investigated biomimetic and enantioselective approaches to access several of 
the prenylated indole alkaloids, Williams reported an asymmetric synthesis of stephacidins and 
notoamide B (29).
121
 The key steps around which the synthesis was based involved an intramolecular 
SN2’ cyclisation reaction to generate the bridged DKP core and a Pd-mediated coupling to generate the 
heptacyclic structure (Figure 5.4).   
 
Figure 5.4 Key disconnections of stephacidin A (35) 
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As has been described in Chapter 3 (Scheme 3.11), (-)-stephacidin A (35) was synthesised in 6% over 
17 synthetic steps. Having in hand the enantiopure (-)-stephacidin A (35), Williams and co-worker 
applied Barans procedure to access (-)-avrainvillamide (36) and its epimer stephacidin B (39).  
 
 
 
Scheme 5.5 
 
5.3 Synthesis of the radical precursor  
As our initial attempts to remove the N-PMB group from indoline 318 (Scheme 4.28) failed, we 
decided to investigate the synthesis of a modified radical precursor possessing an easier to remove 
group on the amide. Moreover, this new approach should involve a protecting unit which could be 
easily removed under neutral or even mildly acidic conditions in order to deliver a suitable synthesis 
for acid sensitive substrates such as the stephacidins. It has been shown by others that amides in 
similar substrates could be reversibly masked as lactim ethers and hydrolysed under mild acidic 
solutions.
32,96,121
 In order to explore this scenario, DKP 345 was smoothly synthesised in three steps 
starting from commercially available Boc-L-Trp-OH (Scheme 5.6). Compounds 342 and 343 were 
subjected to peptide coupling in the presence of HATU and DIPEA to give amide 344. Deprotection 
of the Boc group under acidic conditions and then thermally induced cyclisation of the crude material 
gave the desired DKP 345 in 77% overall yield from Boc-L-Trp.   
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Scheme 5.6      
Compound 345 was then treated with Cs2CO3 and trimethyloxonium tetrafluoroborate in DCM to give 
a 1:1 mixture of 346 and epi-C12-346 (Scheme 5.7).102 Formation of the epimer at the C12 centre 
would not affect our strategy as both of the epimers would lead to the same diastereoisomer after the 
sulfenylation step. Nevertheless due to the low yield of the reaction we turn our attention in an 
alternative approach. 
Scheme 5.7   
Given the failure for the synthesis of 346 in a high yield an alternative synthetic plan (Scheme 5.8) 
was then drawn up which involved double N-Boc protection124 of both the secondary amide and indole 
nitrogen. Such an approach would provide the desired radical precursors in fewer synthetic steps and 
we also anticipate that the bulky Boc groups would control the stereoselectivity in the key step. DKP 
345 in the presence of TEA (1.5 eq), (Boc)2O (3.0 eq) and catalytic 4-DMAP gave the desired doubly 
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N-Boc protected derivative. This corresponding DKP was then treated with LDA under the standard 
conditions for the sulfenylation step and we obtained the radical precursor 347 in 5 steps and 52% 
overall yield starting from commercially available material.  
 
Scheme 5.8 
 
5.4 The radical cyclisation step 
The stage was now set for the critical radical cyclisation, which sets the relative stereochemistry at C4 
during formation of the bicyclo[2.2.2.]diazaoctane core skeleton. Based on the precedent from our 
indoline synthesis, 347 was treated with a solution of Bu3SnH (0.06M in toluene) and ACCN (0.01M 
in toluene) over 8 h, at 120 
o
C (Scheme 5.10). The crude material was purified and three new and 
more polar fractions were isolated. After purification we were able to obtain 348/349/350/351 in 
1.0:3.2:0.5:0.2 ratio and 79% total yield in which indolines 348 and 349 formed an inseparable 
mixture. NMR studies and mass spectrometry of the isolated compounds showed that all of the 
components were diastereoisomers of an indoline core. In theory four possible structures could be 
generated from this radical reaction. The diastereoisomers would share H4 anti or syn with respect to 
the N-Boc group on the bridged DKP core and H14 and H15 would be both anti or syn to H4. Unlike 
with the PMB series, the nOe studies of these products did not show a correlation between H4 and the 
Boc group of the amide. Molecular modelling showed that the molecule prefers a conformation that 
positions the tert-butyl group remote from the bridged DKP core and at a distance longer than 5 Å that 
      
 
113 
 
corresponds to the maximum distance for a nOe correlation. Unfortunately we also failed to grow 
crystals of these compounds and establish their complete configuration by X-ray. 
Scheme 5.10 
It had been demonstrated from previous work in our group that, nOe-correlation on the deprotected 
derivative between the amide NH and H4 was possible. With this in mind we proceeded to deprotect 
of these indoline derivatives under acidic conditions. The mixture of 348 and 349 was treated with 
formic acid to furnish the unprotected indolines 352 and 353 (Scheme 5.11). These compounds had an 
extremely similar Rf but we were able to separate them by preparative TLC purification. During 
subsequence NMR studies we faced several difficulties due to the low solubility of the compounds in 
NMR solvents and the dependency of the spectra on the concentration of the samples. nOe studies 
showed that for 352 the H4, H14 and H15 protons were placed on the same face but unfortunately we 
could not confirm the stereochemistry at C4 as the peak of the NH was broad and it did not shown 
correlations. nOe spectra for the minor indoline 353 were also low quality but we were able to confirm 
that H4 was anti to H14 and H15.  
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Scheme 5.11 
When each of the substances 352 and 353 were diluted in MeOH we were pleased to observe crystals 
of both of the indolines form after slow evaporation. The orthorhombic crystal system of structure 352 
clearly shows that the hydrogen atom H4 was placed on the same side as the NH and being syn to the 
hydrogen atoms H14 and H15 (Figure 5.5).  
 
 
Figure 5.5   Crystal structure of indoline 352 
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The crystal system of 353 was also orthorhombic with H4 anti to proline and NH amide and also to 
H14 and H15 (Figure 5.6). Moreover C8 was disordered over two positions at a refined occupancy 
ratio of 0.74 (1):0.26 (1). 
 
Figure 5.6    Crystal structure of indoline 353          
In the meantime we also analysed compounds 350 and 351 by nOe studies which showed that 350 had 
H4 anti to H14, H15 and 351 possessed H4 syn to H14, H15. Unfortunately in that case, nOe 
correlation between amide and H4 did not provide to us convincing information about the 
stereochemistry at C4. Having already assigned the cis 352 we could conclude that of 351 also had 
H4, H14 and H15 placed on the same side but anti to the amide. As a consequence our interest was 
now the assignment of indoline 350. Deprotection of substrate 350 was allowed by treatment with 
formic acid and after purification of the crude material by flash column chromatography we obtained 
indoline 354 in good yield (Scheme 5.12).  
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Scheme 5.12      
         
NMR studies shown, hydrogen atom H4 appeared at 2.47 ppm in the proton NMR spectra and H14 
and H15 were overlapping with H9a,b at 3.56 and 3.39 ppm respectively (Figure 5.7). Unlike with the 
previous indoline derivatives we did not observe any solubility problems with this sample. Moreover 
the signal for the NH peak of the amide was less broad this time with clear correlations in the nOe 
experiments. Upon studying the nOe spectra we were able to observe correlations between the amide 
NH and H4 and no signal between the protons H4 with H15 and H14 (Figure 5.8). 
 
 
Figure 5.7 
1H-NMR spectrum of indoline 354 
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Figure 5.8 nOe spectrum of indoline 354. nOe correlations of H15 with H14 and NH with H4     
 
As we were able to achieve a full assignment for compound 354 we could also report that the 
selectivity at the C4 centre for the radical cyclisation was 3:1. The lower selectivity at C4 from these 
results shows the effect of the Boc group. The conclusion to be drawn from the overall results is that 
PMB is the protective group which leads to highly selective cyclisations but there are difficulties in the 
process of deprotection.   
Baran’s group were the first which synthesised indolines 352/354 in 8 steps and 6% overall yield 
starting from 355.
79
 Baran et al. began with indole 355 (Scheme 5.13) which was coupled with a 
racemic mixture of proline derivative 356 to give an inseparable mixture of diastereomeric amides 357 
in 74% yield. Chemoselective Cbz-deprotection was then applied to the mixture followed by thermal 
cyclisation to furnish the corresponding DKP as 1:1 mixture of diastereoisomers and 87% total yield. 
The two diastereoisomers were then protected in separate steps to give 358 in 86% and 92% yield. 
Intramolecular oxidative heterocoupling of 358, N-MOM removal followed by a Grignard reaction 
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and dehydration of the corresponding alcohol gave 359. A second cyclisation which led to the 
hexacyclic core 352/354 then occurred by treatment with acid. Gribble reduction led cleanly to the 
indoline which was used in an oxidation step to give 360. 
 
Scheme 5.13 
Our approach to access indoline derivatives 352/354 occurs in 6 steps and with an overall yield of 
28%. The key step in our strategy was a cascade radical reaction in which the poly-substituted DKP 
347 underwent a double cyclisation to form two new rings of the final hexacyclic product in a 3:1 ratio 
with the major product possessing the desired configuration at C4.  
 
5.5 Summary and future work  
This work has highlighted the utility of a radical cyclisation strategy for assembling the 
bicyclo[2.2.2]diazaoctane framework. The final products and key precursors in a stephacidin B model 
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system, indolines 352/354, were previously synthesised by Baran
79
 et al. in 8 steps (6% overall yield) 
and delivered the hexacyclic core structure in two separate cyclisation steps.  
We were pleased to report a new synthetic way to access these valuable materials in only 6 steps and 
28% overall yield via a concise radical manipulation of poly-substituted DKP precursor 352/354. In 
our approach the final hexacyclic core structure arises from a cascade radical cyclisation which 
involves formation of two new C–C bonds and two new rings. According to our synthesis, oxidation 
of indolines 352/354 followed by dimerization would lead to the corresponding stephacidin B model 
system in only 8 steps. 
It is hoped that in similar fashion, avrainvillamide (36) and stephacidin B (39) could be synthesised 
via radical cyclisation of sulfide 361 (Scheme 5.14). Oxidation of the resulting indoline 341 will allow 
access to avrainvillamide (36) and via a dimerization to stephacidin B (39). 
          
Scheme 5.14 
Stephacidin B (39) has a unique structure with some intriguing biological activity and it has been a 
vibrant synthetic challenge for several groups. Other interesting targets in this family include 
prenylated alkaloids equipped with a spiro-oxindole motif such as marcfortine C (27), (+)-
versicolamide B (362), notoamides B (29) and N (31) (Figure 5.9).  
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Figure 5.9 Structures of the marcfortines, paraherquamides, notoamides and versicolamide B 
Intramolecular cyclisation of a DKP precursor (363) which is equipped with a substituted indole unit 
at the 2-position would possibly allow to the spiro-oxindole framework as Scheme 5.15 shows. This 
process could rely on either cationic or radical intermediates. The cationic pathway of this proposal 
suggests that the precursor 363 must possess, in addition to the hydroxyl group, an indole ring with a 
substituent like an iodine atom or O-silyl group at the 2-position. Thus, under acidic conditions or the 
established conditions with TMSOTf, 363 could generate a spiro-intermediate such as 367 which upon 
hydrolysis would give the desired spiro-oxindole core skeleton 366. Alternatively, if a thiophenyl 
group is introduced onto the O-silylated indole substrate 363 could initiate a radical cyclisation to 
furnish spiro-indoline 366 after removal of the silyl group.  
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Scheme 5.15 
Another desirable and interesting area for exploration lies on the rapid synthesis of the poly-
substituted DKP substrates such as 371 (Scheme 5.16). Acylation or aldol coupling are some of the 
possible approaches to access the DKP core of key precursors in a more efficient and direct fashion. 
Model system (372) of notoamide F could be synthesised by an aldol coupling of 369 and 370 
followed by cationic cyclisation and a deprotection step (Scheme 5.16). 
Scheme 5.16            
From DKP 373 it might also be possible to achieve a short access to indole nitrones derivatives like 
avrainvillamide such as 375 (Scheme 5.17). Cationic cyclisation of DKP 373 followed by subsequent 
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activation of the hydroxyl as a mesyl group would generate intermediate 374. Nucleophilic addition on 
the N-benzyloxy group of 374 would form the nitrone unit and will trigger the elimination of the 
mesyl group to give 375.  
Scheme 5.17  
It might also be possible to assemble core structures similar to notoamide I as indicated in Scheme 
5.18. Following the procedure described by Snider et al.,125 we believe that substrate 377 could be 
cyclised via a cationic/radical pathway to give notoamide I in one pot. Alternatively, installation of a 
thiophenyl function would possibly allow the cyclisation to proceed through radical intermediates.   
 
Scheme 5.18           
      
 
123 
 
Chapter 6 
Experimental 
6.1 General procedures  
All glassware was flame-dried under a steady flow of nitrogen or oven-dried at 100 ºC overnight 
before use and all reactions were performed under an atmosphere of nitrogen or argon unless 
otherwise stated. All other solvents and reagents were used as received from commercial suppliers 
unless otherwise stated. Pet. ether refers to the fraction boiling between 40 ºC and 60 ºC. Dry-purified 
solvents collected and transferred under Ar by a Pure Solv-MD Solvent Purification System (alumina 
columns) from Innovative Technology.
126
 Solvents and solutions for radical reactions were degassed 
before use by bubbling a steady stream of dry N2 gas through them for 45 minutes. Reaction progress 
was monitored by thin layer chromatography (TLC) performed on aluminium or plastic plates coated 
with kieselgel F254 with 0.2 mm thickness. Visualisation was achieved by a combination of ultraviolet 
light (254 nm) and ethanolic phosphomolybdic acid (PMA), acidic potassium permanganate or 
anisaldehyde. Flash column chromatography was performed using silica gel 60 (230-400 mesh, Merck 
and co.). All reaction temperatures refer to values recorded for an external bath and room temperature 
implies temperatures in the range 18-25 ºC.  
Solution infra-red spectra were recorded using a Perkin Elmer 100-series FTIR spectrometer using 
chloroform as solvent. Neat infra-red spectra were also recorded using a Perkin Elmer 100-series FTIR 
spectrometer. Wavelengths (ν) are reported in cm-1. Optical rotations were recorded as dilute solutions 
in the indicated solvent in a 25 mm glass cell using a JASCO DIP370 digital polarimeter at 294 nm. 
Mass spectra were obtained using a VG Micromass 70E or VG Micron Autospec spectrometer, using 
electrospray ionisation (ESI) with meta-nitrobenzyl alcohol as matrix. All 
1
H-NMR and 
13
C-NMR 
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experiments were recorded using Bruker AC300, AV300, AV400 and DMX500 NMR spectrometers. 
Chemical shifts (δ) are quoted in ppm and coupling constants (J) are quoted in Hz. The 7.27 ppm 
resonance of residual CHCl3 and 77.1 ppm resonance of CDCl3 were used as internal references, 
(MeOD signal as reference, 
1
H = 3.31 ppm, 
13
C = 49.0 ppm, benzene-d6 signal as reference, 
1
H = 7.16 
ppm, 
13
C = 49.0 ppm). The following abbreviations apply: (br) broad, (s) singlet, (d) doublet, (t) 
triplet, (q) quartet, (m) multiplet, (dd) double doublet, etc. The chemical shifts of multiplets 
corresponding to a single proton are quoted as a point, representing the centre of the multiplet. When 
signals for two or more protons overlap, a range is quoted. Required assignments were confirmed by 
two-dimensional homonuclear (
1
H-
1
H) and heteronuclear (
1
H-
13
C) correlation spectroscopy on a 
Bruker AV400 spectrometer. Single crystal data collection at room temperature and structural 
solutions were performed by Dr Louise Male at the University of Birmingham. Tetrahydrofuran (THF) 
was distilled immediately prior to use from sodium and benzophenone.  
 
6.2 Experimental 
 1,4-di(but-3-en-1-yl)piperazine-2,5-dione (S1) 
 
NaH (705 mg, 17.6 mmol, 2.2 equiv) as dispersion in mineral oil, was washed with Pet. ether (3 × 
5mL) and added to a round bottom flask along with DMF (15 mL). The mixture was cooled to 0 ºC, 
glycine anhydride 114 (934 mg, 8.2 mmol) was added and stirred for 30 min before 4-bromobut-1-ene 
115 (2.16 mL, 21.3 mmol, 2.6 equiv) was added dropwise. The reaction mixture was stirred for 5 h 
and then the excess NaH was quenched by careful addition of saturated NH4Claq solution (20 mL). The 
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mixture was separated and the aqueous phase was extracted with EtOAc (3 × 20 mL). The combined 
organic extracts were washed with a saturated solution of CaCl2aq (2 × 20 mL), water (20 mL) and 
brine (7 mL) and then dried over MgSO4 and evaporated under reduced pressure. The crude material 
was purified by flash column chromatography on silica gel (eluent: Pet. ether/EtOAc, 1:2) to give S1 
(1.56 g, 7.02 mmol, 80%) as a white solid.  
Rf: 0.32 (EtOAc/MeOH, 9:1); mp: 84-86 ºC; FTIR (ATR) νmax 1654, 1477, 1433, 1327, 1189, 1152, 
997, 914, 843, 776; 
1
H NMR (300 MHz, CDCl3) δ 5.76 (ddt, J 17.0, 10.1, 6.9, 2H, H2), 5.15 – 5.06 
(m, 4H, H1), 3.96 (s, 4H, H5), 3.47 (t, J 7.0, 4H, H4), 2.34 (q, J 7.0, 4H, H3) ppm;
 13
C NMR (75 MHz, 
CDCl3) δ 163.3 (C6), 134.2 (C2), 117.4 (C1), 50.0 (C5), 45.1 (C4), 31.1 (C3) ppm; HRMS (ESΙ) 
calculated for C12H18N2NaO2 [M+Na]
+
 245.1266, found 245.1269. 
 
 1,4-di(but-3-en-1-yl)-3-(phenylselanyl)piperazine-2,5-dione (108) 
 
LiHMDS (6.2 mL of 0.51 M solution in THF, 3.18 mmol, 1.2 equiv) was added to a solution of S1 
(590 mg, 2.65 mmol) in dry THF (12 mL) at -10 ºC. After the reaction mixture was stirred for 1 h, it 
was cooled to -78 ºC and a solution of PhSeCl (1.0 g, 5.3 mmol, 2.0 equiv) in dry THF (4 mL) was 
added. The mixture was then allowed to warm to rt and stirred for 5 h before being quenched with 
saturated NH4Claq (8 mL) and extracted with EtOAc (2 × 10 mL). The extracted organic layers were 
washed with brine (8 mL), dried over MgSO4 and the solvent was evaporated under reduced pressure. 
The crude material was purified by flash column chromatography on silica gel (eluent: Pet. 
ether/EtOAc, 12:1) to give 108 (652 mg, 1.72 mmol, 65%) as a yellow solid. 
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Rf: 0.35 (Pet. ether/EtOAc, 9:1); mp: 64-66ºC; FTIR (ATR) νmax 3071, 2924, 1655, 1461, 1437, 1302, 
1258, 1192, 1151, 1021, 998, 911, 794, 741, 672; 
1
H NMR (500 MHz, CDCl3) δ ppm 7.61 (dd, J 8.0, 
1.1, 2H, H14), 7.49 – 7.43 (m, 1H, H16), 7.33 – 7.30 (m, 2H, H15), 5.79 – 5.66 (m, 2H, H7, H11), 
5.20 (s, 1H, H1), 5.12 – 5.01 (m, 4H, H8, H12), 4.11 (ddd, J 13.9, 7.2, 7.1, 1H, H5a), 3.43 (d, J 15.0 
1H, H3a), 3.41 – 3.34 (m, 1H, H9a), 3.16 – 3.11 (m, 2H, H5b, H9b), 2.54 (d, J 15.0, 1H, H3b), 2.39 – 
2.35 (m, 2H, H6), 2.27 – 2.20 (m, 1H, H10a), 2.18 – 2.11 (m, 1H, H10b); 13C NMR (126 MHz, 
CDCl3) δ 164.0 (C4), 163.0 (C2), 138.0 (2 C14), 133.9 (C7), 133.9 (C11), 129.90 (C16), 128.9 (2 C-
15), 124.5 (C13), 117.5 (C8), 117.2 (C12), 60.1 (C1), 49.0 (C3), 45.5 (C9), 43.6 (C5), 31.0 (C6), 30.8 
(C10) ppm; HRMS (ESΙ) calculated for C18H22N2NaO2Se [M+Na]
+
 401.0744, found 401.0739. 
 
General procedure for radical cyclisation  
Fused DKP (116) and (117) 
In a two neck flask connected with a condenser, 1,4-di(but-3-enyl)-3-(phenylselenyl)piperazine-2,5-
dione (108) (110 mg, 0.29 mmol) was dissolved in degassed toluene (9.6 mL) under inert atmosphere. 
The mixture was warmed to reflux and solution of AIBN 0.003 M (4.7 mg, 0.029 mmol, 0.1 equiv) 
and Bu3SnH 0.036 M (94 μL, 0.35 mmol, 1.2 equiv) in degassed toluene were added over 8 h via 
syringe pump. After completion of the addition the mixture was allowed to cool to rt and the solvent 
was evaporated under reduced pressure. The crude material was purified by flash column 
      
 
127 
 
chromatography on silica gel (eluent: Pet. ether/EtOAc, 70/1) to give 116 (30 mg, 46%) as a 
colourless oil and 117 (15 mg, 24%) as a colourless oil.  
116: Rf: 0.4 (EtOAc/MeOH, 9:1); νmax (CHCl3)/cm
-1
 2971, 2935, 1650, 1464, 1329, 1184, 993, 914, 
732; 
1
H NMR (500 MHz, CDCl3) δ 5.75 (ddt, J 17.1, 10.2, 6.9, 1H, H11), 5.12 – 5.04 (m, 2H, H12), 
4.65 (dt, J 13.0, 2.5, 1H, H5a), 3.98 (d, J 17.5, 1H, H8a), 3.92 (d, J 17.5, 1H, H8b), 3.81 (d, J 11.5, 
1H, H1), 3.58 – 3.45 (m, 1H, H9a), 3.40 – 3.35 (m, 1H, H9b), 2.50 (td J 13.0, 2.5, 1H, H5b) 2.39 – 
2.29 (m, 3H, H10 + H2a), 2.00 – 1.97 (m, 1H, H3a), 1.72 – 1.70 (m, 1H, H4a), 1.55 (qt, J 13.0, 3.5, 
1H, H3b), 1.44 (qt, J 13.0, 3.5, 1H, H4b), 1.42 (qd, J 12.5, 3.5, 1H, H2b) ppm;
 13
C NMR (126 MHz, 
CDCl3) δ: 165.2 (CO), 161.6 (CO), 134.4 (C11), 117.5 (C12), 59.3 (C1), 49.4 (C8), 45.1 (C9), 42.4 
(C5), 31.4 (C2), 31.0 (C10), 24.5 (C4), 24.4 (C3); HRMS (ESΙ) calculated for C12H18N2NaO2 [M+Na]
+
 
245.1266, found 245.1268. 
117: Rf: 0.2 (EtOAc/MeOH, 9:1); νmax (CHCl3)/cm
-1
 3504, 2971, 2934, 1652, 1463, 1329, 1151, 915, 
731; 
1
H NMR (500 MHz, CDCl3) δ: 5.72 (ddt, J 17.1, 10.1 7.0, 1H, H11), 5.11 – 5.04 (m, 2H, H12), 
4.12 (d, J 4.5, 1H, H1), 4.08 (d, J 16.5, 1H, H8a), 3.86 (d, J 16.5, 1H, H8b), 3.74 (dt, J 11.0, 8.0, 1H, 
H5a), 3.57 (dt, J 13.5, 7.0, 1H, H9a), 3.50 (t, J 11.0, 1H, H5b), 3.40 (dt, J 13.5, 7.0, 1H, H9b), 2.77 – 
2.73 (m, 1H, H2), 2.33 (q, J 7.0, 2H, H10), 2.08 – 2.00 (m, 1H, H4a), 1.73 (dd, J 12.6, 8.0, 1H, H4b), 
0.90 (d, J 7.0, 3H, H3) ppm; 13C NMR (126 MHz, CDCl3) δ 165.3 (CO), 162.7 (CO), 134.5 (C11), 
117.5 (C12), 62.9 (C1), 51.4 (C8), 45.0 (C9), 43.2 (C5), 35.1 (C2), 31.4 (C10), 29.5 (C4), 13.6 (C3) 
ppm; HRMS (ESΙ) calculated for C12H18N2NaO2 [M+Na]
+
 245.1266, found 245.1268.  
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1-((3-bromobut-3-en-1-yl)sulfonyl)-4-methylbenzene (153) 
 
LiHMDS 1.0 M in THF (7.95 mL, 7.95 mmol, 1.2 equiv) was added slowly to a solution of 152 (1.0 g, 
6.62 mmol) in dry THF (30 mL) at -30 ºC. The reaction mixture was stirred for 30 min at -30 ºC and 
then solution of TsCl (1.6 g, 8.60 mmol, 1.3 equiv) in dry THF (4 mL) was added. After stirring for 20 
min. the ice-bath was removed and the reaction mixture was left to warm to rt and stirred for further 
20 min. To the mixture was added diethyl ether (30 mL) and the organic layer washed with saturated 
NH4Claq (20 mL) and brine (2 × 20 mL). The combined organic layers were dried over MgSO4, and 
concentrated. The crude material was purified by flash column chromatography on silica gel (eluent: 
Pet. ether/EtOAc, 20:1 to 5:1) to give 153 (2.0 g, 6.39 mmol, 96%) as a colourless oil.  
Rf: 0.58 (Pet. ether/EtOAc, 2:1); νmax (CHCl3)/cm
-1
 2929, 1631, 1597, 1356, 1174, 1145, 1096, 976, 
903, 814, 771; 
1H NMR (300 MHz,CDCl3) δ: 7.77 (d, J 8.0, 2H, H6), 7.33 (d, J 8.0, 2H, H7), 5.63 (s, 
1H, H1a) ppm 5.45 (s, 1H, H1b) 4.16 (t, J 6.0, 2H, H4) 2.72 (t, J 6.0, 2H, H3) 2.42 (s, 3H, H9) ppm; 
13
C NMR (75 MHz, CDCl3) δ: 145.0 (C8+C5), 132.7 (C2), 129.8 (2C7), 127.9 (2C6), 120.1 (C1) 67.2 
(C4), 40.7 (C3), 21.6 (C9) ppm; HRMS (ESΙ) calculated for C11H13BrNaO3 [M+Na]
+
 326.9666, found 
326.9665. 
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4-(3-bromobut-3-en-1-yl)piperazin-2-one (154) 
 
Potassium iodide (182 mg, 1.58 mmol) was added to a solution of 2-oxopiperazine 138 (315 mg, 3.15 
mmol, 2.0 equiv) and 153 (962 mg, 3.15 mmol, 2.0 equiv) in MeOH (7 mL) at rt. The reaction mixture 
was heated at 80 ºC and stirred for 48 h. After cooling the reaction mixture to rt the solvents were 
evaporated under reduced pressure and the crude material was purified by flash column 
chromatography on silica gel (EtOAc/MeOH, 1:0 to 8:2) to give 154 (340 mg, 46%) as an orange 
solid. 
Rf: 0.42 (EtOAc/MeOH, 8:2); mp: 95-97 ºC; νmax (CHCl3)/cm
-1
 3189, 3068, 2933, 2828, 1658, 1501, 
1419, 1358, 1326, 1161, 1105, 1010, 976, 896, 856; 
1
H NMR (300 MHz, CDCl3) δ 6.92 (s, 1H, NH), 
5.56 (s, 1H, H1a), 5.36 (s, 1H, H1b), 3.26 (s, 2H, H8), 3.08 (s, 2H, H5), 2.81 – 2.39 (m, 6H, H7, H4, 
H3); 
13
C NMR (75 MHz) δ 169.9 (C6), 131.5 (C2), 118.2 (C1), 56.7 (C7), 55.5 (C4), 49.0 (C5), 41.2 
(C3), 38.9 (C8); HRMS (ESΙ) calculated for C8H13N2ONaBr 255.0109, found [M+Na]
+
 255.0115. 
General procedure for amide N-Boc protection 
tert-butyl 4-(3-bromobut-3-en-1-yl)-2-oxopiperazine-1-carboxylate (140) 
 
(Boc)2O (457 mg, 2.1 mmol, 1.6 equiv), 4-DMAP (29 mg, 0.26 mmol, 0.2 equiv) were added to a 
solution of 154 (300 mg, 1.29 mmol) in THF (10 mL). The reaction mixture was stirred at rt for 5 h 
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and then diethyl ether (20 mL) was added. The mixture was washed with saturated NH4Claq (20 mL) 
and brine (1 × 10 mL) and the combined organic layers were dried over MgSO4, and concentrated. The 
crude material was purified by flash column chromatography on silica gel (eluent: EtOAc) to give 140 
(319 mg, 74%) as a yellow foam.  
Rf: 0.73 (EtOAc/MeOH, 8:2); vmax (CHCl3)/cm
-1
 2980, 2930, 1736, 1464, 1368, 1294, 1198, 1151, 
1024, 910, 776; 
1
H NMR (400 MHz, CDCl3) δ 5.52 (d, J 1.8, 1H, H1a), 5.43 (d, J 1.8, 1H, H1b), 3.67 
– 3.62 (m, 2H, H8), 3.24 (s, 2H, H5), 2.72 – 2.68 (m, 2H, H7), 2.62 – 2.56 (m, 4H, H4, H3), 1.40 (s, 
9H, H11); 
13
C NMR (75 MHz, CDCl3) δ 167.3 (C6), 151.6 (C9), 131.3 (C2), 118.2 (C1), 83.4 (C10), 
59.1 (C5), 55.1 (C4), 49.7 (C7), 45.6 (C8), 38.8 (C3), 28.0 (C11); HRMS (ESΙ) calculated for 
C13H21N2O3NaBr [M+Na]
+
 355.0633, found 355.0640.    
 
monoketopiperazines (155) and (156) 
 
The general procedure for radical cyclisation of ketopiperazines (page 126) was followed using 140 
(74 mg, 0.22 mmol) in 8 mL degassed toluene, 0.009 M AIBN (10 mg, 0.07 mmol, 0.3 equiv), 0.033 
M Bu3SnH (67 μL, 0.26 mmol, 1.8 equiv). AIBN and Bu3SnH were added over 8 h via syringe pump 
to a solution of 140 at reflux. The crude material was purified by flash column chromatography on 
silica gel (eluent: Pet. ether/EtOAc, 5:1 to 1:1) to give 155 (38 mg, 68%) as a colourless oil and 156 (4 
mg, 7%) as a colourless oil.  
155: Rf: 0.2 (Pet. ether/EtOAc, 2:1); vmax (CHCl3)/cm
-1
 2933, 1762, 1656, 1460, 1327, 1145, 1106, 
896, 850; 
1
H NMR (500 MHz, CDCl3) δ: 3.75 – 3.59 (m, 2H, H4), 2.97 – 2.83 (m, 2H, H11a, H5a), 
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2.53 (dd, J 11.0, 2.5, 1H, H7), 2.45 (td, J 12.0, 4.5, 1H, H5b), 2.33 (brd, J 13.0, 1H, H8a), 2.07 (td, J 
11.5, 3.0, 1H, H11b), 1.86 (brd, J 13.0, 1H, H9a), 1.65 – 15.9 (m, 1H, H10a), 1.60 – 1.52 (m, 1H, 
H10b), 1.53 (s, 9H, H1), 1.43 (qd, J 13.0, 3.5, 1H, H8b), 1.34 – 1.24 (m, 1H, H9b) ppm: 13C NMR 
(126 MHz, CDCl3) δ: 169.4 (C6), 152.3 (C3), 83.0 (C2), 67.6 (C7), 56.0 (C11), 51.5 (C5), 45.3 (C4), 
28.0 (C1), 27.7 (C8), 25.0 (C10), 24.3 (C9); HRMS (ESΙ) calculated for C13H2N22NaO3 [M+Na]
+
 
277.1528, found 277.1522.  
156: Rf: 0.12 (Pet. ether/EtOAc, 1:2); vmax (CHCl3)/cm
-1
 2983, 2920, 2850, 1719, 1469, 1293, 1151, 
1025, 911, 851, 751; traces - not enough for NMR assignment; HRMS (ESΙ) calculated for 
C13H2N22NaO3 [M+Na]
+
 277.1528, found 277.1520. 
 
but-3-yn-1-yl 4-methylbenzenesulfonate (173)
127
  
 
n-BuLi (4.6 mL, 2.5 M in hexane, 11.2 mmol, 2.0 equiv) was added slowly to a solution of but-3-yn-
1-ol S2 (0.5 mL, 5.75 mmol) in dry THF (12 mL) at 0 ºC. The reaction mixture was stirred for 30 min 
at 0 ºC and then solution of TsCl (2.84 g, 17.2 mmol, 3.0 equiv) in dry THF (4 mL) was added. After 
stirring for 5 min the ice-bath was removed and the reaction mixture was left to warm to rt and stirred 
for further 4 h. To the mixture diethyl ether (15 mL) was added and the organic layer washed with 
saturated NH4Claq (2 × 6 mL) and brine (2 × 6 mL). The combined organic layers were dried over 
MgSO4, and concentrated. The crude material was purified by flash column chromatography on silica 
gel (eluent: Pet. ether/EtOAc, 15:1 to 5:1) to give 173 (2.44 g, 10.9 mmol, 94%) as a colourless oil;  
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Rf: 0.68 (Pet. ether/EtOAc, 1:1); 1H NMR (300 MHz,CDCl3) δ: 7.81 (d, J 8.2, 2H, H6), 7.34 (brd, J 
8.2, 2H, H7), 4.11 (t, J 7.0, 2H, H4), 2.56 (t, J 7.0, 2H, H3), 2.46 (s, 3H, H9), 1.98 (t, J 3.0, 1H, H1) 
ppm; 
13
C NMR (75 MHz, CDCl3) δ: 145.2 (C5), 132.9 (C8), 130.1 (2C7), 128.2 (2C6), 78.6 (C2), 71.0 
(C1), 67.6 (C4), 21.8 (C9), 19.6 (C3) ppm; HRMS (ESΙ) calculated for C11H12NaO3S [M+Na]
+
 
247.0405, found 247.0409. 
 
ethyl 2-(but-3-yn-1-ylamino)acetate (174) 
 
KI (904 mg, 5.6 mmol, 0.2 equiv) and Et3N (3.4 mL, 24.5 mmol, 0.6 equiv) were added to a solution 
of glycine ethyl ester hydrochloride 172 (5.2 g, 37.6 mmol) in EtOH (80 mL) and a white suspension 
was observed. After 5 min, but-3-ynyl 4-methylbenzenesulfonate 173 (4.22 g, 56.4 mmol, 1.5 equiv) 
was added slowly and the reaction mixture stirred at 80 ºC overnight. To the mixture EtOAc, diethyl 
ether 8:2 (30 mL) were added and the mixture was extracted with saturated NH4Claq (2 × 20 mL) and 
brine (2 × 20 mL). The aqueous phase was extracted with EtOAc, diethyl ether 8:2 (2 × 20 mL). The 
combined organic layers were dried over MgSO4, and concentrated. The crude material was purified 
by flash column chromatography on silica gel (eluent: Pet. ether/EtOAc, 2:1 to 0:1) to give 174 (954 
mg, 6.15 mmol, 33%) as a yellow oil.  
Rf: 0.14 (Pet. ether/EtOAc, 2:1); vmax (CHCl3)/cm
-1
 3292, 2982, 2914, 2843, 1733, 1467, 1372, 1185, 
1147, 1026, 762; 
1
H NMR (300 MHz, CDCl3) δ 4.00 (q, J 7.1, 2H, H7), 3.24 (s, 2H, H5), 2.60 (t, J 
6.7, 2H, H4), 2.19 (td, J 6.7, 2.6, 2H, H3), 1.84 (t, J 2.6, 1H, H1), 1.67 (s, 1H, NH), 1.08 (t, J 7.1, 3H, 
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H8); 
13
C NMR (101 MHz, CDCl3) δ 172.0 (C6), 82.0 (C2), 69.4 (C1), 60.6 (C7), 50.5 (C5), 47.6 (C4), 
19.6 (C3), 14.1 (C8); HRMS (EΙ) calculated for C8H13NO2 [M]
+
 155.0946, found 155.0949, m/z (EI) 
155 (7) [CH3CH2COCH2NH CH2CH2CCH]
+
, 116 (94) [CH3CH2COCH2NHCH2]
+
, 88 (6) 
[CH3CH2COCH2]
+
,
 
82 (100) [CH2NHCH2CH2CCH]
+
. 
 
ethyl 2-(N-(but-3-yn-1-yl)-2-((tert-butoxycarbonyl)amino)acetamido)acetate (175) 
 
To a round bottom flask Boc-Gly-OH (1.18 g, 6.76 mmol, 1.1 equiv), and ethyl 2-(but-3-ynylamino) 
acetate 174 (954 mg, 6.15 mmol) were dissolved in DCM (40 mL). To the mixture was then added 
NMM (743 μL, 6.76 mmol, 1.1 equiv) and solution DCC (6.15 mL, of 1.0 M in DCM, 6.15 mmol). A 
precipitate formed within minutes and the reaction mixture was stirred at rt. After 3 h the solids were 
filtered off and washed with DCM (20 mL). The filtrate solution was then evaporated to dryness. The 
crude was purified by flash column chromatography on silica gel (eluent: Pet. ether/EtOAc, 1:1) to 
give 175 (1.53 g, 80%) as a pale yellow oil. The compound was obtained as an inseparable mixture 
(1.0:1.5*) of rotamers. 
Rf: 0.4 (Pet. ether/EtOAc, 1:1); vmax (CHCl3)/cm
-1
 3427, 3302, 2979, 2935, 1743, 1708, 1657, 1461, 
1366, 1200, 1161, 1027, 961, 918, 964, 731; 
1
H NMR (400 MHz, CDCl3) δ 5.35 (s, 1H, NH), 5.33 (s, 
1H, NH*), 4.16 – 4.05 (m, 4H, H12, H12*), 4.05 – 3.99 (m, 6H, H5, H5*, H8*), 3.79 (d, J 4.3, 2H, 
H8), 3.46 (t, J 6.7, 2H, H4), 3.41 (t, J 6.7, 2H, H4*), 2.44 – 2.32 (m, 4H, H3, H3*), 1.96 (t, J 2.6, 1H, 
H1*), 1.89 (t, J 2.6, 1H, H1), 1.34 (s, 18H, H11, H11*), 1.19 (dt, J 8.3, 7.2, 6H, H13, H13*); 13C 
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NMR (101 MHz, CDCl3) δ 169.3 (2CO), 168.9 (2CO), 168.7 (2CO), 81.7 (C2), 80.11 (C2*), 79.8 
(C10, C10*), 71.4 (C1*), 70.2 (C1), 62.0 (C12), 61.5 (C12*), 50.0 (C5), 48.0 (C5*), 47.2 (C4), 46.6 
(C4*), 42.2 (C8, C8*), 28.41 (3C11, 3C11*), 18.8 (C3*), 17.8 (C3), 14.2 (C13, C13*); HRMS (ESΙ) 
calculated for C15H24NaN2O5 [M+Na]
+ 
335.1583, found 335.1579. 
 
1-(but-3-yn-1-yl)piperazine-2,5-dione (177)  
 
Deprotection: TFA (5.46 mL, 73.8 mmol, 15.0 equiv) was added to a solution of ethyl 2-(N-(but-3-
ynyl)-2-(tert-butoxycarbonylamino)acetamido)acetate 175 (1.5 g, 4.92 mmol) in DCM (30 mL) and 
stirred for 1.5 h. The reaction mixture was washed with a saturated NH4Claq solution (20 mL) and 
brine (20 mL), dried over MgSO4 and concentrated. The deprotected amide was confirmed by HRMS 
(ESΙ) calculated for C10H17N2O3 213.1239, found [M]
+
:213.1233. Rf: 0.23 (EtOAc/MeOH 9/1). The 
crude was carried through to the next step without any purification; Intramolecular cyclization: The 
crude material 176 (937 mg, 4.42 mmol) was diluted in EtOH (30 mL) and K2CO3 (4.80 g, 35.3 mmol, 
8.0 equiv) was added and stirred overnight at 90 ºC. The crude was filtrated and purified by flash 
column chromatography on silica gel (eluent with EtOAc/MeOH, 15:1) to give 177 (513 mg, 3.1 
mmol in 63% overall yield) as a white solid. 
 Rf: 0.23 (EtOAc/MeOH, 9:1); mp: 77-79 ºC; vmax (CHCl3)/cm
-1
 1669, 1575, 1430, 1203, 1173, 1119, 
834, 801, 721; 
1H NMR (300 MHz, MeOD) δ 4.89 (s, 1H, NH), 4.14 (s, 2H, H5), 3.96 (s, 2H, H8), 
3.55 (t, J 6.9, 2H, H4), 2.51 (td, J 6.9, 2.7, 2H, H3), 2.36 (t, J 2.7, 1H, H1); 13C NMR (101 MHz, 
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MeOD) δ 168.3 (C6), 166.6 (C7), 81.8 (C2), 71.5 (C1), 51.4 (C5), 46.5 (C4), 45.6 (C8), 17.5 (C3); 
HRMS (EΙ) calculated for C8H10N2O2 [M]
+ 
166.0742 , found 166.0737. 
tert-butyl 4-(but-3-yn-1-yl)-2,5-dioxopiperazine-1-carboxylate (169) 
 
The general procedure of amide N-protection (page 129) was followed using 1-(but-3-ynyl)piperazine-
2,5-dione 177 (257 mg, 1.55 mmol), Et3N (0.32 mL, 2.3mmol, 1.5 equiv), (Boc)2O (501 mg, 2.3 
mmol, 1.5 equiv) and 4-DMAP (52 mg, 0.46 mmol, 0.3 equiv) in DCM (9 mL) The mixture was 
stirred for 1 h at reflux. The crude material was purified by flash column chromatography on silica gel 
(eluent: Pet. ether/EtOAc, 3:1 to 1:2) to give 169 (360 mg, 1.35 mmol, 87%) as a white foam.  
Rf: 0.6 (EtOAc/MeOH, 9:1); vmax (CHCl3)/cm
-1
 1677, 1523, 1487, 1209, 1153, 1123, 839, 808, 731;  
1
H NMR (300 MHz, CDCl3) δ: 4.17 (s, 2H, H5), 4.06 (s, 2H, H8), 3.40 (t, J 6.6, 2H, H4), 2.34 (td, J 
6.6, 2.6, 2H, H3), 1.95 (t, J 2.6, 1H, H1), 1.37 (s, 9H, H11) ppm; 13C NMR (101 MHz, CDCl3) δ: 
164.5 (C7), 164.3 (C6), 149.6 (C9), 84.4 (C10), 80.8 (C2), 70.9 (C1), 52.8 (C5), 48.1 (C4), 44.9 (C8), 
27.8 (3C11), 17.3 (C3); HRMS (ESΙ) calculated for C13H18N2NaO4 [M+Na]
+
 289.1164, found 
289.1154. 
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diketopiperazines (170) and (178) 
 
To a refluxing solution of 169 (70 mg, 0.26 mmol) in degassed toluene (30 mL) under inert 
atmosphere 0.11 M AIBN in toluene (54 mg, 0.34 mmol, 1.3 equiv) and 0.11 M PhSH in toluene (35 
μL, 0.34 mmol, 1.3 equiv) were added via syringe pump over 3 h. After completion of the reaction the 
mixture was allowed to cool to rt then concentrated and purified by flash column chromatography on 
silica gel (eluent: Pet. ether/EtOAc, 10:1 to 0:1) to give first 178 (45 mg, 0.12 mmol, 43%) as a 
colourless oil and then 170 (15 mg, 0.04 mmol, 27%) as a colourless oil. Compound 178 was obtained 
as 1.5:1.0 Z/E* inseparable mixture of isomers. 
178: Rf: 0.30 (Pet. ether/EtOAc, 1:2); vmax (CHCl3)/cm
-1
: 2980, 2933, 1777, 1725, 1725, 1668, 1583, 
1479, 1440, 1368, 1292, 1246, 1147, 970, 853, 742, 691; 
1
H NMR (300 MHz, CDCl3) δ: 7.34 – 7.30 
(m, 10H, Ar(E), Ar(Z)), 6.33 (d, J 9.3, 1H, H11*), 6.25 (d, J 15.0, 1H, H11), 5.82 – 5.72 (m, 2H, 
H10*, H10), 4.32 (s, 2H, H4), 4.31 (s, 2H, H4*), 4.10 (s, 2H, H7*), 4.01 (s, 2H, H7), 3.54 (t, J 6.9, 
2H, H8*), 3.47 (t, J 7.2, 2H, H8), 2.53 (q, J 6.9, 2H, H9*), 2.42 (q, J 7.2, 2H, H9), 1.53 (s, 9H, H1), 
1.52 (s, 9H, H1*) ppm; 
13
C NMR (101 MHz, CDCl3) δ 164.6 (CO, CO*), 164.4 (CO, CO*), 149.8 
(NCO, NCO*), 135.4 (C12), 134.4 (C12*), 129.9 (11), 129.5 (11*), 129.2 (2C13, 2C13*), 129.2 
(2C14, 2C14*), 127.7 (C10*), 127.0 (C10), 126.8 (C15), 126.0 (C15*), 85.0 (C2*), 84.9 (C2), 52.2 
(C7), 52.2 (C7*), 48.4 (C4), 48.3 (C4*), 45.6 (C8*), 45.1 (C8), 30.9 (C9*), 28.0 (C(CH3), C(CH3)*), 
27.3 (C9). HRMS (ESΙ) calculated for C19H24N2NaO4S [M+Na]
+
 399.1354, found 399.1350. 
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170: Rf: 0.22 (Pet. ether/EtOAc, 1:2); vmax (CHCl3)/cm
-1
 2979, 2928, 1776, 1726, 1675, 1480, 1440, 
1368, 1295, 1149, 850, 744, 692; 
1
H NMR (400 MHz, CDCl3) δ 7.41 (d, J 8.0, 2H, H13), 7.30 (t, J 
7.7, 2H, H14), 7.19 (t, J 7.3, 1H, H15), 4.64 (d, J 16.5, 1H, H4a), 4.06 (d, J 16.5, 1H, H4b), 4.00 (d, J 
9.0, 1H, H7), 3.74 – 3.60 (m, 2H, 8a, 11a), 3.43 (dd, J 18.8, 10.3, 1H, H8b), 3.03 (dd, J 13.4, 8.4, 1H, 
H11b), 2.95 – 2.75 (m, 1H, H10), 2.32 – 2.26 (m, 1H, H9a), 1.82 (dt, J 20.3, 10.3, 1H, H9b), 1.55 (s, 
9H, H1); 
13
C NMR (101 MHz, CDCl3) δ 167.4 (C5), 163.3 (C6), 149.9 (C3), 135.7 (C12), 129.2 
(2C13), 129.0 (2C14), 126.3 (C15), 84.9 (C2), 62.7 (C7), 49.7 (C4), 43.8 (C8), 41.7 (C10), 36.0 
(C11), 28.8 (C9), 28.0 (3C1); HRMS (ESΙ) calculated for C19H24N2NaO4S [M+Na]
+
 399.1354, found 
399.1347. 
 
4-(but-3-yn-1-yl)piperazin-2-one (179). 
 
The general procedure of amide N-alylation (page 129) was followed using 2-oxopiperazine 138 (50 
mg, 0.5 mmol), but-3-ynyl 4-methylbenzenesulfonate 179 (112 mg, 0.5 mmol) and potassium iodide 
(6.4 mg, 0.04 mmol, 0.1 equiv) in MeOH (2 mL). The reaction mixture was stirred at 80 ºC for 8 h and 
then the mixture was allowed to cool to rt, was concentrated under reduced pressure and purified by 
flash column chromatography on silica gel (EtOAc/MeOH, 1:0 to 8:2) to give 179 (41 mg, 53%) as a 
yellow solid. 
Rf: 0.42 (EtOAc/MeOH, 8:2); mp: 100-102 ºC; vmax (CHCl3)/cm
-1
 3406, 3237, 2950, 2824, 1644, 
1498, 1462, 1351, 1087, 1008; 
1
H NMR (300 MHz, CDCl3) δ 7.67 (s, 1H, NH), 3.32 (brs, 2H, H8), 
3.2 (s, 2H, H5), 2.67 (t, J 5.4, 2H, H7), 2.62 (t, J 7.2, 2H, H4), 2.37 (td, J 7.2, 2.4, 2H, H3), 1.98 (t, J 
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2.4, 1H, H1) ppm;
 13
C NMR (75 MHz, CDCl3) δ 170.5 (C6), 82.0 (C2), 69.5 (C1), 56.5 (C4), 55.6 
(C8), 48.5 (C5), 40.8 (C7), 16.9 (C3) ppm; HRMS (ESΙ) calculated for C8H12N2NaO [M+Na]
+
 
175.0847, found 175.0842. 
 
tert-butyl 4-(but-3-yn-1-yl)-2-oxopiperazine-1-carboxylate (180) 
 
The general procedure (page 129) was followed using 179 (41 mg, 0.27 mmol), (Boc)2O (100 mg, 0.5 
mmol, 1.8 equiv), 4-DMAP (30 mg, 0.27 mmol) in DCM (2 mL) and stirred for 5 h at rt. The crude 
material was purified by chromatography on silica gel (eluent: EtOAc) to give 180 (0.05 g, 0.19 mmol, 
75%) as a white foam. 
Rf: 0.73 (EtOAc/MeOH, 8:2); vmax (CHCl3)/cm
-1
 3265, 3004, 2970, 2947, 1737, 1455, 1367, 1288, 
1229, 1146, 848, 778, 628; 
1
H NMR (300 MHz, CDCl3) δ 3.71 – 3.65 (m, 2H, H8), 3.27 (s, 2H, H5), 
2.77 – 2.71 (m, 2H, H7), 2.60 (t, J 7.3, 2H, H4), 2.37 (td, J 7.3, 2.6, 2H, H3), 1.99 (t, J 2.6, 1H, H1), 
1.45 (s, 9H, H11) ppm;
 13
C NMR (75 MHz, CDCl3) δ 167.0 (C6), 151.5 (C9), 83.2 (C10), 81.7 (C2), 
69.5 (C1), 58.8 (C4), 55.2 (C8), 49.3 (C5), 45.4 (C7), 27.8 (3C11), 16.8 (C3) ppm; HRMS (ESΙ) 
calculated for [M+Na]
+
 C13H20N2O3Na 275.1372, found 275.1365. 
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tert-butyl 8a-(2-cyanopropan-2-yl)-1-oxo-8-(phenylthiomethyl)-hexahydropyrrolo[1,2-
a]pyrazine-2(1H)-carboxylate (181) 
 
 
 
To a refluxing solution of 180 (53 mg, 0.21 mmol) in degassed toluene (20 mL) and under an inert 
atmosphere solution of 0.42 M AIBN (68 mg, 0.42 mmol, 2.0 equiv) and PhSH 0.42 M (43 μL, 0.42 
mmol, 2.0 equiv) in degassed toluene were added via syringe pump over 16 h. The crude material was 
allowed to cool to rt and then it was concentrated and purified by HPLC to give 181 (18 mg, 20%) as a 
colourless oil.  
Rf: 0.55 (Pet. ether/EtOAc, 1:1); vmax (CHCl3)/cm
-1
 2977, 2929, 2874, 2200, 2180, 1768, 1725, 1370, 
1288, 1257, 1212, 1150, 747; 
1
H-NMR (500 MHz, CDCl3) δ: 7.37 (d, J 7.9, 2H, H10), 7.28 (t, J 7.7, 
2H, H11), 7.19 (t, J 7.4, 1H, H12), 3.80 (dt, J 6.0, 3.5, 1H, H2a), 3.73 (td, J 11.5, 3.5, 1H, H2b), 3.50 
(dd, J 12.6, 3.0, 1H, H8a), 3.30 (ddd, J 11.5, 8.5, 6.5, 1H, H7a), 3.18 (ddd, J 15.0, 11.5, 3.5, 1H, H3a 
), 3.09 – 3.01 (m, 2H, H3b, H7b), 2.82 – 2.76 (m, 1H, H5a), 2.64 (t, J 12.6, 1H, H8b), 2.31 (td, J 12.6, 
6.5, 3.02, 1H, H6a), 1.82 – 1.74 (m, 1H, H6b), 1.51 (s, 9H, H19), 1.47 (s, 3H, H15), 1.46 (s, 3H, H14) 
ppm; 
13
C NMR (126 MHz, CDCl3) δ: 171.0 (C1), 152.0 (C17), 135.4 (C9), 129.5 (2C10), 129.0 
(2C11), 126.4 (C12), 125.0 (C16), 83.9 (C18), 78.1 (C4), 53.1 (C7), 49.1 (C3), 48.6 (C5), 44.2 (C2), 
43.0 (C13), 36.2 (C8), 32.8 (C6) 28.0 (3C19), 24.3 (C15), 23.8 (C14); HRMS (ESΙ) calculated for 
C23H31N3NaO3S [M+Na]
+
 452.1984 found 452.1982.   
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tert-butyl 6-bromo-3-formyl-1H-indole-1-carboxylate (244) 
 
Formylation: POCl3 (1.7 mL, 3.06 mmol, 1.1 equiv) was added to dry DMF (25 mL) dropwise at       
0 ºC. The solution was stirred for 20 min before a solution of 6-bromoindole 243 (2.88 g, 14.7 mmol) 
in dry DMF (20 mL) was added dropwise and the reaction mixture was allowed to warm to rt. After    
1 h the mixture was cooled to 0 ºC and a solution of sodium hydroxide 4.0 M was added until the        
pH ≈ 7.8. The reaction mixture was allowed to warm to room temperature and stirred for another 1.5 h 
before water (100 mL) was added and the aqueous phase was extracted with EtOAc (3 × 50 mL). The 
combined organic extracts were washed with brine (3 × 50 mL), dried (MgSO4) and concentrated 
under reduced pressure. The crude 6-bromo-1H-indole-3-carbaldehyde intermediate was used directly 
in the next step without additional purification. Protection: 6-bromo-1H-indole-3-carbaldehyde (2.58 
g, 11.5 mmol) was dissolved in THF (60 mL) and Boc2O (3.27 g, 15.0 mmol, 1.3 equiv) and 4-DMAP 
(281 mg 2.30 mmol, 0.2 equiv) were added at room temperature. The resulting mixture was stirred at 
room temperature for 1.5 h and the solvent was evaporated under reduced pressure. The residue was 
purified by flash column chromatography on silica gel (Pet. ether/EtOAc, 9:1) to give N-Boc formyl 
indole 244 (3.57 g, 84% over 2 steps) as a white solid.  
Rf: 0.45 (Pet. ether/EtOAc, 2:1); mp: 144-145 ºC FTIR (ATR) vmax 1735, 1670, 1549, 1391, 1374, 
1346, 1309, 1164, 1136, 1102, 841, 818, 802, 762; 
1
H NMR (400 MHz, CDCl3) 
1
H NMR (300 MHz, 
CDCl3) δ 10.01 (s, 1H, H12), 8.29 (d, J 1.5 Hz, 1H, H7), 8.13 (s, 1H, H1), 8.06 (d, J 8.4 Hz, 1H, H4), 
7.42 (dd, J 8.4, 1.5 Hz, 1H, H5), 1.70 (s, 9H, H11). 13C NMR (101 MHz, CDCl3) δ 185.2 (C12), 148.1 
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(C9), 136.3 (C8+C1), 127.6 (C5), 124.7 (C3), 123.0 (C4), 121.0 (C2), 119.6 (C6), 118.3 (C7), 85.1 
(C10), 28.0 (3C11); HRMS (ESI) calculated for C14H14NO3NaBr [M+Na]
+
 346.0055, found 346.0052. 
General procedure for aldol condensation 
tert-butyl 6-bromo-3-(1-hydroxy-3-methoxy-3-oxo-2-((2-(trimethylsilyl)ethoxy)methoxy)propyl)-
1H-indole-1-carboxylate (245) 
 
Methyl methoxy acetate 233 (4.36 mL, 19.8 mmol, 1.7 equiv) was dissolved in THF (70 mL) and to 
this was added LiHMDS (16.3 mL, 1.0 M in THF, 16.3 mmol, 1.4 equiv) at -78 ºC and the reaction 
mixture was stirred for 30 min. To the mixture was then added a solution of formyl indole 244 (3.78 g, 
11.7 mmol) in THF (40 mL). The solution was stirred at -78 ºC for an additional 2 h and then 
quenched with a saturated NH4Claq solution (10 mL). After the mixture was warmed to room 
temperature it was concentrated under reduced pressure and EtOAc (50 mL) and water (50 mL) was 
added. The layers were separated and the aqueous phase was extracted with EtOAc (2 × 50 mL). The 
combined organic extracts were washed with brine (50 mL), dried over MgSO4 and concentrated 
under reduced pressure. The residue was purified by flash column chromatography (Pet. ether/EtOAc, 
8:1) to give aldol adduct 245 (5.20 g, 9.57 mmol, 82%) as a light yellow oil. The compound was 
obtained as a 2.1:1.0* mixture of isomers.   
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Rf: 0.31 (Pet. ether/EtOAc, 2:1); FTIR (ATR) Vmax 3457, 2952, 2903, 1736, 1605, 1556, 1455, 1433, 
1369, 1309, 1283, 1248, 1154, 1090, 1059, 1030, 859, 835, 767; 
1
H NMR (400 MHz, CDCl3) δ 8.28 
(s, 1H, H7*), 8.25 (s, 1H, H7), 7.53 (s, 1H, H1), 7.51 (s, 1H, H1*), 7.46 (d, J 8.4, 1H, H4), 7.41 (d, J 
8.4, 1H, H4*), 7.27 (dd, J 8.4, 1.8, 1H, H5*), 7.24 (dd, J 8.4, 1.8, 1H, H5), 5.19 (t, J 5.6, 1H, H12*), 
5.15 (dd, J 5.6, 1H, H12), 4.66 (d, 7.1, 2H, H14*), 4.61 (d, J 4.0, 2H, H14), 4.43 (d, J 5.6, 1H, H13), 
4.39 (d, J 4.7, 1H, H13*), 3.60 (s, 3H, H19), 3.57 (s, 3H, H19*), 3.42 – 3.28 (m, 2H, H15), 3.30 (ddd, 
J 11.8, 9.6, 5.4, 1H, H15a*), 3.16 (ddd, J 11.5, 9.6, 5.9, 1H, H15b*), 2.98 (d, J 5.6, 1H, OH), 2.94 (d, 
J 5.8, 1H, OH*), 1.57 (s, 9H, H11*), 1.56 (s, 9H, H11), 0.60 (ddd, J 13.6, 11.5, 5.4, 1H, H16a*), 0.75 
– 0.56 (m, 2H, H16), 0.47 (ddd, J 13.6, 11.8, 5.9, 1H, H16b*), -0.17 (s, 9H, H17*), -0.15 (s, 9H, H17); 
13
C NMR (101 MHz, CDCl3) δ 171.0 (C18), 170.8 (C18*), 149.2 (C9, C9*), 136.4 (C8*), 136.3 (C8), 
127.8 (C3), 127.2 (C3*), 126.0 (C5, C5*), 124.6 (C1), 124.4 (C1*), 121.2 (C4), 120.8 (C4*), 119.3 
(C2, C2*), 118.7 (C7*), 118.6 (C7, C6*), 118.4 (C6), 94.9 (C14), 94.8 (C14*), 84.6 (C10*), 84.5 
(C10), 78.9 (C13), 78.7 (C13*), 69.0 (C12*), 68.3 (C12), 66.2 (C15, C15*), 52.3 (C19, C19*), 28.2 
(C11), 28.1(C11*), 17.9 (C16), 17.8 (C16*), -1.5 (C17), -1.4 (C17); HRMS (ESI) calculated for 
C23H34NO7NaSiBr [M+Na]
+
 566.1186, found 566.1190. 
General procedure for β-elimination 
tert-butyl 6-bromo-3-(3-methoxy-3-oxo-2-((2-(trimethylsilyl)ethoxy)methoxy)prop-1-en-1-yl)-1H-
indole-1-carboxylate (246) 
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The mixture (dr. 2.1:1.0) of alcohols 245 (5.20 g, 9.57 mmol) was dissolved in dry DCM (100 mL) 
and MsCl (1.48 mL, 19.1 mmol, 2.0 equiv) was added followed by Et3N (3.99 mL, 28.7 mmol, 3.0 
equiv) at room temperature under inert atmosphere. After 4 h at room temperature the resulting 
mixture was quenched with a saturated NH4Claq solution (20 mL) and diluted with water (40 mL). The 
layers were separated and the aqueous phase was extracted with DCM (2 × 50 mL). The combined 
organic extracts were dried over MgSO4, concentrated under reduced pressure and the residue was 
purified by flash column chromatography on silica gel (Pet. ether/EtOAc, 7:1) to give the desired enol 
ester 246 (4.79 g, 9.05 mmol, 94%) as a yellow oil. The compound was obtained as 1.1:1.0 Z/E* 
inseparable mixture of stereoisomers.  
 
Rf: 0.54 (Pet. ether/EtOAc, 2:1); FTIR (ATR) νmax 2953, 1719, 1368, 1243, 1150, 1086, 857, 834, 755; 
1
H NMR (400 MHz, CDCl3) δ 8.26 (s, 2H, H7, H7*), 8.19 (s, 1H, H1*), 7.96 (s, 1H, H1), 7.47 (d, J 
8.4, 1H, H4*), 7.31 (dd, J 8.4, 1.7, 1H, H5*), 7.27 – 7.26 (m, 2H, H4, H5), 7.09 (s, 1H, H12*), 6.60 
(d, J 0.9, 1H, H12), 5.19 (s, 2H, H14*), 5.10 (s, 2H, H14), 3.76 (s, 3H, H19*), 3.75 – 3.69 (m, 2H, 
H15), 3.67 (s, 3H, H19), 3.61 – 3.48 (m, 2H, H15*), 1.59 (s, 9H, H11), 1.58 (s, 9H, H11*), 0.96 – 0.87 
(m, 2H, H16), 0.80 – 0.70 (m, 2H, H16*), -0.05 (s, 9H, H7, H17), -0.23 (s, 9H, H17*); 13C NMR (75 
MHz, CDCl3) δ 164.5 (C18*), 164.3 (C18), 149.5 (C9), 149.4 (C9*), 144.6 (C13), 142.32 (C13*), 
136.0 (C8), 135.9 (C8*), 129.6 (C3), 128.8 (C3*), 128.4 (C1*), 126.8 (C1), 126.6 (C5*), 126.3 (C5), 
120.4 (C4*), 120.2 (C4), 119.0 (C6*), 118.9 (C7+C7*), 118.6 (C6), 114.6 (C12*), 113.8 (C2*), 113.6 
(C12), 109.3 (C2), 95.6 (C14*), 95.0 (C14), 85.2 (C10*), 84.8 (C10), 68.0 (C15*), 67.2 (C15), 52.5 
(C19*), 52.5 (C19), 28.5 (3C11, 3C11*), 18.5 (C16), 18.4 (C16*), -1.0 (3C17), -1.3 (3C17*); HRMS 
(ESI) calculated for C23H32NO6BrSiNa [M+Na]
+
 548.1080, found 548.1077. 
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General procedure for ester hydrolysis 
3-(6-bromo-1-(tert-butoxycarbonyl)-1H-indol-3-yl)-2-((2-(trimethylsilyl)ethoxy)methoxy)acrylic 
acid (247) 
 
LiOH·H2O (1.46 g, 35.0 mmol, 5.0 equiv) was added to a solution of the mixture (dr. 1.1:1.0) of enol 
ester 246 (3.70 g, 6.99 mmol) in THF/H2O (126 mL, 2:1) at room temperature under inert atmosphere. 
The resulting mixture was stirred for 24 h before the volatile organics were removed under reduced 
pressure and the residue was diluted with water (40 mL). To the solution was added slowly 1.0 N 
aqueous potassium hydrogen sulfate solution to reach pH ≈ 2. The resulting solution was extracted 
with EtOAc (3 x 30 mL). The combined organic extracts were washed with brine (20 mL), dried over 
MgSO4 and concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (Pet. ether/EtOAc, 2:1) to give α,β-unsaturated acid 247 (2.16 g, 4.19 
mmol, 60%) as a yellow solid. The compound was obtained as an inseparable mixture (2.1:1.0 Z*/E) 
of isomers. 
Rf: 0.3 (Pet. ether/EtOAc, 2:1); mp: 104-105 ºC; FTIR (ATR) νmax 2950, 1737, 1686, 1374, 1250, 
1153, 834; 1H NMR (400 MHz, CDCl3) δ 11.14 (s, 2H, CO2H, CO2H*), 8.75 – 8.44 (m, 4H, H1, H1*, 
H7, H7*), 7.76 (d, J 8.4, 1H, H4*), 7.62 – 7.55 (m, 3H, H4, H5, H5*), 7.57 (s, 1H, H12*), 7.11 (d, J 
0.8, 1H, H12), 5.56 (s, 2H, H14*), 5.47 (s, 2H, H14), 4.19 – 4.06 (m, 2H, H15), 4.00 – 3.86 (m, 2H, 
H15*), 1.93 (s, 9H, H11*), 1.92 (s, 9H, H11), 1.35 – 1.19 (m, 2H, H16), 1.19 – 0.98 (m, 2H, H16*), 
0.35 – 0.22 (m, 9H, H17), 0.16 – 0.04 (m, 9H, H17*); 13C NMR (101 MHz, CDCl3) δ 168.8 (C18*), 
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167.3 (C18), 149.0 (C9), 148.9 (C9*), 142.4 (C13), 141.1 (C13*), 135.4 (C8+C8*), 129.2 (C3), 128.5 
(C1*), 128.2 (C3*), 127.9 (C1), 126.3 (C5*), 126.0 (C5), 119.9 (C4*), 119.5 (C4), 118.6 (C6*), 118.4 
(C7+C7*), 118.3 (C6), 116.6 (C12*), 113.3 (C2*), 112.8 (C12), 112.4 (C2), 95.3 (C14*), 95.0 (C14), 
84.9 (C10*), 84.5 (C10), 67.8 (C15*), 66.9 (C15), 28.1 (3C11, 3C11*), 18.1 (C16), 17.9 (C16*), -1.4 
(3C17), -1.7 (3C17*); HRMS (ESI) calculated for C22H29NO6BrSi [M]
+
 510.0948, found 510.0942. 
 
General procedure for coupling reaction 
tert-butyl (R)-3-(3-(2-((benzyloxy)carbamoyl)-2-(3-methylbut-2-en-1-yl)pyrrolidin-1-yl)-3-oxo-2-
((2-(trimethylsilyl)ethoxy)methoxy)prop-1-en-1-yl)-6-bromo-1H-indole-1-carboxylate (248) 
 
DIPEA (1.0 mL, 6.2 mmol, 1.5 equiv) and HATU (7.7 g, 4.6 mmol, 1.1 equiv) were added at rt to 
proline derivative 238
128
 (1.8 g, 6.2 mmol, 1.5 equiv) and to a mixture of (dr. 2.1:1.0) enol acid 247 
(2.16 g, 4.19 mmol) in dry MeCN (100 mL). The resulting mixture was stirred for 16 h before the 
solvents were removed under reduced pressure. To the resulting crude oil was added EtOAc (40 mL) 
and the organic phase was washed successively with 1.0 N aqueous potassium hydrogen sulfate 
solution (15 mL), water (15 mL) and brine (15 mL). The organic layer was dried over MgSO4 and 
concentrated under reduced pressure. The crude mixture was purified by flash column 
chromatography on silica gel (Pet. ether/EtOAc, 2:1) to afford first (Z)-248 (1.38 g, 1.76 mmol, 42%) 
as a yellow oil and then (E)-248 (980 mg, 1.26 mmol, 30%) as a yellow oil.  
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(Z)-248 Rf: 0.64 (Pet. ether/EtOAc, 1:1); [α]D
22
: -52 (c 0.66, CHCl3); FTIR (ATR) νmax 2958, 1736, 
1628, 1366, 1250, 1153, 1153, 1083, 1005, 836, 750, 697; 
1
H NMR (400 MHz, CDCl3) δ 10.30 (s, 1H, 
NH), 8.23 (s, 1H, H17), 7.95 (s, 1H, H15), 7.39 – 7.19 (m, 7H, H19, H20, H24, H25, H26), 5.78 (s, 
1H, H13), 5.15 (d, J 6.7, 1H, H30a), 5.02 – 4.97 (m, 1H, H4), 4.89 (d, J 11.2, 1H, H22a), 4.79 (d, J 
6.7, 1H, H30b), 4.78 (d, J 11.2, 1H, H22b), 3.72 – 3.54 (m, 2H, H9a, H31a), 3.54 – 3.37 (m, 2H, H9b, 
H31b), 3.04 (dd, J 14.7, 7.6, 1H, H5a), 2.71 (dd, J 14.7, 7.1, 1H, H5b), 2.52 – 2.48 (m, 1H, H7a), 2.07 
– 1.99 (m, 1H, H7b), 1.69 (s, 3H, H1), 1.67 – 1.64 (m, 1H, H8a), 1.59 (s, 9H, H29), 1.58 – 1.56 (m, 
1H, H8b), 1.55 (s, 3H, H2), 0.93 – 0.81 (m, 1H, H32a), 0.78 – 0.65 (m, 1H, H32b), -0.15 (s, 9H, H33); 
13
C-NMR (75 MHz, CDCl3) δ 171.4 (C11), 164.4 (C10), 149.4 (C27), 146.0 (C12), 136.7 (C3), 135.8 
(C23), 135.4 (C21), 129.3 (2C24, C16), 128.5 (C26), 128.4 (2C25), 126.0 (C15 + C19), 125.9 (C18) 
119.5 (C20), 118.6 (C17), 117.5 (C4), 113.3 (C14), 102.4 (C13), 92.3 (C30), 84.6 (C28), 77.7 (C22), 
70.6 (C6), 67.6 (C31), 52.1 (C9), 35.0 (C7), 31.6 (C5), 28.1 (3C29), 26.4 (C1), 23.1 (C8), 18.3 (C2), 
17.9 (C32), –1.6 (3C33); HRMS (ESI) calculated for C39H52N3O7SiNaBr [M+Na]
+
 804.2656, found 
804.2667.  
(E)-248 Rf: 0.54 (Pet. ether/EtOAc, 1:1); [α]D
22
: -59 (c 0.62, CHCl3); FTIR (ATR) νmax 2958, 1736, 
1628, 1366, 1250, 1153, 1153, 1083, 1005, 836, 750, 697; 
1
H- NMR (400 MHz, CDCl3) 10.45 (s, 1H, 
NH), 8.40 (br s, 1H, H17), 7.58 (s, 1H, H15), 7.41 – 7.31 (m, 7H, H19, H20, H24, H25, H26), 6.11 (s, 
1H, H13), 5.17 (d, J 6.8, 1H, H30a), 5.10 (d, J 6.8, 1H, H30b), 4.92 (d, J 10.8, 1H, H22a), 4.83 (d, J 
10.8, 1H, H22b), 4.66 (t, J 7.6, 1H, H4), 3.86 – 3.74 (m, 2H, H31), 3.66 – 3.60 (m, 1H, H9a), 3.18 – 
3.07 (m, 2H, H9b, H5a), 2.57 – 2.49 (m, 2H, H5b, H7a), 1.65 – 1.59 (m, 3H, H7b, H8), 1.58 (s, 9H, 
H29), 1.55 (s, 3H, H1), 1.54 (s, 3H, H2), 1.02 – 0.98 (m, 2H, H32), 0.06 (s, 9H, H33); 13C NMR (75 
MHz, CDCl3) δ 170.4 (C11), 165.6 (C10), 150.0 (C27), 149.0 (C12), 136.0 (C21), 135.9 (C3), 135.6 
(C23), 129.3 (C16), 128.5 (2C24), 128.4 (C26+2C25), 126.1 (C15), 123.9 (C19, C18), 119.9 (C20), 
118.6 (C17), 117.7 (C4), 113.4 (C14), 96.5 (C13), 93.4 (C30), 84.4 (C28), 78.0 (C22), 70.8 (C6), 67.4 
(C31), 50.5 (C9), 34.9 (C7), 32.5 (C5), 28.0 (3C29) 26.1 (C1), 23.0 (C8), 18.3 (C2), 18.2 (C32), -1.3 
(3C33); HRMS (ESI) calculated for C39H52N3O7SiNaBr [M+Na]
+
 804.2656, found 804.2661. 
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General procedure for DKP preparation 
tert-butyl 3-(((8aR)-2-(benzyloxy)-3-hydroxy-8a-(3-methylbut-2-en-1-yl)-1,4- 
dioxooctahydropyrrolo[1,2-a] pyrazin-3-yl)methyl)-6-bromo-1H-indole-1-carboxylate (249) 
 
 
CBr4 (199 mg, 0.6 mmol, 0.2 equiv) was added to a solution of the mixture (dr. 1.4:1.0) of SEM enol 
248 (2.36 g, 3.02 mmol) in dry i-PrOH (100 mL) at room temperature. The mixture was heated to 50 
ºC and after 24 h allowed to cool to rt and the solvent was evaporated under reduced pressure. The 
resulting crude material was purified by flash column chromatography on silica gel (Pet. ether/EtOAc, 
3:1) to afford a single diastereoisomer of 249 (1.24 g, 62%) as a yellow solid. 
Rf: 0.43 (Pet. ether/EtOAc, 1:1); mp: 77-78 ºC, [α]D
20.5
: +44 (c 2.55, CHCl3); FTIR (ATR) νmax 3325, 
2980, 1736, 1642, 1365, 1252, 1153, 1084, 749, 697; 
1
H NMR (400 MHz, CDCl3) δ 8.31 (s, 1H, H17), 
7.65 – 7.63 (m, 2H, H24), 7.45 – 7.41 (m, 4H, H26, H25, H20), 7.38 (s, 1H, H15), 7.29 (dd, J 8.5, 1.8, 
1H, H19), 5.20 (d, J 9.1, 1H, H22a), 5.08 (d, J 9.1, 1H, H22b), 5.08 – 5.04 (m, 1H, H4), 4.15 (brs, 1H, 
OH), 3.68 (d, J 14.1, 1H, H13a), 3.45 (d, J 14.1, 1H, H13b), 3.23 (ddd, J 12.5, 9.7, 6.2, 1H, H9a), 3.18 
(ddd, J 12.5, 10.1, 5.0, 1H, H9b), 2.44 (dd, J 14.3, 8.3, 1H, H5a), 2.22 (dd, J 14.3, 7.3, 1H, H5b), 1.84 
– 1.76 (m, 1H, H7a), 1.74 (s, 3H, H1), 1.72 – 1.68 (m, 1H, H8a), 1.64 (s, 9H, H29), 1.56 (s, 3H, H2), 
0.95 – 0.87 (m, 1H, H8b), 0.76 – 0.68 (m, 1H, H7b); 13C-NMR (75 MHz, CDCl3) δ 165.3 (C11), 164.4 
(C10), 149.1 (C27), 137.9 (C3), 135.7 (C21), 135.5 (C23), 129.5 (2C24), 128.8 (C26+C16), 128.5 
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(2C25), 127.2 (C15), 125.8 (C19), 121.1 (C20), 118.3 (C18), 118.0 (C17), 117.2 (C4), 112.8 (C14), 
90.9 (C12), 84.3 (C28), 78.8 (C22), 67.7 (C6), 44.3 (C9), 36.4 (C5), 33.8 (C7), 33.5 (C13), 28.1 
(3C29), 26.0 (C1), 19.1 (C8), 18.1 (C2); HRMS (ESI) calculated for C33H38N3O6NaBr [M+Na]
+
 
674.1842, found 674.1848. 
General procedure for cationic cyclisation 
Bridged DKP (230) 
 
TfOH (32 μL, 0.36 mmol, 2.2 equiv) was added to solution of hydroxy-DKP 249 (107 mg, 0.16 mmol) 
in DCM (6.5 mL) at -50 ºC under inert atmosphere. The resulting mixture was stirred for 8 h between   
-50 ºC and -40 ºC, then allowed to warm to rt and stirred for 16 h before triethylamine (112 μL, 0.8 
mmol, 5.0 equiv) was added. The resulting mixture was diluted with DCM (5 mL), and washed 
successively with H2O (10 mL), saturated NH4Claq (10 mL), and brine (10 mL). The organic extracts 
were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by flash 
column chromatography on silica gel (Pet. ether/EtOAc, 1:1) to afford first compound 230 (45 mg, 
0.08 mmol, 52%) as a yellow solid and epi-C4-230 (14 mg, 0.03 mmol, 16%) as a yellow foam. 
 
230: Rf: 0.23 (EtOAc/MeOH 4:1); mp: 202-204 ºC; [α]D
20 
-50 (c 0.7, CHCl3); FTIR (ATR) νmax 3310, 
2958, 1680, 1463, 1362, 1055; 
1
H NMR (500 MHz, CDCl3) δ 7.79 (s, 1H, NH), 7.53 – 7.46 (m, 2H, 
H25), 7.46 – 7.34 (m, 5H, H24, H26, H17, H20), 7.22 (d, J 8.3, 1H, H19), 5.10 (d, J 9.8, 1H, H22a), 
4.99 (d, J 9.8, 1H, H22b), 3.59 (d, J 15.8, 1H, H13a), 3.45 (dt, J 11.5, 7.1, 1H, H9a), 3.42 (dt, J 11.5, 
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7.1, 1H, H9b), 3.30 (d, J 15.8, 1H, H13b), 2.89 (dt, J 13.2, 6.6, 1H, H7a), 2.57 (dd, J 10.2, 4.6, 1H, 
H4), 2.20 (dd, J 13.3, 10.2 1H, H5a), 2.05 (dd, J 12.0, 6.5, 2H, H8), 2.00 – 1.87 (m, 2H, H7b, H5b), 
1.25 (s, 3H, H1), 1.06 (s, 3H, H2); 
13
C NMR (126 MHz, CDCl3) δ 170.0 (C11), 167.0 (C10), 139.4 
(C15), 137.4 (C16), 134.4 (C23), 129.9 (2C25), 129.3 (C26), 128.7 (2C24), 126.2 (C21), 122.7 (C19), 
119.8 (C20), 115.3 (C18), 113.6 (C17), 105.2 (C14), 79.8 (C22), 68.8 (C6), 66.2 (C12), 47.8 (C4), 
44.3 (C9), 35.0 (C3), 31.4 (C5), 29.8 (C7), 28.3 (C1), 24.5 (C8), 22.5 (C2), 20.2 (C13); HRMS (ESI) 
calculated for C28H28N3O3NaBr [M+Na]
+
 556.1212, found 556.1219. 
epi-C4-230: Rf: 0.17 (EtOAc/MeOH 4:1); [α]D
20 
+73 (c 1.00, CHCl3); FTIR (ATR) νmax 3290, 2938, 
1689, 1456, 1355, 1052; 
1
H NMR (300 MHz, CDCl3) δ 8.20 (br s, 1H, NH), 7.45 – 7.06 (m, 8H, H17, 
H19, H20, H24, H25, H26), 4.89 (d, J 10.1, 1H, H22a), 4.81 (d, J 10.1, 1H, H22b), 3.62 (d, J 18.0, 
1H, H13a), 3.52 (t, J 6.6, 2H, H9), 3.12 (d, J 18.0, 1H, H13b), 2.86 (dt, J 13.2, 6.6, 1H, H7a), 2.33 (dd, 
J 9.6, 4.4, 1H, H4), 2.14 – 1.97 (m, 3H, H5a, H8), 1.97 – 1.80 (m, 2H, H7b, H5b), 1.26 (s, 3H, H2), 
1.17 (s, 3H, H1); 
13
C NMR (75 MHz, CDCl3) δ 168.7 (C11), 167.8 (C10), 140.1 (C15), 137.3 (C16), 
134.1 (C23), 129.5 (2C25), 129.1 (C26), 128.6 (2C24), 126.0 (C21), 122.6 (C19), 119.5 (C20), 115.1 
(C18), 113.8 (C17), 105.0 (C14), 79.1 (C22), 68.8 (C6), 67.2 (C12), 46.3 (C4), 44.3 (C9), 34.4 (C5), 
32.5 (C3), 29.5 (C1), 28.6 (C7), 24.5 (C13), 23.2 (C2), 20.3 (C8); HRMS (ESI) calculated for 
C28H28N3O3NaBr [M+Na]
+
 556.1212, found 556.1215. 
Bridged DKP (S3) 
 
TfOH (20 μL, 0.23 mmol, 1.4 equiv) was added to solution of hydroxyl-DKP 249 (107 mg, 0.16 
mmol) in DCM (6.5 mL) at 0 ºC under inert atmosphere. The resulting mixture was stirred for 30 min 
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and triethylamine (112 μL, 0.8 mmol, 5.0 equiv) was added. The resulting mixture was diluted with 
DCM (5 mL), and washed successively with H2O (10 mL), saturated NH4Claq (10 mL), and brine (10 
mL). The organic extracts were dried over MgSO4 and concentrated under reduced pressure. The 
residue was purified by flash column chromatography on silica gel (Pet. ether/EtOAc, 1:1) to afford 
first compound S3 (64 mg, 0.12 mmol, 74%) as a yellow foam.  
S3: Rf: 0.32 (EtOAc/MeOH 4:1); [α]D
20 
-34 (c 0.7, CHCl3); FTIR 
(ATR) νmax 3320, 2955, 1670, 1443, 1378, 1089; 
1
H NMR (300 
MHz, CDCl3) δ 8.41 (s, 1H, NH), 7.52 (d, J 1.6, 1H, Ar, CH), 
7.41 (d, J 8.5, 1H, Ar, CH), 7.35 (d, J 2.3, 1H, Ar, CH), 7.30 – 
7.08 (m, 4H, Ar, CH), 6.91 – 6.71 (m, 2H, Ar, CH), 4.82 (d, J 8.5, 
1H, H22a), 4.77 (s, 1H, H2a), 4.63 (s, 1H, H2b), 3.85 (d, J 8.5, 
1H, H22b), 3.65 (t, J 6.8, 2H, H9), 3.40 (s, 2H, H13), 3.07 (dd, J 
10.2, 6.1, 1H, H4), 2.82 (dt, J 13.4, 6.8, 1H, H7a), 2.25 (dd, J 13.4, 10.2, 1H, H5a), 2.16 – 1.99 (m, 
2H, H8), 1.92 (dd, J 13.4, 7.0, 1H, H7b), 1.81 (dd, J 13.4, 6.1, 1H, H5b), 1.55 (s, 3H, H1); 13C NMR 
(101 MHz, CDCl3) δ 172.0 (C11), 167.2 (C10), 142.2 (C3), 136.2 (Ar, C), 134.0 (Ar, C), 129.8 (2Ar, 
CH), 128.8 (Ar, CH), 128.2 (2Ar, CH), 127.8 (C15), 125.0 (Ar, C), 122.6 (Ar, CH), 120.3 (Ar, CH), 
116.1 (Ar, C), 1153 (C2), 113.8 (Ar, CH), 110.6 (C14), 78.6 (C22), 74.2 (C12), 66.7 (C6), 50.2 (C4), 
44.9 (C9), 37.7 (C5), 29.4 (C7), 24.2 (C8), 23.6 (C13), 19.3 (C1); HRMS (ESI) calculated for 
C28H28N3O3NaBr [M+Na]
+
 556.1212, found 556.1227. 
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tert-butyl 6-(benzyloxy)-3-formyl-1H-indole-1-carboxylate (232)
129
 
 
Formylation was achieved according to the general procedure (page 140) using 6-benzyloxyindole 231 
(4.44 mg 19.9 mmol) in dry DMF (20 mL), POCl3 (2.37 mL, 25.8 mmol, 1.3 equiv) in dry DMF (30 
mL), NaOH until pH ≈ 7.8. The resulting 6-(benzyloxy)-1H-indole-3-carbaldehyde which was used 
directly in the next step without additional purification. The general procedure for N-Boc protection 
was then followed dissolving the crude material in THF (80 mL), using Boc2O (5.2 g, 23.9 mmol, 1.2 
equiv) and 4-DMAP (486 mg, 3.98 mmol, 0.2 equiv). The residue was purified by flash column 
chromatography on silica gel (Pet. ether/EtOAc, 8:1) to give N-Boc formyl indole 232 (5.58 g, 80% 
over 2 steps) as a yellow solid.  
 Rf: 0.50 (Pet. ether/EtOAc, 1:1); mp: 115-116 ºC; 1H NMR (400 MHz, CDCl3) δ 10.05 (s, 1H, H12), 
8.17 (d, J 8.7, 1H, H4), 8.12 (s, 1H, H1), 7.83 (d, J 1.9, 1H, H7), 7.48 (d, J 7.2, 2H, H15), 7.41 (t, J 
7.2, 2H, H16), 7.36 (d, J 7.2, 1H, H17), 7.09 (dd, J 8.7, 2.3, 1H, H5), 5.15 (s, 2H, H13), 1.71 (s, 9H, 
H11); 
13
C NMR (101 MHz, CDCl3) δ 185.5 (C12), 157.8 (C6), 148.6 (C9), 136.9 (C8), 136.7 (C14), 
135.4 (C1), 128.4 (2C16), 127.8 (C17), 127.4 (2C15), 122.4 (C4), 121.4 (C2), 119.7 (C3), 114.1 (C5), 
100.3 (C7), 85.3 (C10), 70.1 (3C13), 27.9 (C11); HRMS (ESI) calculated for C21H21NO4Na [M+Na]
+
 
374.1368, found 374.1374. 
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tert-butyl 6-(benzyloxy)-3-(1-hydroxy-3-methoxy-3-oxo-2-((2(trimethylsilyl)ethoxy) 
methoxy)propyl)-1H-indole-1-carboxylate (234) 
 
The general procedure (page 141) for aldol condensation was followed using formylindole 232 (920 
mg, 2.62 mmol), ester 233 (1.15 g, 5.24 mmol, 2.0 equiv), LiHMDS (3.93 mL, 1.0 M in THF, 3.93 
mmol, 1.5 equiv) and THF (15 mL + 10 mL). The crude material was purified by flash column 
chromatography (Pet. ether/EtOAc, 4:1) to give aldol adduct 234 (1.39 g, 2.43 mmol, 94%) as a 
yellow oil. The compound was obtained as an inseparable 1.2:1.0 mixture of isomers.   
Rf: 0.38 (Pet. ether/EtOAc, 1:1); FTIR (ATR) νmax 3463, 2952, 2894, 1731, 1617, 1570, 1485, 1440, 
1370, 1319, 1249, 1206, 1156, 1015, 1092, 1024, 934, 857, 835, 767, 696; 
1
H NMR (400 MHz, 
CDCl3) δ 7.85 (s, 1H, H7*), 7.57 (d, J 8.7, 1H, H4*), 7.56 (s, 1H, H1*), 7.51 – 7.44 (m, 2H, H20*), 
7.87 (s, 1H, H7), 7.59 – 7.49 (m, 2H, H4 + H1), 7.49 – 7.44 (m, 2H, H20), 7.43 – 7.36 (m, 4H, H21*, 
H21), 7.36 – 7.30 (m, 2H, H22*, H22), 6.97 (m, 2H, H5*, H5), 5.33 – 5.27 (m, 1H, H12), 5.26 – 5.22 
(m, 1H, H12*), 5.12 (s, 4H, H18*, H18), 4.80 (d, J 7.1, 1H, H14a), 4.73 (d, J 7.1, 1H, H14b), 4.72 (d, 
J 2.9, 2H, H14*), 4.56 (d, J 5.6, 1H, H13*), 4.53 (d, J 4.7, 1H, H13), 3.71 (s, 3H, H24*), 3.68 (s, 3H, 
H24), 3.57 – 3.37 (m, 2H, H15*), 3.42 (ddd, J 11.8, 9.7, 5.4, 1H, H15a), 3.28 (ddd, J 11.8, 9.7, 5.9, 
1H, H15b), 3.04 (d, J 5.6, 1H, OH*), 3.02(d, J 5.8, 1H, OH), 1.66 (s, 9H, H11), 1.65 (s, 9H, H11*), 
0.87 – 0.68 (m, 3H, H16*, H16a), 0.60 (ddd, J 13.6, 11.8, 5.9, 1H, H16b), -0.07 (s, 9H, H17), -0.04 (s, 
9H, H17*); 
13
C NMR (101 MHz, CDCl3) δ 171.2 (C23*), 171.0 (C23), 157.4 (C6, C9), 157.2 (C9*, 
C6*), 149.8 (C8), 149.7 (C8*), 137.3 (C19), 137.2 (C19*), 136.6 (2C21*), 128.7 (2C21), 128.6 
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(C22*), 128.1 (C22), 127.9 (2C20*), 127.8 (2C20), 122.9 (C1*, C3*), 122.8 (C1, C4*), 122.5 (C3),  
120.4 (C2*), 120.2 (C4), 119.6 (C2), 119.4 (C5*), 113.0 (C5), 112.8 (C7*), 100.9 (C7), 100.7 (C14*), 
94.9 (C14), 94.8 (C10*), 83.9 (C10), 83.7 (C13*), 78.9 (C18*), 78.8 (C13), 70.6 (C18), 70.4 (C12*), 
69.4 (C12), 68.6 (C15*), 66.2 (C15), 52.4 (C24), 52.2 (C24*), 28.4 (C11), 28.2 (C11*), 17.9 (C16*, 
C16), -1.5 (C17*) -1.4 (C17); HRMS (ESI) calculated for C30H41NO8NaSi [M+Na]
+
 594.2499, found 
594.2501.  
 
tert-butyl 6-(benzyloxy)-3-(3-methoxy-3-oxo-2-((2-(trimethylsilyl)ethoxy)methoxy)prop-1-en-1-
yl)-1H-indole-1-carboxylate (235) 
 
The general procedure for β-elimination (page 142) was followed using mixture (dr. 1.2:1.0) of 
hydroxyl ester 234 (1.34 g, 2.34 mmol), MsCl (0.36 mL, 4.68 mmol, 2.0 equiv), Et3N (0.98 mL, 7.02 
mmol, 3.0 equiv), DCM (24 mL) and DBU (1.75 mL, 11.7 mmol, 5.0 equiv). The residue was purified 
by flash column chromatography (Pet. ether/Et2O, 9:1) to give 235 (1.19 g, 2.15 mmol, 91%) as a 
yellow oil. The compound was obtained as a Z:E*=1.4:1.0 inseparable mixture of isomers.  
Rf: 0.42 (Pet. ether/EtOAc, 4:1); FTIR (ATR) νmax 2952, 1734, 1615, 1487, 1439, 1372, 1327, 1249, 
1221, 155, 1089, 995, 857, 767, 696; 
1
H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H, H1*), 7.89 (s, 1H, 
H1), 7.76 (s, 1H, H7), 7.75 (s, 1H, H7*), 7.51 (d, J 8.7, 1H, H4*), 7.38 (d, J 7.2, 4H, H20, H20*), 7.34 
– 7.27 (m, 5H, H4, H21, H21*), 7.27 – 7.20 (m, 2H, H22, H22*), 7.14 (s, 1H, H12), 6.92 (dd, J 8.7, 
2.3, 1H, H5*), 6.89 (dd, J 8.6, 2.3, 1H, H5), 6.65 (d, J 0.9, 1H, H12*), 5.18 (s, 2H, H14*), 5.09 (s, 2H, 
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H14), 5.05 (s, 4H, H18, H18*), 3.77 (s, 3H, H24*), 3.76 – 3.69 (m, 2H, H15), 3.68 (s, 3H, H24), 3.64 
– 3.55 (m, 2H, H15*), 1.58 (s, 18H, H11, H11*), 0.97 – 0.88 (m, 2H, H16), 0.81 – 0.71 (m, 2H, 
H16*), -0.05 (s, 9H, H17), -0.22 (s, 9H, H17*); 
13
C NMR (101 MHz, CDCl3) δ 164.2 (C23*), 164.1 
(C23), 157.3 (C6*), 157.1 (C6), 149.5 (C9), 149.4 (C9*), 143.7 (C13), 141.5 (C13*), 137.1 (C19), 
137.0 (C19*), 135.8 (C8, C8*), 128.4 (2C21, 2C21*), 127.8 (C22, C22*), 127.5 (2C20, 2C20*), 126.7 
(C1*), 124.9 (C1), 124.4 (C3), 123.5 (C3*), 119.4 (C4*), 119.0 (C4), 115.1 (C12*), 113.5 (C2*), 
113.2 (C2), 113.0 (C5*), 112.7 (C5), 110.0 (C12), 100.6 (C7, C7*), 95.1 (C14*), 94.7 (C14), 84.0 
(C10*), 83.7 (C10), 70.4 (C18+C18*), 67.5 (C15*), 66.6 (C15), 52.0 (C24, C24*), 28.1 (3C11, 
3C11*), 18.0 (C16), 17.9 (C16*), -1.4 (3C17), -1.7 (3C17*); HRMS (ESI) calculated for 
C30H39NO7SiNa [M+Na]
+
 576.2394, found 576.2402. 
 
3-(6-(benzyloxy)-1-(tert-butoxycarbonyl)-1H-indol-3-yl)-2-((2-(trimethylsilyl) ethoxy) methoxy) 
acrylic acid (237) 
 
 
The general procedure for ester hydrolysis (page 144) was followed using mixture (dr. 1.4:1.0) of ester 
235 (510 mg, 0.92 mmol), LiOH·H2O (193 mg, 4.60 mmol, 5.0 equiv) and THF/H2O (20 mL, 2:1). 
The crude oil was purified by flash column chromatography (Pet. ether/Et2O, 4:1 to 3:2) to give enol 
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acid 237 (360 mg, 60%) as a light yellow solid. The compound was obtained as 1:1 Z/E* inseparable 
mixture of isomers. 
Rf: 0.18 (Pet. ether/EtOAc, 2:1); mp: 121-122 ºC; FTIR (ATR) νmax 2918, 2959, 1731, 1615, 1487, 
1441, 1369, 1248, 1218, 1150, 1087, 1021, 934, 833, 806, 733, 694; 
1
H NMR (400 MHz, CDCl3) δ 
8.35 (d, J 0.8, 1H, H1*), 8.30 (s, 1H, H1), 7.91 (s, 1H, H7*), 7.87 (s, 1H, H7), 7.67 – 7.60 (m, 1H, 
H4), 7.56 – 7.30 (m, 11H, H4, H21, H21*, H22, H22* H20, H20*), 7.07 – 7.01 (m, 2H, H5*, H5), 
6.98 (s, 2H, H12, H12*), 5.32 (s, 2H, H14), 5.25 (s, 2H, H14*), 5.17 (s, 2H, H18), 5.15 (s, 2H, H18*), 
3.93 – 3.84 (m, 2H, H15*), 3.78 – 3.70 (m, 2H, H15), 1.70 (s, 9H, H11), 1.69 (s, 9H, H11*), 1.06 (m, 
2H, H16), 0.95 – 0.88 (m, 2H, H16*), 0.07 (s, 9H, H17*), -0.09 (s, 9H, H17); 13C NMR (101 MHz, 
CDCl3) δ 168.9 (C23*), 166.8 (C23), 157.4 (C6*), 157.2 (C6), 149.6 (C9), 149.5 (C9*), 141.9 (C13), 
140.8 (C13*), 137.1 (C19), 137.0 (C19*), 135.9 (C8, C8*), 128.6 (2C21, 2C21*), 128.0 (C22, C22*) 
127.6 (2C20, 2C20*), 127.5 (C1*), 126.9 (C1), 124.5 (C3), 123.4 (C3*), 119.5 (C4*), 118.9 (C4), 
114.0 (C12*), 113.5 (C2*), 113.2 (C5*), 113.0 (C5), 112.4 (C2), 111.6 (C12), 100.7 (C7), 100.6 
(C7*), 95.4 (C14), 95.3 (C14*), 84.3 (C10), 84.0 (C10*), 70.5 (C18, C18*), 67.8 (C15*), 67.0 (C15), 
28.2 (3C11), 28.2 (3C11*), 18.2 (C16), 18.0 (C16*), -1.3 (3C17), -1.6 (3C17*); HRMS (ESI) 
calculated for C29H36NO7Si [M]
+
 538.2261, found 538.2267. 
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(R)-tert-butyl 6-(benzyloxy) -3-(3-(2-((benzyloxy)carbamoyl) -2-(3-methylbut-2-en-1-yl) 
pyrrolidin-1-yl)-3-oxo-2-((2-(trimethylsilyl)ethoxy)methoxy)prop-1-en-1-yl)-1H-indole-1 
carboxylate (239) 
 
The general procedure for the coupling reaction (page 145) was followed using of proline derivative 
238 (158 mg, 0.55 mmol), mixture (dr. 1:1) of acid 237 (300 mg, 0.55 mmol), HATU (229 mg, 0.60 
mmol, 1.1 equiv), DIPEA (0.14 mL, 0.83 mmol, 1.5 equiv) and MeCN (15 mL). The crude material 
was purified by flash column chromatography (Pet. ether/EtOAc, 4:1) to give (E)-239 (90 mg, 20%) as 
a light yellow oil followed by (Z)-239 (250 mg, 56%) as a light yellow oil.  
(E)-239: Rf: 0.50 (Pet. ether/EtOAc, 1:1); [α]D
20.5
: -28 (c 0.58, CHCl3); FTIR (ATR) νmax 2954, 1730, 
1621, 1485, 1442, 1250, 1212, 1153, 1086, 1024, 968, 856, 836, 751, 697, 665; 
1
H NMR (400 MHz, 
CDCl3) δ 10.54 (s, 1H, NH), 7.89 (s, 1H, H17), 7.50 (s, 1H, H15), 7.45 – 7.28 (m, 11H, H20, H24, 
H25, H26, H36, H37, H38), 7.00 (dd, J 8.6, 2.3, 1H, H19), 6.15 (s, 1H, H13), 5.18 (d, J 6.9, 1H, 
H30a), 5.14 (s, 2H, H34), 5.12 (d, J 6.9, 1H, H30b), 4.93 (d, J 10.9, 1H, H22a), 4.83 (d, J 10.9, 1H, 
H22b), 4.74 – 4.70 (m, 1H, H4), 3.89 – 3.72 (m, 2H, H31), 3.68 – 3.59 (m, 1H, H9a), 3.23 – 3.03 (m, 
2H, H5a, H9b), 2.61 – 2.46 (m, 2H, H5b, H7a), 1.65 – 1.62 (m, 1H, H7b), 1.62 – 1.59 (m, 2H, H8), 
1.58 (s, 9H, H29), 1.57 (s, 3H, H1), 1.55 (s, 3H, H2), 1.06 – 0.99 (m, 2H, H32), 0.10 – 0.06 (m, 9H, 
H33); 
13
C NMR (101 MHz, CDCl3) δ 170.4 (C11), 165.7 (C10), 160.0 (C18), 149.5 (C12), 
149.4(C27), 137.0(C35), 136.9 (C21) 136.5 (C3), 136.0 (C23), 135.6 (C16), 129.5 (2C24), 128.8 
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(2C36), 128.5 (C26), 128.4 (2C25), 128.0 (C38), 127.9 (2C37), 127.56 (C15), 119.2 (C20), 117.8 
(C4), 113.5 (C14), 112.9 (C19), 100.6 (C17), 95.9 (C13) 93.3 (C30), 83.7 (C28), 77.9 (C22), 68.2 
(C6+C34), 67.2 (C31), 50.5 (C9), 34.9 (C7), 32.4 (C5), 27.9 (3C29), 26.0 (C1), 22.9 (C8), 18.2 (C2), 
18.1 (C32), -1.6 (3C33); HRMS (ESI) calculated for C46H59N3O8SiNa [M+Na]
+
 832.3969, found 
832.3951. 
(Z)-239: Rf: 0.42 (Pet. ether/EtOAc, 1:1); [α]D
20.5
: -44 (c 0.58, CHCl3); FTIR (ATR) νmax 2954, 1731, 
1692, 1628, 1552, 1372, 1321, 1251, 1221, 1156, 1083, 1007, 856, 837, 749, 697; 
1
H NMR (400 
MHz, CDCl3) δ 10.18 (s, 1H, NH), 8.00 (s, 1H, H15), 7.83 (s, 1H, H17), 7.54 – 7.28 (m, 11H, H20, 
H24, H25, H26, 36, H37, H38), 7.01 (dd, J 8.6, 2.3, 1H, H19), 5.92 (s, 1H, H13), 5.27 (d, J 6.7, 1H, 
H30a), 5.15 (s, 2H, H34), 5.10 (t, J 7.5, 1H, H4), 5.01 (d, J 11.2, 1H, H22a), 4.90 (d, J 6.7, 1H, H30b), 
4.92 – 4.86 (d, J 11.2, 1H, H22b), 3.84 – 3.72 (m, 1H, H31a), 3.72 – 3.65 (m, 1H, H9a), 3.64 – 3.48 
(m, 2H, H31b, H9b), 3.16 (dd, J 14.7, 7.6, 1H, H5a), 2.81 (dd, J 14.7, 7.2, 1H, H5b), 2.50 (dd, J 12.7, 
5.7, 1H, H7a), 2.04 (td, J 12.7, 6.6, 1H, H7b), 1.81 (s, 3H, H1), 1.78 – 1.71 (m, 2H, H8), 1.68 (s, 9H, 
H29), 1.67 (s, 3H, H2), 1.04 – 0.93 (m, 1H, H32a), 0.87 – 0.77 (m, 1H, H32b), -0.04 (s, 9H, H33);13C 
NMR (101 MHz, CDCl3) δ 171.6 (C11), 164.8 (C10), 157.2 (C18), 149.8 (C27), 145.4 (C12), 137.1 
(C35), 136.7 (C3), 135.8 (C23), 135.6 (C16), 129.3 (2C24), 128.6 (2C36), 128.5 (C26), 128.4 (2C25), 
128.0 (C38), 127.6 (2C37), 124.6 (C15), 123.7 (C21), 118.9 (C20), 117.5 (C4), 113.4 (C14), 103.3 
(C19), 112.8 (C13), 100.8 (C17), 92.2 (C30), 83.9 (C28), 77.8 (C22), 70.5 (C6+C34), 67.51 (C31), 
52.2 (C9), 35.1 (C7), 31.5 (C5), 28.2 (3C29), 26.5 (C1), 23.2 (C8), 18.3 (C2), 17.9 (C32), -1.6 (3C33); 
HRMS (ESI) calculated for C46H59N3O8SiNa [M+Na]
+
 832.3969, found 832.4003. 
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tert-butyl 6-(benzyloxy)-3-(((8aR)-2-(benzyloxy)-3-hydroxy-8a-(3-methylbut-2-en-1-yl)-1,4-
dioxooctahydropyrrolo[1,2-a]pyrazin-3-yl)methyl)-1H-indole-1-carboxylate (228) 
 
 
 
The general procedure for SEM cleavage and cyclization (page 147) was followed using mixture (dr. 
2.8:1.0) of SEM ether 239 (340 mg, 0.42 mmol), CBr4 (27 mg, 0.08 mmol, 0.2 equiv) and i-PrOH (15 
mL). The residue was purified by flash column chromatography (Pet. ether/EtOAc, 4:1) to afford a 
single diastereoisomer of hydroxy-DKP 228 (130 mg, 45%) as a light yellow oil.  
Rf: 0.51 (Pet. ether/EtOAc, 1:1); [α]D
21
: +36 (c 0.9, CHCl3); FTIR (ATR) νmax 3420, 2900, 1805, 1662, 
1324, 1249, 1233, 1189, 1112, 1089, 1055, 980, 749, 697 ; 
1
H NMR (400 MHz, CDCl3) δ 7.83 (s, 1H, 
H17), 7.69 (dd, J 7.7, 1.6, 2H, H20), 7.53 – 7.35 (m, 9H, H24, H25, H26 ,H29, H30 ,H31), 7.34 (s, 
1H, H15), 6.93 (dd, J 8.7, 2.3, 1H, H19), 5.22 (d, J 9.1, 1H, H27a), 5.13 (s, 2H, H22), 5.12 (d, J 9.1, 
1H, H27b), 5.11 – 5.07 (t, J 8.3, 1H, H4), 4.48 (s, 1H, OH), 3.71 (d, J 13.8, 1H, H13a), 3.48 (d, J 13.8, 
1H, H13b), 3.35 (ddd, J 12.3, 9.8, 6.1, 1H, H9a), 3.16 (ddd, J 12.3, 10.2, 5.0, 1H, H9b), 2.47 (dd, J 
14.2, 8.3, 1H, H5a), 2.22 (dd, J 14.2, 7.0, 1H, H5b), 1.84 – 1.79 (m, 1H, H7a), 1.77 (s, 3H, H1), 1.75 – 
1.69 (m, 1H, H8a) 1.67 (s, 9H, H34), 1.59 (s, 3H, H2), 1.13 – 0.97 (m, 1H, H8b), 0.72 (dt, J 12.3, 
10.2, 1H, H7b); 
13
C NMR (101 MHz, CDCl3) δ 165.3 (C10), 164.6 (C11), 157.0 (C18), 149.6 (C32), 
137.5 (C3), 137.1 (C23), 136.0 (C16), 135.6 (C28), 129.4 (2xAr, CH), 128.7 (Ar, CH), 128.5 (2xAr, 
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CH), 128.4 (2xAr, CH), 127.9 (Ar, CH), 127.6 (2xAr, CH), 125.6 (C15), 124.0 (C21), 120.4 (C20), 
117.2 (C4), 112.8 (C14), 112.5 (C19), 100.2 (C17), 90.9 (C12), 83.6 (C33), 78.7 (C27), 70.4 (C22), 
67.7 (C6), 44.2 (C9), 36.3 (C5), 33.8 (C7), 33.6 (C13), 28.2 (3C34), 26.0 (C1), 19.0 (C8), 18.1 (C2); 
HRMS (ESI) calculated for C40H45N3O7Na [M+Na]
+
 702.3155, found 702.3168. 
 
(6R,7R,8aR)-10-(benzyloxy)-6-((6-(benzyloxy)-1H-indol-3-yl)methyl)-7-(prop-1-en-2-yl) 
tetrahydro-1H-6,8a-(epiminomethano)indolizine-5,9(6H)-dione (240) 
 
The general procedure for cationic cyclisation (page 148) was followed using hydroxy-DKP 228 (32 
mg, 0.05 mmol) in dry DCM (2.0 mL). TfOH (10 μL, 0.12 mmol, 2.5 equiv) was added at 0 ºC and the 
reaction mixture was stirred for 20 min before Et3N (65 μL, 0.47 mmol, 5.0 equiv) was added. The 
residue was purified by flash column chromatography on silica gel (Pet. ether/EtOAc, 1:1) to afford 
240 (11 mg, 42%) as a yellow oil.  
Rf: 0.25 (Pet. ether/EtOAc, 1:2); [α]D
22
: -28 (c 0.4, CHCl3); FTIR (ATR) νmax 2955, 1678, 1627, 1453, 
1366, 1262, 1164, 1014, 907, 747, 696, 667; 
1
H NMR (400 MHz, CDCl3) δ 7.99 (s, 1H, NH), 7.60 – 
7.11 (m, 12H, Ar, CH), 7.00 – 6.78 (m, 2H, Ar, CH), 5.12 (s, 2H, H22), 4.80 (d, J 8.5, 1H, H27a), 4.78 
(s, 1H, H2a), 4.67 (s, 1H, H2b), 3.91 (d, J 8.4, 1H, H27b), 3.65 (td, J 6.9, 2.6, 2H, H9), 3.41 (d, J 2.6, 
2H, H13), 3.11 (dd, J 10.2, 6.1, 1H, H4), 2.82 (dt, J 13.5, 6.9, 1H, H7a), 2.25 (dd, J 13.3, 10.2, 1H, 
H5a), 2.16 – 2.03 (m, 2H, H8), 2.00 – 1.85 (m, 1H, H7b), 1.81 (dd, J 13.3, 6.1, 1H, H5b), 1.56 (s, 3H, 
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H1); 
13
C NMR (101 MHz, CDCl3) δ 172.1 (C10), 167.3 (C11), 155.6 (C18), 142.3 (C3), 137.6 (C23), 
135.9 (C16), 134.2 (C28), 130.0 (2xAr, CH), 128.7 (Ar, CH), 128.6 (2xAr, CH), 128.2 (2xAr, CH), 
127.8 (Ar, CH), 127.4 (2xAr, CH), 123.6 (C21), 123.2 (C15), 119.7 (C20), 116.0 (C2), 110.4 (C14), 
110.0 (C19), 95.8 (C17), 78.7 (C27), 74.3 (C12), 70.7 (C22), 66.7 (C6), 50.2 (C4), 44.2 (C9), 37.8 
(C5), 29.4 (C7), 24.2 (C8), 23.7 (C13), 19.4 (C1); HRMS (ESI) calculated for C35H35N3O4Na [M+Na]
+
 
584.2525, found 584.2520. 
 
Bridged DKP (274) 
 
HNTf2 (26 μL of 0.5 M solution in DCM, 0.04 mmol) was added to a solution of 222 (22 mg, 0.04 
mmol) in DCM (0.5 mL) at -10 ºC. The ice bath was removed and the mixture was stirred until no 
starting material was shown by TLC analysis. Then DCM (10 mL) was added and the crude mixture 
was washed with NaHCO3 (7 mL) and brine (5 mL), dried over MgSO4 before being concentrated 
under reduced pressure. The crude product was purified by flash column chromatography on silica gel 
(eluent: Pet. ether/EtOAc, 1:1) and semi prep-HPLC (H2O:MeCN gradient 40.14 min) to give 274 (4 
mg, 0.30 mmol, 20%) as a light yellow oil.  
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Rf: 0.34 (Pet. ether/EtOAc, 1:2); [α]D
21
 - 14 (c 0.35, CHCl3); FTIR (ATR) νmax 2974, 2926, 2854, 1792, 
1693, 1589, 1397, 1350, 1277, 1155, 1119, 980, 812, 754; 1H NMR (300 MHz, CDCl3) δ 7.56 (s, 1H, 
Ar, CH), 7.25 – 7.15 (m, 4H, Ar, CH), 7.04 (d, J 9.9 Hz, 1H, H19), 6.92 (d, J 6.6 Hz, 2H, Ar, CH), 
6.78 (d, J 8.4 Hz, 1H, Ar, CH), 5.62 (d, J 9.9 Hz, 1H, H18), 4.91 (d, J 8.6 Hz, 1H, H30a), 4.78 (s, 1H, 
H2a), 4.68 (s, 1H, H2b), 4.14 (d, J 8.6 Hz, 1H, H30b), 3.70 – 3.60 (m, 2H, H9), 3.27 (s, 2H, H13), 
3.11 (dd, J 10.2, 6.1 Hz, 1H, H4), 2.83 (dt, J 13.4, 6.9 Hz, 1H, H7a), 2.28 (dd, J 13.3, 10.2 Hz, 1H, 
H5a), 2.15 – 2.04 (m, 2H, H8), 1.92 (dd, J 13.4, 7.0 Hz, 1H, H7b), 1.81 (dd, J 13.3, 6.1 Hz, 1H, H5b), 
1.57 (s, 9H, H29), 1.52 (s, 3H, CH3), 1.50 (s, 3H, CH3), 1.27 (s, 3H, CH3); Due to insufficient amount 
of material we were not able to run 13C NMR to complete the assignment; HRMS (ESI) calculated for 
C38H43N3O6Na [M+Na]
+
 660.3050, found 660.3052. 
 
tert-butyl 3-(((3S,8aR)-2-(4-methoxybenzyl)-8a-(3-methylbut-2-en-1-yl)-1,4-dioxo-3-(phenylthio) 
octahydropyrrolo[1,2-a]pyrazin-3-yl)methyl)-1H-indole-1-carboxylate (218) 
 
LDA (569 μL of 0.8 M in Pet. Ether, 0.46 mmol, 1.3 equiv) was added to a solution of DKP 217 (200 
mg, 0.35 mmol) in dry THF (10 mL) at -78 ºC. After 10 min, a solution of Ph2S2 (152 mg, 0.70 mmol, 
2.0 equiv) in THF (3 mL) was then added and the reaction mixture was stirred for an additional 30 
min. The reaction was quenched at -78 ºC by addition of 2 mL of water and was allowed to warm up 
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to rt. EtOAc (15 mL) was added and the organic phase was washed with saturated NH4Claq (7 mL) and 
brine (7 mL) dried over MgSO4, and concentrated. The crude material was purified by flash column 
chromatography on silica gel (eluent: Pet. ether/EtOAc, 2:1) to give 218 (220 mg, 0.32 mmol, 92%) as 
a light yellow solid.  
Rf: 0.58 (Pet. ether/EtOAc, 1:4); mp: 78-79 ºC; [α]D
18.5
 - 26 (c 0.70, CHCl3); FTIR (ATR) νmax 2979, 
2934, 1733, 1658, 1611, 1513, 1453, 1368, 1307, 1271, 1250, 1156, 1109, 1080, 1035, 1017, 853, 
813, 750; 
1
H NMR (400 MHz, CDCl3) δ 7.90 (d, J 8.1, 1H, H17), 7.48 (d, J 7.7, 1H, H20), 7.39 (d, J 
6.7, 2H, H32), 7.28 (t, J 7.0, 1H, H34), 7.24 (d, J 7.4, 2H, H33), 7.20 (d, J 8.7, 2H, H27), 7.11 (t, J 
7.5, 1H, H18), 7.04 (t, J 7.5, 1H, H19), 6.65 (d, J 8.7, 2H, H28), 6.53 (s, 1H, H15), 5.42 (d, J 15.2, 1H, 
H25a), 4.85 (d, J 15.2, 1H, H25b), 4.74 – 4.70 (m, 1H, H4), 3.83 (d, J 15.0, 1H, H13a), 3.66 (s, 3H, 
H30), 3.42 (ddd, J 12.6, 9.8, 6.9, 1H, H9a), 3.33 (d, J 15.0, 1H, H13b), 2.98 (ddd, J 12.6, 10.4, 4.2, 
1H, H9b), 1.84 (dd, J 14.7, 8.2, 1H, H5a), 1.65 – 1.60 (m, 2H, H5b, H7), 1.43 (s, 12H, H24, H2), 1.40 
– 1.31 (m, 1H, H8a), 1.29 – 1.14 (m, 1H, H8b), 1.12 (s, 3H, H1), 0.46 – 0.37 (m, 1H, H7b); 13C NMR 
(101 MHz, CDCl3) δ 170.0 (C10), 162.0 (C11), 158.8 (C29), 149.2 (C22), 137.4 (2C32), 134.9 (C3), 
134.7 (C21), 130.6 (C16), 130.2 (C34), 130.1 (2C28), 129.7 (C31), 129.7 (C26), 129.1 (2C33), 125.6 
(C15), 124.2 (C18), 122.5 (C19), 120.1 (C20), 118.0 (C4), 114.6 (C17), 114.0 (2C27), 113.8 (C14), 
83.5 (C12), 83.3 (C23), 66.7 (C6), 55.1 (C30), 47.3 (C25), 44.8 (C9), 38.5 (C5), 32.0 (C7), 32.0 
(C13), 28.0 (3C24), 25.8 (C2), 18.9 (C8), 17.5 (C1); HRMS (ESI) calculated for C40H45N3O5NaS 
[M+Na]
+
 702.2978, found 702.2980. 
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tert-butyl 3-(((3S,8aR)-2-(4-methoxybenzyl)-8a-(3-methylbut-2-en-1-yl)-1,4-dioxo-3-(phenylthio) 
octahydropyrrolo[1,2-a]pyrazin-3-yl)methyl)-1H-indole-1-carboxylate (218) 
 
LDA (0.27 mL of 0.8 M in Pet. ether, 0.22 mmol, 1.1 equiv) was added to a solution of DKP 309 (100 
mg, 0.20 mmol) in dry THF (5 mL) at -78 ºC and the mixture was stirred for 10 min. Prenyl bromide 
(23 μL, 0.20 mmol, 1.0 equiv) was added and the reaction mixture was stirred for 30 min before LDA 
(0.35 μL of 0.8 M in Pet. ether, 0.28 mmol, 1.4 equiv) was added at -78 ºC. The mixture was stirred 
for additional 10 min and a solution of Ph2S2 (86 mg, 0.40 mmol, 2.0 equiv) in THF (3 mL) was then 
added. After 30 min the crude was quenched at -78 ºC by addition of 1mL of water and was allowed to 
warm up to rt. EtOAc (15 mL) was added and the crude was washed with saturated NH4Claq (10 mL), 
brine (10 mL) dried over MgSO4, and concentrated. The crude material was purified by flash column 
chromatography on silica gel (eluent: Pet. ether/EtOAc, 2:1) to give 218 (99 mg, 0.15 mmol, 74%) as 
a light yellow solid. For full assignment of 218 see page 161 
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Bridged DKP (299)  
 
Silver triflate (190 mg, 0.51 mmol, 1.5 equiv) was added to a solution of 218 (230 mg, 0.34 mmol) in 
THF (10 mL) at -10 ºC. After stirring the solution for 1 h, 1.0 M NaOH (5 mL) was added. The phases 
were separated and the aqueous phase was extracted with CH2Cl2 (10 mL). The combined organic 
extracts were washed with brine (5 mL), dried over MgSO4 and the solvent was evaporated under 
reduced pressure. The crude product was purified by flash column chromatography on silica gel 
(eluent: Pet. ether/EtOAc, 1:1) to give 299 (170 mg, 0.30 mmol, 88%) as a light yellow foam.  
 
Rf: 0.21 (Pet. ether/EtOAc, 1:1); [α]D
21
 - 54 (c 1.2, CHCl3); FTIR (ATR) νmax 3318, 2926, 1677, 1612, 
1512, 1440, 1394, 1247, 1177, 1100, 1030, 804; 
1
H NMR (400 MHz, CDCl3) δ 8.21 (s, 1H, NH), 7.60 
(d, J 7.5, 1H, H17), 7.32 (d, J 7.4, 1H, H20), 7.22 – 7.14 (m, 2H, H18, H19), 7.09 (s, 1H, H15), 6.88 
(d, J 8.7, 2H, H25), 6.72 (d, J 8.7, 2H, H24), 4.75 (s, 1H, H2a), 4.73 (d, J 15.3, 1H, H22a), 4.55 (s, 
1H, H2b), 4.31 (d, J 15.3, 1H, H22b), 3.77 (s, 3H, H27), 3.70 – 3.57 (m, 2H, H9), 3.47 (d, J 17.4, 1H, 
H13a), 3.30 (d, J 17.4, 1H, H13b), 3.03 – 2.80 (m, 2H, H7a, H4), 2.22 (dd, J 13.4, 10.3, 1H, H5a), 
2.15 – 2.00 (m, 2H, H8), 2.00 – 1.88 (m, 1H, H7b), 1.84 (dd, J 13.4, 5.4, 1H, H5b), 1.60 (s, 3H, H1); 
13
C NMR (101 MHz, CDCl3) δ 173.9 (C11), 167.8 (C10), 158.7 (C26), 143.0 (C3), 135.8 (C16), 130.5 
(C23), 128.6 (2C25), 128.1 (C21), 123.5 (C15), 122.1 (C18), 119.4 (C19), 118.4 (C17), 116.2 (C2), 
113.7 (2C24), 111.1 (C20), 110.2 (C14), 69.6 (C12), 66.2 (C6), 55.3 (C27), 52.5 (C4), 45.8 (C22), 
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44.5 (C9), 36.6 (C5), 30.0 (C7), 25.3 (C13), 24.5 (C8), 19.1 (C1); HRMS (ESI) calculated for 
C29H31N3O3Na [M+Na]
+
 492.2263, found 492.2260. 
Bridged DKP (299) via Oxidative Radical Cyclisation  
 
 
A condenser and an additional funnel containing CuCl2 (245 mg, 1.82 mmol, 8.0 equiv) were 
connected to a three neck round bottom flask under argon atmosphere. Solution of DKP 217 (130 mg, 
0.23 mmol) in dry THF (7 mL) was added to the flask and the solution was cooled to -78 ºC. LDA 
(0.40 mL of 0.8 M in Pet. ether, 0.32 mmol, 1.4 equiv) was then added and the mixture was stirred for 
10 min. CuCl2 was added portion-wise over 10 min and the solution immediately turned to dark blue-
green. The cool bath was removed and the mixture was stirred for 15 min at rt and then gradually 
heated to reflux After 1 h the oil bath was removed and the crude mixture was allow to cooled to rt. 
EtOAc (15 mL) was added and the crude was washed with 10 mL H2O, saturated NH4Claq (2 × 10 
mL), brine (10 mL) dried over MgSO4, and concentrated. The crude product was purified by flash 
column chromatography on silica gel (eluent: Pet. ether/EtOAc, 1:1) to give 299 (170 mg, 0.30 mmol, 
88%) as a light yellow foam. For full assignment of 299 see page 164 
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(3S,8aR)-3-((1H-indol-3-yl)methyl)-2-(4-methoxybenzyl)-8a-(3-methylbut-2-en-1-yl)-3-
(phenylthio)hexahydropyrrolo[1,2-a]pyrazine-1,4-dione (S4) 
 
TFA (37 mg, 0.15 mmol, 1.5 equiv) was added to a solution of 218 (50 mg, 0.10 mmol) in DCM (2 
mL) at rt. The crude material was stirred overnight before being washed with NaHCO3 (5 mL) and 
brine (5 mL) and the organic extracts were dried over MgSO4 and the solvent was evaporated under 
reduced pressure. The crude product was purified by flash column chromatography on silica gel 
(eluent: Pet. ether/EtOAc, 1:1) to give S4 (25 mg, 0.04 mmol, 66%) as a light yellow foam. 
  
Rf: 0.19 (Pet. ether/EtOAc, 1:1); [α]D
21 - 61 (c 0.55, CHCl3); FTIR (ATR) νmax 3313, 2964, 1772, 
1651, 1512, 14391246, 1177, 1034, 809, 742, 693; 
1
H NMR (300 MHz, CDCl3) δ 7.88 (s, 1H, NH), 
7.79 (d, J 6.8, 1H, H17), 7.55 – 7.42 (m, 4H, H29, H25), 7.39 – 7.29 (m, 3H, H31, H30), 7.17 (d, J 
6.6, 1H, H20), 7.11 – 6.99 (m, 2H, H18, H19), 6.86 (d, J 8.7, 2H, H24), 5.61 (s, 1H, H15), 5.57 (d, J 
15.1, 1H, H22a), 5.05 (d, J 15.1, 1H, H22b), 4.62 - 4352 (m, 1H, H4), 4.01 (d, J 14.7, 1H, H13a), 3.82 
(s, 3H, H27), 3.44 (d, J 14.7, 1H, H13b), 3.44 – 3.35 (m, 1H, H9a), 2.96 (ddd, J 12.6, 10.3, 4.2, 1H, 
H9b), 1.78 – 1.62 (m, 1H, H7a), 1.49 (s, 3H, H1), 1.46 – 1.38 (m, 1H, H5a), 1.38 – 1.32 (m, 1H, H8a), 
1.30 – 1.25 (m, 1H, H5b), 1.25 – 1.20 (m, 1H, H8b), 1.13 (s, 3H, H2), 0.65 (dt, J 12.8, 10.4, 1H, H7b); 
13
C NMR (101 MHz, CDCl3) δ 170.5 (C10), 162.3 (C11), 159.1 (C26), 137.2 (2C29), 135.5 (C16), 
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134.6 (C3), 131.2 (C28), 131.1 (2C25), 130.2 (C23), 130.0 (C31), 129.0 (2C30), 127.7 (C21), 125.0 
(C15), 122.0 (C19), 120.6 (C17), 119.6 (C18), 118.1 (C4), 114.0 (2C24), 110.5 (C20), 108.8 (C14), 
84.8 (C12), 66.5 (C6), 55.4 (C27), 47.5 (C22), 45.0 (C9), 38.4 (C5), 32.8 (C7), 32.2 (C13), 25.8 (C1), 
18.9 (C8), 17.5 (C2); HRMS (ESI) calculated for C35H37N3O3NaS [M+Na]
+
 602.2453, found 
602.2432. 
Indolines (316) and (epi-316) 
 
In a two neck flask connected with a condenser 218 (60 mg, 0.09 mmol) was dissolved in degassed 
toluene (3 mL) under an inert atmosphere. The mixture was warmed to reflux and solutions of      
0.009 M ACCN in degassed toluene (6.0 mg, 0.026 mmol, 0.3 equiv) and 0.044 M Bu3SnH in 
degassed toluene (35 μL, 0.132 mmol, 1.5 equiv) were added via a syringe pump over 8 h. After 
completion of the addition the mixture was allow to cooled to rt and the solvents was evaporated under 
reduced pressure. The crude material was purified by flash column chromatography on silica gel 
(eluent: Pet. ether/EtOAc, 1:1) to give epi-C4-316 (7 mg, 0.01 mmol, 15%) and 316 (35 mg, 0.06 
mmol, 71%).  
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epi-C4-316: Rf: 0.27 (Pet. ether/EtOAc, 1:1); [α]D
20.5 +100 (c 0.32, 
CHCl3); FTIR (ATR) νmax 2924, 1683, 1612, 1513, 1481, 1384, 1367, 
1276, 1249, 1172, 11440, 1035, 752, 667; 
1
H NMR (400 MHz, CDCl3) 
δ 7.39 (d, J 7.7, 1H, H17), 7.32 (d, J 7.5, 1H, H20), 7.01 (t, J 7.7, 1H, 
H18), 6.91 (d, J 8.6, 2H, H27), 6.84 (td, J 7.5, 0.9, 1H, H19), 6.74 (d, J 
8.6, 2H, H28), 5.11 (d, J 15.9, 1H, H25a), 4.32 (d, J 9.2, 1H, H15), 
4.11 (d, J 15.9, 1H, H25b), 3.78 (t, J 8.0 1H, H14), 3.70 (s, 3H, H30), 
3.40 – 3.26 (m, 1H, H9a), 3.21 – 3.03 (m, 2H, H13a+9b), 2.71 (dt, J 
12.6, 6.1, 1H, H7a), 2.30 (dd, J 15.5, 6.0, 1H, H13b), 1.91 – 1.78 (m, 
2H, H8), 1.77 – 1.69 (m, 1H, H4), 1.68 – 1.56 (m, 2H, H5a, H7b), 1.55 – 1.49 (m, 1H, H5b), 1.46 (s, 
9H, H24), 0.84 (s, 3H, H1), 0.81 (s, 3H, H2); 
13
C NMR (101 MHz, CDCl3) δ 173.9 (C11), 169.8 (10), 
159.0 (C29), 153.2 (C22) 142.7 (C16), 133.6 (C21), 129.3 (C26), 128.6 (C27), 127.2 (C18), 125.6 
(C20), 123.0 (C19), 115.4 (C17), 114.2 (C28), 81.2 (C23), 66.2 (C15), 65.6 (C6), 63.2 (C12), 55.3 
(C30), 44.9 (C25), 44.4 (C9), 42.5 (C4), 38.0 (C3), 36.6 (C14), 30.8 (C5), 30.2 (C7), 28.5 (C24), 24.6 
(C8), 23.5 (C2), 23.3 (C1), 19.4 (C13); HRMS (ESI) calculated for C34H41N3O5Na [M+Na]
+
 594.2944, 
found 594.2936. 
 
316: Rf: 0.20 (Pet. ether/EtOAc, 1:1); [α]D
20.5 +11 (c 1.25, CHCl3); 
FTIR (ATR) νmax 2972, 1680, 1611, 1512, 1478, 1460, 1383, 
1351, 1278, 1247, 1172, 1145, 1107, 1054, 1034, 999, 813, 665; 
 
1
H NMR (400 MHz, CDCl3) δ 7.35 (d, J 7.4, 1H, H20), 7.30 (d, J 
7.7, 1H, H17), 7.04 (d, J 8.6, 2H, H27), 7.01 (d, J 7.7, 1H, H18), 
6.95 (d, J 7.4, 3.8, 1H, H19), 6.79 (d, J 8.6, 2H, H28), 4.85 (d, J 
16.0, 1H, H25a), 4.24 (d, J 16.0, 1H, H25b), 4.06 (d, J 8.2, 1H, 
H15), 3.73 (s, 3H, H30), 3.63 (t, J 8.5, 1H, H14), 3.41 (ddd, J 
11.8, 6.7, 5.4, 1H, H9a), 3.19 – 3.07 (m, 2H, H9b, H13a), 2.84 – 2.68 (m, 1H, H7a), 2.19 (dd, J 14.3, 
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9.4, 1H, H13b), 2.05 (dd, J 13.2, 10.6, 1H, H5a), 1.89 (dd, J 10.6, 5.4, 1H, H4), 1.87 – 1.82 (m, 2H, 
H8), 1.76 – 1.62 (m, 2H, H7b, H5b), 1.44 (s, 9H, H24), 0.83 (s, 3H, H2), 0.23 (s, 3H, H1); 13C NMR 
(101 MHz, CDCl3) δ 173.3 (C11), 168.8 (C10), 159.0 (C29), 153.3 (C22), 142.6 (C16), 134.6 (C21), 
130.5 (C26), 128.0 (C27), 127.0 (C18), 123.8 (C20), 123.0 (C19), 116.0 (C17), 114.4 (C28), 81.2 
(C23), 67.79 (C15), 66.2 (C6), 63.5 (C12), 55.3 (C30), 49.0 (C4), 44.4 (C25), 44.3 (C9), 39.5 (C3), 
38.5 (C14), 31.8 (C5), 30.3 (C7), 28.6 (C2), 28.4 (C24), 24.5 (C8), 22.3 (C13), 15.7 (C1); HRMS 
(ESI) calculated for C34H41N3O5Na [M+Na]
+
 594.2944, found 594.2950. 
 
Deprotection of Indolines (318) 
 
Indoline 316 (29 mg, 0.05 mmol) was diluted in 10 mL formic acid and stirred overnight at rt. Formic 
acid was then evaporated under reduced pressure and the crude material was purified by flash column 
chromatography on silica gel (eluent: Pet. ether/EtOAc, 1:2) to give from 318 (19 mg, 0.04 mmol, 
78%).   
Rf: 0.10 (Pet Ether/EtOAc, 1:1); mp: 233-235 ºC; [α]D
20
 +11 (c 1.8, CHCl3); FTI (ATR) νmax 
1
H NMR 
(400 MHz, CDCl3) δ 7.19 (d, J = 8.6 Hz, 2H, H24), 7.01 (td, J = 7.7, 1.0 Hz, 1H, H18), 6.96 (d, J = 
7.2 Hz, 1H, H20), 6.90 (d, J = 8.6 Hz, 2H, H25), 6.69 (t, J = 7.2 Hz, 1H, H19), 6.57 (d, J = 7.7 Hz, 
1H, H17), 4.89 (d, J = 15.9 Hz, 1H, H22a), 4.56 (d, J = 15.9 Hz, 1H, H22b), 3.79 (s, 3H, H27), 3.66 – 
3.58 (m, 2H, H15, H9a), 3.47 (dt, J = 11.4, 7.5 Hz, 1H, H9b), 3.00 – 2.89 (m, 1H, H7a), 2.83 – 2.77 
(m, 2H, H13a, H14), 2.23 – 2.12 (m, 2H, H13b, H5a), 2.08 – 1.97 (m, 3H, H8, H4), 1.94 – 1.84 (m, 
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1H, H7b), 1.71 (dd, J = 12.8, 8.0 Hz, 1H, H5b), 0.94 (s, 3H, H2), 0.77 (s, 3H, H1); NH not observed ; 
13
C NMR (101 MHz, CDCl3) δ 173.1 (C11), 168.7 (C10), 159.0 (C26), 150.4 (C16), 131.0 (C21), 
130.3 (C23), 128.3 (2C24), 127.9 (C18), 124.3 (C20), 118.6 (C19), 114.4 (2C25), 109.1 (C17), 68.1 
(C15), 66.2 (C6), 64.9 (C12), 55.3 (C27), 51.3 (C4), 44.5 (C22, C9), 38.5 (C14), 35.6 (C3), 32.6 (C5), 
30.4 (C7), 29.9 (C2), 25.9 (C13), 24.5 (C8), 17.5 (C1); HRMS (ESI) calculated for C29H33N3O3Na 
[M+Na]
+
 494.2420, found 494.2402. 
 
(3S,8aR)-3-((1H-indol-3-yl)methyl)-8a-(3-methylbut-2-en-1-yl)hexahydropyrrolo[1,2-a]pyrazine-
1,4-dione (345) 
 
A solution of Boc-L-Trp-OH 343 (3.9 g, 13.0 mmol) and proline 322 (3.0 g, 13.0 mmol) in MeCN 
(200 mL), was cooled to 0 ºC and HATU (5.4 g, 14.3 mmol, 1.1 equiv), DIPEA (5.1 mL, 28.6 mmol, 
2.2 equiv) were added. After 16 h the mixture was concentrated under reduced pressure and the 
resulting crude oil was dissolved in EtOAc (50 mL) and washed successively with a 1.0 N aqueous 
potassium hydrogenosulfate solution (15 mL), water (15 mL) and brine (15 mL). The organic layer 
was dried over MgSO4 and the solvent was evaporated under reduced pressure. The crude material 
was dissolved in formic acid (100 mL) stirred for 20 h at rt and then the acid was evaporated under 
reduced pressure. To the residual oil, 2-butanol (150 mL) and toluene (50 mL) were added and the 
mixture was heated at reflux for 20 h. The solvent evaporated under reduced pressure and the crude 
product was purified by flash column chromatography on silica gel (EtOAc/MeOH, 9:1) to give 345 
(3.5 g, 77%) as a white solid.  
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Rf: 0.37 (EtOAc/MeOH, 9:1); mp: 182-183 ºC; [α]D
20
 -81 (c 1.8, CHCl3); FTI (ATR) νmax 3277, 2977, 
2925, 1642, 1424, 1299, 1214, 1102, 1010, 741, 665; 
1
H NMR (400 MHz, CDCl3) δ 8.59 (s, 1H, 
CONH), 7.57 (d, J 7.8, 1H, H20), 7.39 (d, J 7.8, 1H, H17), 7.23 (t, J 7.4, 1H, H18), 7.13 (t, J 7.8, 1H, 
H19), 7.05 (s, 1H, H15), 5.76 (s, 1H, NH), 5.10 – 5.06 (m, 1H, H4), 4.40 (dd, J 11.2, 3.1, 1H, H12), 
3.85 – 3.81 (m, 1H, H9a), 3.81 – 3.73 (m, 1H, H13a), 3.63 – 3.51 (m, 1H, H9b), 2.86 (dd, J 14.8, 11.2, 
1H, H13b), 2.45 (qd, J 14.2, 8.3, 2H, H5), 2.13 – 2.08 (m, 2H, H7), 2.06 – 1.93 (m, 2H, H8), 1.69 (s, 
3H, H1), 1.57 (s, 3H, H2); 
13
C NMR (101 MHz, CDCl3) δ 171.6 (C11), 165.5 (C10), 137.8 (C16), 
136.8 (C21), 126.6 (C3), 123.6 (C15), 122.7 (C18), 119.9 (C19), 118.6 (C20), 117.2 (C4), 111.7 
(C17), 109.9 (C14), 68.6 (C6), 54.5 (C12), 45.1 (C9), 36.1 (C5), 34.6 (C7), 28.2 (C13), 26.0 (C1), 
20.5 (C8), 17.8 (C2); HRMS (ESI) calculated for C21H25N3O2Na [M+Na]
+
 374.1844, found 374.1849. 
 
(8aR)-tert-butyl 3-((1-(tert-butoxycarbonyl)-1H-indol-3-yl)methyl)-8a-(3-methylbut-2-en-1-yl)-
1,4-dioxohexahydropyrrolo [1,2-a]pyrazine-2(1H)-carboxylate (S5) 
 
(Boc)2O (5.7 g, 26.5 mmol, 3.0 equiv), 4-DMAP (336 mg, 2.65 mmol, 0.3 equiv) and TEA (3.0 mL, 
22.1 mmol, 2.5 equiv) was added to a solution of 345 (3.1 g, 8.83 mmol) in DCM (70 mL) was added 
at rt. After 16 h stirring the crude mixture was washed with NH4Claq, brine and the solvents was 
evaporated under reduced pressure. The crude material was purified by flash column chromatography 
on silica gel (eluent: Pet. ether/EtOAc, 1:2) to give S5 (3.4 g, 71%) as a white solid 
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Rf: 0.71 (Pet. ether/EtOAc, 2:1); mp: 107-108 ºC; [α]D
23
 120 (c 1.0, CHCl3); FTI (ATR) νmax 2979, 
1732, 1659, 1455, 1368, 1256, 1155, 1082, 748; 
1
H NMR (400 MHz, CDCl3) δ 8.09 (d, J 8.2, 1H, 
H17), 7.49 (d, J 7.8, 1H, H20), 7.33 – 7.25 (td, J 7.7, 1.0, 1H, H18), 7.26 (s, 1H, H15), 7.23 – 7.15 (td, 
J 7.7, 1.0, 1H, H19), 4.96 – 4.91 (m, 1H, H4), 4.84 (dd, J 4.8, 2.4, 1H, H12), 3.63 (ddd, J 12.4, 9.8, 
6.0, 1H, H9a), 3.56 (dd, J 14.5, 2.4, 1H, H13a), 3.47 (dd, J 14.5, 4.8, 1H, H13b), 3.28 – 3.16 (m, 1H, 
H9b), 2.29 (dd, J 14.2, 8.5, 1H, H5a), 2.18 (dd, J 14.2, 7.2, 1H, H5b), 166 (s, 3H, H2), 1.65 (s, 9H, 
C(CH3)3), 1.63 – 1.61 (m, 1H, H8a), 1.61 – 1.59 (m, J 4.5, 2.8, 1H, H7a), 1.57 (s, 9H, C(CH3)3), 1.52 
(s, 3H, H1), 1.27 – 1.15 (m, 1H, H8b), 0.66 – 0.51 (m, 1H, H7b); 13C NMR (101 MHz, CDCl3) δ 169.0 
(C11), 164.0 (C10), 151.0 (CO2C(CH3)3), 149.4 (CO2C(CH3)3), 137.4 (C3), 135.2 (C16), 130.4 (C21), 
126.0 (C15), 124.7 (C18), 122.5 (C19), 119.8 (C20), 116.5 (C4), 115.0 (C17), 114.1 (C14), 83.7 
(CO2C(CH3)3), 83.6 (CO2C(CH3)3), 69.2 (C6), 60.2 (C12), 44.20 (C9), 37.6 (C5), 33.6 (C13), 29.2 
(C7), 28.2 (CO2C(CH3)3), 28.1 (CO2C(CH3)3), 26.1 (C1), 19.2 (C8), 17.9 (C2); HRMS (ESI) 
calculated for C31H41N3O6Na [M+Na]
+
 574.2893, found 574.2886. 
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(8aR)-tert-butyl 3-((1-(tert-butoxycarbonyl)-1H-indol-3-yl)methyl)-8a- (3-methylbut-2-en-1-yl) -
1,4-dioxo-3-(phenylthio)hexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate (347) 
 
The general procedure (page 161) was followed using S5 (200 mg, 0.36 mmol) in THF (20 mL), 0.8 
M LDA (0.64 mL, 0.51 mmol, 1.4 equiv), Ph2S2 (158 mg, 0.73 mmol, 2.0 equiv) in THF (7 mL). The 
crude material was purified by flash column chromatography on silica gel (eluent: Pet. ether/EtOAc, 
1:1) to give 347 (227 mg, 0.34 mmol, 95%) as white solid.  
Rf: 0.71 (Pet. ether/EtOAc, 1:2); mp: 102-103 ºC; [α]D
23
 118 (c 1.1, CHCl3); FTI (ATR) νmax 2978, 
1733, 1659, 1453, 1364, 1252, 1148, 1080, 851, 749, 694; 
1
H NMR (400 MHz, CDCl3) δ 8.06 (d, J 
7.9, 1H, H17), 7.75 (d, J 7.4, 1H, H20), 7.64 (d, J 7.0, 2H, H29), 7.60 (s, 1H, H15), 7.41 – 7.33 (m, 
1H, H31), 7.31 (d, J 7.6, 2H, H30), 7.28 – 7.22 (td, J 7.7, 1.0, 1H, H18), 7.20 (td, J 7.7, 1.0, 1H, H19), 
4.53 – 4.49 (m, 1H, H4), 4.10 (d, J 14.4, 1H, H13a), 3.91 (d, J 14.4, 1H, H13b), 3.37 – 3.23 (m, 1H, 
H9a), 3.15 – 2.99 (m, 1H, H9b), 1.71 – 1.67 (m, 1H, H7a), 1.64 (s, 9H, OCCH3), 1.63 (s, 9H, 
OCCH3), 1.45 (s, 3H, H1), 1.41 – 1.29 (m, 3H, H8, H5a), 1.06 (s, 3H, H2), 0.91 (dd, J 14.8, 7.2, 1H, 
H5b), 0.86 -0.77 (m, 1H, H7b);
 13
C NMR (101 MHz, CDCl3) δ 169.2 (C10), 162.1 (C11), 151.7 
(CO2C(CH3)3), 149.5 (CO2C(CH3)3), 138.1 (2C29), 135.25 (C16), 134.9 (C3), 130.3 (C28), 130.1 
(C31), 130.0 (C21), 128.7 (2C30), 126.5 (C15), 124.6 (C18), 122.7 (C19), 120.7 (C17), 116.9 (C4), 
115.0 (C20), 114.5 (C14), 84.7 (CO2C(CH3)3), 83.7 (CO2C(CH3)3), 80.0 (C12), 67.5 (C6), 45.0 (C9), 
36.6 (C5), 32.2 (C13), 31.0 (C7), 28.2 (CO2C(CH3)3), 28.0 (CO2C(CH3)3), 25.8 (C1), 18.8 (C8), 17.3 
(C2); HRMS (ESI) calculated for C37H45N3O6NaS [M+Na]
+
 682.2927, found 682.2939. 
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Indolines (348), (349), (350) and (351) 
 
The general procedure for radical cyclisation (page 167) was followed using SPh-DKP 347 (500 mg, 
0.76 mmol) in degassed toluene (25 mL), 0.02 M ACCN (93 mg, 0.38 mmol, 0.5 equiv) and 0.06 M 
Bu3SnH (326 μL, 1.21 mmol, 1.6 equiv) which were added via of a syringe pump over 8 h. After 
completion of the addition the mixture was allow to cooled to rt and the solvents was evaporated under 
reduced pressure. The crude material was purified by flash column chromatography on silica gel 
(eluent: Pet. ether/EtOAc, 1:1) to give as yellow light yellow foam, 348 and 349 as an inseparable 
mixture (275 mg, 67%), 350 (38 mg, 9%) and 351 (13 mg, 3%) in 79% total yield and ratio 
348/349/350/351 =1.0:3.2:0.5:0.2;  
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Mixture 348*:349: Rf: 0.54 (Pet. 
ether/EtOAc, 1:2); FTI (ATR) νmax 
2978, 1724, 1690, 1480, 1459, 1383, 
1270, 1250, 1146, 750; 
1
H NMR (400 
MHz, CDCl3) δ 7.54 (d, J 7.4 Hz, 1H, 
H20
*
), 7.47 (d, J 7.5 Hz, 2H, H20), 
7.17 – 6.97 (m, 6H, Ar, CH), 4.49 (d, 
J 9.2 Hz, 1H, H15*), 4.41 (d, J 8.5 Hz, 1H, H15), 3.93 (t, J 7.8 Hz, 2H, H14, H14*), 3.64 – 3.53 (m, 
2H, H13a, H9a), 3.53 – 3.43 (m, 2H, H9a*, H13a*), 3.33 – 3.17 (m, 2H, H9b, H9b*), 2.82 – 2.74 (m, 
1H, H7a), 2.74 – 2.67 (m, 1H, H7a*), 2.37 (dd, J 10.2, 6.4 Hz, 1H, H4), 2.22 – 2.14 (m, 4H, H5a, 
H5a*, H13b, H13b*), 1.98 – 1.84 (m, 5H, H8, H8*, H4*), 1.82 – 1.71 (m, 4H, H5b, H5b*, H7b, 
H7b*), 1.57 (s, 18H, (CH3)3, (CH3)3*), 1.56 (s, 9H, (CH3)3,), 1.55 (s, 9H, (CH3)3*), 1.12 (s, 3H, CH3*), 
0.99 (s, 3H, CH3), 0.96 (s, 3H, CH3*), 0.37 (s, 3H, CH3); 
13
C NMR (101 MHz, CDCl3) δ 171.0 (C11, 
C11*), 167.2 (C10, C10*), 153.4 (COC(CH3)3, COC(CH3)3*), 150.8 (COC(CH3)3, COC(CH3)3*), 
142.7 (C16,C16*), 135.1 (C21, C21*), 127.3 (C18*), 127.1 (C18), 125.4 (C20*), 123.7 (C20), 123.3 
(C19), 123.1 (C19*), 16.1 (C17), 115.5 (C17*), 81.2 (*C(CH3)3), 81.2 (C(CH3)3), 81.2 (C(CH3)3, 
*C(CH3)3), 68.0 (C15*), 66.3 (C6), 66.0 (C15*), 65.7(C6*) 64.1 (C12,C12*), 48.4 (C4), 44.5 (C9), 
44.4 (C9*), 41.9 (C4*), 39.4 (C3), 38.2 (C14), 38.0 (C14*), 36.9 (C3*), 31.89 (C5,C5), 30.1 (C7), 
30.0 (C7*), 28.5 (C(CH3)3, (CH3)3)*, CH3, CH3*), 28.0 (C(CH3)3), 27.9 ((CH3)3), 24.4 (C8*), 24.2 
(C8), 23.8 (C13), 21.8 (C13*), 15.6(CH3, CH3); HRMS (ESI) calculated for C31H41N3O6Na [M+Na]
+
 
574.2893, found 574.2887. 
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350: Rf: 0.32 (Pet. ether/EtOAc, 1:2); [α]D
23
 -80.4 (c 1.7, CHCl3); 
FTI (ATR) νmax 2978, 1724, 1690, 1479, 1458, 1367, 1250, 1146, 
848, 750; 
1
H NMR (400 MHz, CDCl3) δ 7.52 (d, J 8.0 Hz, 1H, 
H17), 7.17 (t, J 7.7 Hz, 1H, H18), 7.07 (d, J 7.3 Hz, 1H, H20), 
6.97 (t, J 7.4 Hz, 1H, H19), 4.43 (d, J 9.3 Hz, 1H, H15), 4.05 – 
3.95 (m, 1H, H14), 3.68 (ddd, J 11.6, 7.7, 4.0 Hz, 1H, H9a), 3.49 – 
3.40 (m, 1H, H9b), 3.36 – 3.21 (m, 2H, H13), 2.77 – 2.68 (m, 1H, 
H7a), 2.23 (t, J 9.3 Hz, 1H, H4), 2.01 – 1.92 (m, 2H, H8a, H5a), 
1.93 – 1.83 (m, 1H, H8b), 1.77 – 1.68 (m, 1H, H7b), 1.60 (s, 9H, C(CH3)3), 1.56 (s, 9H, C(CH3)3), 
1.53 – 1.48 (m, 1H, H5b), 0.94 (s, 3H, CH3), 0.91 (s, 3H, CH3); 
13
C NMR (101 MHz, CDCl3) δ 171.0 
(C11), 168.0 (C10), 153.4 (COC(CH3)3), 150.4 (COC(CH3)3), 143.0 (C16), 135.4 (C21), 127.6 (C18), 
123.2 (C20), 122.7 (C19), 116.2 (C17), 84.8 (C(CH3)3), 81.3 (C(CH3)3), 66.2(C6), 66.1 (C15), 64.6 
(C12), 46.7 (C4), 44.6 (C9), 38.0 (C14), 37.6 (C3), 32.9 (C5), 30.4 (C7), 28.4 (C(CH3)3), 28.0 
(C(CH3)3), 24.2 (C8), 24.0 (CH3), 23.0 (CH3), 19.8 (C13); HRMS (ESI) calculated for C31H41N3O6Na 
[M+Na]
+
 574.2893, found 574.2894. 
Deprotection of indolines 
Indolines 352 and 353 
 
Indoline derivatives 348 and 349 (528 mg, 0.96 mmol) were diluted in 25 mL formic acid and stirred 
overnight at rt. Formic acid was then evaporated under reduced pressure and the crude material was 
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purified by flash column chromatography on silica gel (eluent: Pet. ether/EtOAc, 1:3) to give 352 (180 
mg, 0.51 mmol, 52%), 353 (130 mg, 0.37 mmol, 38%) as white solids. 
 
352: Rf: 0.18 (Pet. ether/EtOAc, 1:2); mp: 246-247 ºC; [α]D
23
 -69 
(c 1.0, CHCl3); FTI (ATR) νmax 2958, 1676, 1606, 1461, 1395, 
1257, 1070, 1022, 746, 665;
1
H NMR (400 MHz, CDCl3) δ 7.22 (d, 
J 7.2 Hz, 1H, H20), 7.02 (t, J 7.6 Hz, 1H, H18), 6.87 (s, 1H, NH), 
6.76 (t, J 7.2 Hz, 1H, H19), 6.61 (d, J 7.6 Hz, 1H, H17), 3.70 – 
365 (m, 1H, H15), 3.64 – 3.49 (m, 2H, H14, H9a), 3.41 – 3.30 (m, 1H, H9b), 3.12 (dd, J 15.1, 7.8 Hz, 
1H, H13a), 2.76 (brs, 1H, H7a), 2.16 – 2.04 (m, 1H, H5a), 2.06 – 1.90 (m, 3H, H8, H4), 1.86 – 1.73 
(m, 2H, H7b, 13b), 1.73 – 1.62 (m, 1H, H5b), 0.94 (s, 3H, H1), 0.63 (s, 3H, H2); NH not observed; 13C 
NMR (101 MHz, CDCl3) δ 169.0 (C11, C10), 150.2 (C16), 130.9 (C21), 127.7 (C20), 124.1 (C18), 
118.9 (C19), 108.9 (C17), 68.7 (C15), 60.1 (C6), 51.0 (C4), 44.2 (C9), 38.5 (C14), 36.5 (C3), 32.2 
(C5), 29.5 (C7), 28.9 (C2), 27.3 (C13), 24.6 (C8), 16.6 (C1); HRMS (ESI) calculated for 
C21H25N3O2Na [M+Na]
+
 374.1844, found 374.1836. 
 
353: Rf: 0.18 (Pet. ether/EtOAc, 1:2); mp: 260-261 ºC; [α]D
21
 -70 
(c 0.3, CHCl3); FTI (ATR) νmax 2918, 2849, 1682, 1611, 1482, 
1464, 1408, 1321, 1294, 1251, 1122, 1028, 940, 919, 744, 665, 
589; 
1
H NMR (300 MHz, CDCl3) δ 7.15 (d, J 7.2 Hz, 1H, H20), 
7.06 (td, J 7.7, 1.2 Hz, 1H, H18), 6.82 (s, 1H, NH), 6.77 (td, J 7.2, 
0.9 Hz, 1H, H19), 6.70 (d, J 7.7 Hz, 1H, H17), 3.80 (brs, 1H, NH) 
3.47 (d, J 6.9 Hz, 1H, H15), 3.45 (dd, J 6.2, 2.0 Hz, 2H, H9), 3.19 (dt, J 12.1, 6.1 Hz, 1H, H14), 2.78 
(dt, J 13.1, 6.5 Hz, 1H, H7a), 2.30 (dd, J 10.2, 4.7 Hz, 1H, H4), 2.11 – 2.01 (m, 2H, H7b, H5a), 2.01 – 
1.89 (m, 2H, H13), 1.89 – 1.80 (m, 3H, H5b, H8), 1.04 (s, 3H, H2), 1.03 (s, 3H, H1); 13C NMR (101 
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MHz, CDCl3) δ 173.5 (C11), 169.5 (C10), 149.6 (C16), 134.8 (C21), 127.7 (C18), 123.7 (C20), 119.6 
(C19), 110.7 (C17), 70.8 (C15), 66.8 (C6), 60.8 (C12), 53.5 (C3), 44.1 (C9), 40.4 (C4), 35.2 (C14), 
32.7 (C5), 29.4 (C7), 29.2 (C8), 27.2 (C2), 24.5 (C13), 22.8 (C1). HRMS (ESI) calculated for 
C21H25N3O2Na [M+Na]
+
 374.1844, found 374.1848. 
Indoline (354) 
 
Indoline derivatives 350 (88 mg, 0.16 mmol) was diluted in 15 mL formic acid and stirred overnight at 
rt. Formic acid was then evaporated under reduced pressure and the crude material was purified by 
flash column chromatography on silica gel (eluent: EtOAc) to give 354 (50 mg, 0.14 mmol, 87%) as 
white solid. 
Rf: 0.22 (EtOAc); mp: 210-211 ºC; [α]D
23
 -17 (c 1.0, CHCl3); FTI 
(ATR) νmax 2925, 1673, 1610, 1463, 1401, 1368, 1330, 1124, 
1017, 746, 665; 
 1
H NMR (400 MHz, CDCl3) δ 7.20 (d, J 7.5 Hz, 
1H, H20), 7.06 (td, J 7.7, 1.2 Hz, 1H, H18), 6.77 (td, J 7.5, 0.8 Hz, 
1H, H19), 6.72 (d, J 7.7 Hz, 1H, H17), 6.30 (s, 1H, NH), 3.84 (s, 
1H, NH), 3.60 – 3.52 (m, 2H, H14, H9a), 3.44 – 3.32 (m, 2H, H15, H9b), 2.74 (ddd, J 12.7, 6.9, 5.4 
Hz, 1H, H7a), 2.47 (dd, J 10.4, 5.8 Hz, 1H, H4), 2.38 (dd, J 13.0, 6.4 Hz, 1H, H13a), 2.12 (dd, J 13.3, 
10.4 Hz, 1H, H5a), 2.07 – 1.90 (m, 2H, H8), 1.84 – 1.72 (m, 2H, H5b, H7b), 1.22 – 1.13 (m, 1H, 
H13b), 1.04 (s, 3H, H1), 0.90 (s, 3H, H2); 
13
C NMR (101 MHz, CDCl3) δ 173.5 (C11), 169.7 (C10), 
149.2 (C16), 135.1 (C21), 127.6 (C20), 123.8 (C18), 119.7 (C19), 110.6 (C17), 70.8 (C15), 67.3 (C6), 
59.7 (C12), 45.4 (C4), 43.8 (C9), 36.7 (C14), 35.4 (C3), 31.7 (C7,C5), 29.4 (C13), 26.6(C1), 24.6(C8), 
20.2 (C2); HRMS (ESI) calculated for C21H25N3O2Na [M+Na]
+
 374.1844, found 374.1851. 
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(R)-2-methyl-8a-(3-methylbut-2-en-1-yl)hexahydropyrrolo[1,2-a]pyrazine-1,4-dione (325) 
 
Proline derivative 322
59b
 (1.3 g, 5.7 mmol) was dissolved in CHCl3 (40 mL) and to this was added 
triethylamine (1.9 mL, 13.7 mmol, 2.4 equiv) at -10 ºC. The reaction mixture was treated with 
bromoacetyl bromide 323 (1.26 mL, 13. mmol, 2.4 equiv) in chloroform (40 mL). After stirring for 4 
hours the reaction was quenched with water (40 mL) and the layers separated. The organic phase was 
washed with saturated sodium hydrogen carbonate solution (30 mL), brine (30 mL) and the combined 
organic layers were dried over MgSO4 and concentrated under reduced pressure. Rf 0.16 (3:1 Pet. 
ether/EtOAc). The crude material 324 (2.18 g, 5.7 mmol, 1.0 eq) was dissolved in MeOH (20mL) and 
treated with methylamine solution (28.59 mL of 2 M in methanol, 57.2 mmol, 10.0 equiv) at 0 ºC.  
After 3 hours the reaction mixture was allowed to warm to room temperature and the reaction mixture 
concentrated under reduced pressure. The crude product was purified by flash column chromatography 
on silica gel (EtOAc/MeOH, 9:1) to give 325 (0.9 g, 3.8 mmol, 67%) as a white solid.  
Rf: 0.12 (EtOAc); mp: 99-103 ºC; [α]D
21
 -60 (c 0.9, CHCl3); FTI (ATR) νmax 2953, 2880, 2840, 1660, 
1598, 1402, 1385, 1078; 
1
H NMR (400 MHz, CDCl3) δ 5.08 – 5.03 (m, 1H, H4), 4.04 (d, J 17.0, 1H, 
H12a), 3.79 (dt, J 12.3, 8.4, 1H, H9a), 3.71 (d, J 17.0, 1H, H12b), 3.55 – 3.42 (m, 1H, H9b), 2.94 (s, 
3H, H13), 2.51 (dd, J 14.1, 7.8, 1H, H5a), 2.37 (dd, J 14.1, 8.2, 1H, H5b), 2.18 – 2.11 (m, 2H, H7), 
2.04 – 1.92 (m, 2H, H8), 1.70 (m, 3H, H2 ), 1.58 (s, 3H, H1); 13C NMR (101 MHz, CDCl3) δ 169.5 
(C11), 162.7 (C10), 137.8 (C3), 117.2 (C4), 68.2 (C6), 53.6 (C12), 45.0 (C9), 36.7 (C7), 35.2 (C5), 
33.5 (C13), 26.1 (C2), 20.5 (C8), 17.8 (C1); HRMS (ESI) calculated for C13H20N2O2Na [M+Na]
+
 
259.1422, found 259.1419. 
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(R)-2methyl-8a-(3-methylbut-2-en-1yl)-3- methylenehexahydropyrrolo[1,2-a] pyrazine-1,4,-
dione (326) 
 
DKP 325 (0.9 mg, 3.80 mmol) was dissolved in THF (25 mL) and to this was added n-BuLi (7.12 mL 
of 1.6 M in hexane, 11.4 mmol, 3.0 equiv) at -78 ºC. After 10 min formaldehyde (400 mg, 13.3 mmol, 
3.5 equiv) in 5 mL THF was added and the reaction mixture was stirred for 20 min in the same 
temperature. The reaction mixture was allowed to warm to rt and then was warmed to reflux and 
stirred for 2 hours. The reaction mixture was quenched with a saturated NH4Claq solution (10 mL) 
before allowed to cool to rt. EtOAc (50 mL) were added and the crude material was washed with brine 
(50 mL), dried over MgSO4 and concentrated under reduced pressure. The residue was purified by 
flash column chromatography (Pet. ether/EtOAc, 9:1) to give 326 (348 mg, 1.41 mmol, 37%) as a 
white foam. 
Rf 0.5 (EtOAc/MeOH, 9:1); [α]D
21
 -83 (c 0.8, CHCl3); FTI (ATR) νmax 2957, 1680, 1551, 1430, 1405, 
1322, 1048;
 1
H NMR (400 MHz, CDCl3) δ 5.67 (s, 1H, H13a), 4.96 – 4.82 (m, 1H, H4), 4.78 (s, 1H, 
H13b), 3.83 (dt, J 12.5, 8.5 Hz, 1H, H9a), 3.66 – 3.52 (m, 1H, H9b), 3.16 (s, 3H, H14), 2.48 (dd, J 
13.9, 7.8 Hz, 1H, H5a), 2.38 (dd, J 14.0, 8.3 Hz, 1H, H5b), 2.29 – 2.15 (m, 2H, H7), 2.04 - 1.99 (dd, J 
= 10.6, 6.4 Hz, 2H, H8), 1.60 (s, 3H, H2), 1.52 (s, 3H, H1); 
13
C NMR (101 MHz, CDCl3) δ 168.4 
(C11), 157.8 (C10), 139.6 (C12), 138.2 (C3), 116.9 (C4), 100.7 (C13), 68.3 (C6), 45.1 (C9), 37.7 
(C5), 34.8 (C7), 29.8 (C14), 26.1 (C2), 20.2 (C8), 17.7 (C1); HRMS (ESI) calculated for 
C14H20N2O2Na [M+Na]
+
 271.1422, found 271.1413. 
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Crystallographic information 
Sulfide 218 
Table 1.  Crystal data and structure refinement for 218. 
Identification code  218 
Empirical formula  C40H45N3O5S, CH3OH 
Formula weight  711.89 
Temperature  120(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P 212121 
Unit cell dimensions a = 10.6567(3) Å α= 90°. 
 b = 13.9156(4) Å β= 90°. 
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 c = 24.7451(6) Å γ= 90°. 
Volume 3669.56(17) Å3 
Z 4 
Density (calculated) 1.289 Mg/m3 
Absorption coefficient 1.202 mm-1 
F(000) 1520 
Crystal size 0.34 x 0.34 x 0.24 mm3 
Theta range for data collection 6.34 to 68.22°. 
Index ranges -11<=h<=12, -16<=k<=16, -29<=l<=29 
Reflections collected 28682 
Independent reflections 6618 [R(int) = 0.0212] 
Completeness to theta = 68.22° 98.9%  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7612 and 0.6853 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6618 / 0 / 467 
Goodness-of-fit on F2 1.044 
Final R indices [I>2sigma(I)] R1 = 0.0332, wR2 = 0.0923 
R indices (all data) R1 = 0.0336, wR2 = 0.0927 
Absolute structure parameter 0.020(13) 
Largest diff. peak and hole 0.730 and -0.547 e.Å-3 
 
Notes: 
The absolute structure has been determined from the diffraction data. The chirality at C(1) is S and at 
C(3) is R. The structure contains one molecule of methanol per diketopiperazine molecule which 
forms a hydrogen bond with O(2). The hydrogen atoms were fixed as riding models. 
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 218.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 8984(2) 6705(1) 1990(1) 25(1) 
C(2) 9335(2) 7096(1) 1018(1) 25(1) 
C(3) 8006(2) 6817(1) 886(1) 25(1) 
C(4) 7575(2) 6645(1) 1865(1) 26(1) 
C(5) 9389(2) 5836(1) 2334(1) 28(1) 
C(6) 9101(2) 4885(1) 2076(1) 24(1) 
C(7) 9685(2) 4486(1) 1648(1) 26(1) 
C(8) 8145(2) 3444(1) 1887(1) 26(1) 
C(9) 8113(2) 4234(1) 2238(1) 27(1) 
C(10) 7233(2) 4257(1) 2654(1) 31(1) 
C(11) 6428(2) 3484(1) 2708(1) 35(1) 
C(12) 6477(2) 2704(1) 2359(1) 34(1) 
C(13) 7341(2) 2664(1) 1945(1) 31(1) 
C(14) 9372(2) 3047(1) 1065(1) 29(1) 
C(15) 10778(2) 2982(1) 285(1) 36(1) 
C(16) 11175(2) 1947(2) 374(1) 47(1) 
C(17) 9752(2) 3064(2) -132(1) 46(1) 
C(18) 11874(2) 3617(2) 145(1) 42(1) 
C(19) 11132(2) 7047(1) 1616(1) 28(1) 
C(20) 12044(2) 6319(1) 1398(1) 27(1) 
C(21) 12684(2) 5699(1) 1742(1) 32(1) 
C(22) 13607(2) 5082(1) 1553(1) 36(1) 
C(23) 13927(2) 5091(1) 1013(1) 33(1) 
C(24) 13285(2) 5693(2) 660(1) 35(1) 
C(25) 12368(2) 6295(1) 852(1) 32(1) 
C(26) 15693(2) 4075(2) 1144(1) 52(1) 
C(27) 8012(2) 5783(1) 635(1) 27(1) 
C(28) 8741(2) 5684(1) 124(1) 32(1) 
C(29) 8274(2) 5563(1) -369(1) 38(1) 
C(30) 6908(2) 5529(2) -503(1) 45(1) 
C(31) 9130(3) 5460(2) -848(1) 58(1) 
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C(32) 7328(2) 7529(1) 522(1) 32(1) 
C(33) 5944(2) 7301(1) 628(1) 36(1) 
C(34) 5900(2) 7048(1) 1228(1) 34(1) 
C(35) 8478(2) 8688(1) 2041(1) 30(1) 
C(36) 7219(2) 8933(1) 2101(1) 34(1) 
C(37) 6715(2) 9671(1) 1794(1) 42(1) 
C(38) 7456(2) 10152(1) 1424(1) 46(1) 
C(39) 8708(3) 9917(2) 1367(1) 48(1) 
C(40) 9222(2) 9190(1) 1679(1) 39(1) 
N(1) 9784(1) 6837(1) 1516(1) 24(1) 
N(2) 7206(1) 6804(1) 1362(1) 26(1) 
N(3) 9111(1) 3609(1) 1516(1) 26(1) 
O(1) 9999(1) 7457(1) 674(1) 31(1) 
O(2) 6818(1) 6518(1) 2234(1) 33(1) 
O(3) 8766(1) 2346(1) 948(1) 39(1) 
O(4) 10342(1) 3409(1) 803(1) 33(1) 
O(5) 14869(1) 4564(1) 785(1) 44(1) 
S(1) 9124(1) 7764(1) 2449(1) 29(1) 
C(101) 6668(4) 7337(3) 3472(1) 94(1) 
O(101) 6911(4) 6478(2) 3336(1) 122(1) 
________________________________________________________________________________ 
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Indoline 318 
 
Table 1.  Crystal data and structure refinement for 318 
Identification code  318 
Empirical formula  C29H33N3O3, 2(CH3OH) 
Formula weight  535.67 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21 
Unit cell dimensions a = 9.7410(9) Å α= 90°. 
 b = 13.9612(9) Å β= 95.382(4)°. 
 c = 10.2677(10) Å γ= 90°. 
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Volume 1390.2(2) Å3 
Z 2 
Density (calculated) 1.280 Mg/m3 
Absorption coefficient 0.087 mm-1 
F(000) 576 
Crystal size 0.56 x 0.38 x 0.03 mm3 
Theta range for data collection 3.03 to 27.48°. 
Index ranges -12<=h<=12, -17<=k<=18, -13<=l<=13 
Reflections collected 17079 
Independent reflections 3316 [R(int) = 0.0789] 
Completeness to theta = 27.48° 99.6%  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9974 and 0.9530 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3316 / 1 / 360 
Goodness-of-fit on F2 1.020 
Final R indices [I>2sigma(I)] R1 = 0.0625, wR2 = 0.1361 
R indices (all data) R1 = 0.0919, wR2 = 0.1499 
Absolute structure parameter ? 
Extinction coefficient 0.039(5) 
Largest diff. peak and hole 0.366 and -0.340 e.Å-3 
 
Notes: 
It has not been possible to determine the absolute structure from the diffraction data as there are no 
heavy atoms present. The absolute structure has been determined from the synthetic scheme. The 
relative chirality of the chiral centres has been determined. The structure contains two methanol 
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groups per molecule. The hydrogen atoms have been fixed as riding models. 
 
 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 318.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 5135(4) 7175(3) 2548(4) 26(1) 
C(2) 5321(4) 8085(3) 3114(4) 31(1) 
C(3) 4286(5) 8759(3) 2849(4) 33(1) 
C(4) 3088(5) 8551(3) 2064(4) 32(1) 
C(5) 2905(5) 7642(3) 1495(4) 31(1) 
C(6) 3930(4) 6968(3) 1731(3) 24(1) 
C(7) 3997(4) 5929(3) 1314(4) 26(1) 
C(8) 3028(4) 5316(3) 2079(4) 26(1) 
C(9) 3214(4) 4238(3) 1908(4) 26(1) 
C(10) 4664(4) 4002(3) 1428(4) 26(1) 
C(11) 5835(4) 4610(3) 2137(4) 25(1) 
C(12) 5539(4) 5672(3) 1707(4) 27(1) 
C(13) 5961(4) 4487(3) 3623(4) 30(1) 
C(14) 7222(4) 4314(3) 1635(5) 35(1) 
C(15) 4874(4) 2905(3) 1464(4) 30(1) 
C(16) 3528(4) 2424(3) 1773(4) 27(1) 
C(17) 2351(4) 2803(3) 796(4) 31(1) 
C(18) 3006(4) 3711(3) 3208(4) 27(1) 
C(19) 2893(5) 1999(3) 3976(4) 31(1) 
C(20) 2597(5) 1164(3) 3041(4) 33(1) 
C(21) 3531(5) 1335(3) 1943(5) 36(1) 
C(22) 989(4) 4238(3) 264(4) 32(1) 
C(23) 1336(4) 4953(3) -774(4) 28(1) 
C(24) 816(4) 5881(3) -803(4) 29(1) 
C(25) 1135(4) 6527(3) -1752(4) 30(1) 
C(26) 1971(4) 6256(3) -2710(4) 29(1) 
C(27) 2490(4) 5325(3) -2717(4) 30(1) 
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C(28) 2172(4) 4682(3) -1747(4) 29(1) 
C(29) 2931(5) 6668(3) -4699(4) 42(1) 
N(1) 5970(3) 6380(2) 2714(3) 28(1) 
N(2) 2190(3) 3763(2) 934(3) 28(1) 
N(3) 3214(4) 2776(2) 3075(3) 29(1) 
O(1) 1656(3) 2292(2) 9(3) 39(1) 
O(2) 2677(3) 4098(2) 4217(3) 30(1) 
O(3) 2239(3) 6952(2) -3597(3) 36(1) 
C(101) 9570(7) 4016(5) 5336(7) 69(2) 
O(101) 10060(5) 4715(4) 4470(5) 80(1) 
C(201) 9634(9) 6791(5) 2831(6) 85(2) 
O(201) 8930(4) 6433(4) 3721(5) 77(1) 
________________________________________________________________________________ 
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Indoline 352 
 
Table 1.  Crystal data and structure refinement for 352 
Identification code  352 
Empirical formula  C21H25N3O2 
Formula weight  351.44 
Temperature  120(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P 212121 
Unit cell dimensions a = 11.25880(10) Å α= 90°. 
 b = 11.7630(2) Å β= 90°. 
 c = 12.8358(2) Å γ= 90°. 
Volume 1699.94(4) Å3 
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Z 4 
Density (calculated) 1.373 Mg/m3 
Absorption coefficient 0.713 mm-1 
F(000) 752 
Crystal size 0.20 x 0.16 x 0.10 mm3 
Theta range for data collection 6.44 to 66.57°. 
Index ranges -13<=h<=13, -13<=k<=14, -14<=l<=15 
Reflections collected 10076 
Independent reflections 2910 [R(int) = 0.0278] 
Completeness to theta = 66.57° 99.4%  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9321 and 0.8705 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2910 / 0 / 237 
Goodness-of-fit on F2 1.068 
Final R indices [I>2sigma(I)] R1 = 0.0329, wR2 = 0.0849 
R indices (all data) R1 = 0.0344, wR2 = 0.0861 
Absolute structure parameter -0.1(2) 
Largest diff. peak and hole 0.362 and -0.318 e.Å-3 
 
Notes: 
It has not been possible to determine the absolute structure from the diffraction data due to the lack of 
heavier atoms, but the relative stereochemistry of the chiral centres has been confirmed. Thus it has 
been confirmed that the chirality of C(7) is opposite to that of C(9), C(10), C(12) and C(16). The 
structure has been shown with C(7) as S and C(9), C(10), C(12) and C(16) as R as this is the absolute 
structure as determined from the synthesis. The hydrogen atoms have been fixed as riding models. 
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Table 2.  Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 352.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 6316(2) 6332(2) 11490(1) 22(1) 
C(2) 5272(2) 5835(2) 11847(1) 23(1) 
C(3) 4515(2) 5335(2) 11128(1) 24(1) 
C(4) 4770(2) 5360(1) 10070(1) 24(1) 
C(5) 5817(2) 5864(1) 9718(1) 22(1) 
C(6) 6594(2) 6336(1) 10428(1) 20(1) 
C(7) 7739(2) 6996(1) 10299(1) 20(1) 
C(8) 8603(2) 6717(1) 9409(1) 20(1) 
C(9) 9528(1) 5811(1) 9648(1) 19(1) 
C(10) 10077(2) 5960(2) 10752(1) 20(1) 
C(11) 9153(2) 5982(2) 11648(1) 21(1) 
C(12) 8266(2) 6969(1) 11419(1) 20(1) 
C(13) 9809(2) 6281(2) 12662(1) 27(1) 
C(14) 8521(2) 4834(2) 11791(1) 22(1) 
C(15) 11081(2) 5066(2) 10885(1) 25(1) 
C(16) 11168(2) 4338(2) 9893(1) 23(1) 
C(17) 11439(1) 5160(1) 8989(1) 21(1) 
C(18) 9085(1) 4580(1) 9478(1) 17(1) 
C(19) 10007(2) 2633(2) 9461(2) 26(1) 
C(20) 11324(2) 2418(2) 9243(2) 30(1) 
C(21) 11961(2) 3294(2) 9925(2) 28(1) 
N(1) 7180(1) 6909(1) 12066(1) 23(1) 
N(2) 10536(1) 5913(1) 8904(1) 20(1) 
N(3) 9975(1) 3853(1) 9674(1) 21(1) 
O(1) 12337(1) 5141(1) 8453(1) 27(1) 
O(2) 8089(1) 4312(1) 9169(1) 21(1) 
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Indoline 353 
 
Table 1.  Crystal data and structure refinement for 353 
Identification code  353 
Empirical formula  C21H25N3O2, CH4O 
Formula weight  383.48 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P 2121 21 
Unit cell dimensions a = 8.0470(17) Å α= 90°. 
 b = 10.678(3) Å β= 90°. 
 c = 22.331(5) Å γ= 90°. 
Volume 1918.8(8) Å3 
Z 4 
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Density (calculated) 1.328 Mg/m3 
Absorption coefficient 0.089 mm-1 
F(000) 824 
Crystal size 0.12 x 0.10 x 0.01 mm3 
Theta range for data collection 3.12 to 27.47°. 
Index ranges -10<=h<=9, -13<=k<=13, -29<=l<=25 
Reflections collected 14736 
Independent reflections 2518 [R(int) = 0.0754] 
Completeness to theta = 27.47° 99.8%  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9991 and 0.9894 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2518 / 4 / 267 
Goodness-of-fit on F2 1.131 
Final R indices [I>2sigma(I)] R1 = 0.0628, wR2 = 0.1274 
R indices (all data) R1 = 0.0727, wR2 = 0.1319 
Absolute structure parameter ? 
Largest diff. peak and hole 0.314 and -0.337 e.Å-3 
 
Notes: 
The structure contains one molecule of methanol per bridge diketopiperazine. It has not been possible 
to determine the absolute structure from the diffraction data due to the lack of heavier atoms, but the 
relative stereochemistry of the chiral centres has been confirmed. Thus it has been confirmed that the 
chirality of C(7) and C(10) is opposite to that of C(9) and C(12). The structure has been shown with 
C(7) and C(10) as S and C(9), C(12) and C(16) as R as the chirality of C(16) has been determined 
from the synthesis. The atom C(20)/C(20’) is disordered over two positions at a refined occupancy 
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ratio of 0.74 (1):0.26 (1). The hydrogen atoms have been fixed as riding models.  
 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 353.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 5305(4) 7426(3) 6455(2) 24(1) 
C(2) 5609(5) 7887(3) 5884(1) 28(1) 
C(3) 4697(5) 7362(3) 5411(2) 33(1) 
C(4) 3518(5) 6441(3) 5506(2) 32(1) 
C(5) 3192(5) 6021(3) 6086(2) 26(1) 
C(6) 4092(4) 6506(3) 6557(1) 23(1) 
C(7) 3980(4) 6300(3) 7227(1) 22(1) 
C(8) 2667(4) 7200(3) 7479(1) 24(1) 
C(9) 2851(4) 7529(3) 8134(1) 20(1) 
C(10) 4683(4) 7875(3) 8305(1) 20(1) 
C(11) 6009(4) 6955(3) 8075(1) 21(1) 
C(12) 5762(4) 6697(3) 7409(1) 22(1) 
C(13) 7746(4) 7531(3) 8176(2) 28(1) 
C(14) 5968(5) 5666(3) 8386(2) 29(1) 
C(15) 4742(4) 8111(3) 8988(1) 23(1) 
C(16) 2979(4) 8070(3) 9245(1) 23(1) 
C(17) 2307(4) 6751(3) 9131(2) 25(1) 
C(18) 1845(4) 8718(3) 8293(1) 22(1) 
C(19) 1283(5) 9973(3) 9230(2) 33(1) 
C(20) 1268(9) 9465(6) 9850(2) 35(2) 
C(21) 2773(5) 8559(3) 9880(1) 29(1) 
C(19') 1283(5) 9973(3) 9230(2) 33(1) 
C(20') 2321(18) 9893(9) 9806(4) 18(4) 
C(21') 2773(5) 8559(3) 9880(1) 29(1) 
N(1) 6052(4) 7766(2) 6997(1) 23(1) 
N(2) 2264(3) 6532(3) 8535(1) 23(1) 
N(3) 1945(4) 8930(3) 8878(1) 26(1) 
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O(1) 1926(3) 5998(2) 9523(1) 36(1) 
O(2) 1077(3) 9382(2) 7930(1) 26(1) 
C(101) -101(5) 3629(4) 8662(2) 31(1) 
O(101) 643(3) 4222(2) 8150(1) 28(1) 
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Appendix 1. 
1
H-NMR spectrum of (116) (500 MHz, CDCl3) 
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Appendix 2. 
13
C-NMR spectrum of (116) (126 MHz, CDCl3)  
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Appendix 3. 
1
H-NMR spectrum of (117) (500 MHz, CDCl3)  
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Appendix 4. 
13
C-NMR spectrum of (117) (126 MHz, CDCl3)  
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Appendix 5. 
1
H-NMR spectrum of (155) (500 MHz, CDCl3) 
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Appendix 6. 
13
C-NMR spectrum of (155) (126 MHz, CDCl3)  
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Appendix 7. 
1
H-NMR spectrum of (170) (400 MHz, CDCl3) 
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Appendix 8. 
13
C-NMR spectrum of (170) (101 MHz, CDCl3)  
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Appendix 9. 
1
H-NMR spectrum of (181) (500 MHz, CDCl3) 
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Appendix 10. 
13
C-NMR spectrum of (181) (126 MHz, CDCl3)   
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Appendix 11. 
1
H-NMR spectrum of (240) (400 MHz, CDCl3) 
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Appendix 12. 
13
C-NMR spectrum of (240) (101 MHz, CDCl3)   
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Appendix 13. 
1
H-NMR spectrum of (230) (500 MHz, CDCl3)  
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Appendix 14. 
13
C-NMR spectrum of (230) (126 MHz, CDCl3) 
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Appendix 15. 
1
H-NMR spectrum of (epi-230) (300 MHz, CDCl3) 
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Appendix 16. 
13
C-NMR spectrum of (epi-230) (75 MHz, CDCl3)  
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Appendix 17. 
1
H-NMR spectrum of (S3) (300 MHz, CDCl3) 
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Appendix 18. 
13
C-NMR spectrum of (S3) (101 MHz, CDCl3)  
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Appendix 19. 
1
H-NMR spectrum of (274) (300 MHz, CDCl3) 
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Appendix 20. 
1
H-NMR spectrum of (316) (400 MHz, CDCl3) 
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Appendix 21. 
13
C-NMR spectrum of (316) (101 MHz, CDCl3)  
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Appendix 22. 
1
H-NMR spectrum of (epi-316) (400 MHz, CDCl3) 
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Appendix 23. 
13
C-NMR spectrum of (epi-316) (101 MHz, CDCl3)  
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Appendix 24. 
1
H-NMR spectrum of (318) (400 MHz, CDCl3) 
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Appendix 25. 
13
C-NMR spectrum of (318) (101 MHz, CDCl3)  
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Appendix 26. 
1
H-NMR spectrum of (350) (400 MHz, CDCl3) 
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Appendix 27. 
13
C-NMR spectrum of (350) (101 MHz, CDCl3)  
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Appendix 28. 
1
H-NMR spectrum of (352) (400 MHz, CDCl3)  
 
 
 
      
 
224 
 
Appendix 29. 
13
C-NMR spectrum of (352) (101 MHz, CDCl3)  
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Appendix 30. 
1
H-NMR spectrum of (353) (300 MHz, CDCl3) 
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Appendix 31. 
13
C-NMR spectrum of (353) (101 MHz, CDCl3) 
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Appendix 32. 
1
H-NMR spectrum of (354) (400 MHz, CDCl3) 
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Appendix 33. 
13
C-NMR spectrum of (354) (101 MHz, CDCl3) 
 
 
 
      
 
229 
 
Appendix 34. Published work 
 
 
      
 
230 
 
 
 
      
 
231 
 
 
 
 
      
 
232 
 
 
 
      
 
233 
 
List of references 
 
 (1) (a) Dinsmore, C. J.; Beshore, D. C. Tetrahedron 2002, 58, 3297;  (b) Martins, 
M. B.; Carvalho, I. Tetrahedron 2007, 63, 9923. 
 (2) (a) Wang, S.; Golec, J.; Miller, W.; Milutinovic, S.; Folkes, A.; Williams, S.; 
Brooks, T.; Hardman, K.; Charlton, P.; Wren, S.; Spencer, J. Bioorg. Med. Chem. Lett. 2002, 
12, 2367;  (b) Folkes, A.; Roe, M. B.; Sohal, S.; Golec, J.; Faint, R.; Brooks, T.; Charlton, 
P. Bioorg. Med. Chem. Lett. 2001, 11, 2589;  (c) Brooks, T. D.; Wang, S. W.; 
Bruenner, N.; Charlton, P. A. Anti-Cancer Drugs 2004, 15, 37;  (d) Einholm, A. P.; 
Pedersen, K. E.; Wind, T.; Kulig, P.; Overgaard, M. T.; Jensen, J. K.; Bodker, J. S.; 
Christensen, A.; Charlton, P.; Andreasen, P. A. Biochem. J. 2003, 373, 723. 
 (3) (a) McCleland, K.; Milne, P. J.; Lucieto, F. R.; Frost, C.; Brauns, S. C.; Van De 
Venter, M.; Du Plessis, J.; Dyason, K. J. Pharm. Pharmacol. 2004, 56, 1143;  (b) Cheng, 
Y.; Manwell, J. In U.S. Pat. Appl. Publ. 2005,US20050096323A1, 23. 
 (4) (a) Kanzaki, H.; Imura, D.; Nitoda, T.; Kawazu, K. J. Biosci. Bioeng. 2000, 90, 
86;  (b) Nicholson, B.; Lloyd, G. K.; Miller, B. R.; Palladino, M. A.; Kiso, Y.; Hayashi, Y.; 
Neuteboom, S. T. C. Anticancer Drugs 2006, 17, 25;  (c) Kanoh, K.; Kohno, S.; Katada, 
J.; Takahashi, J.; Uno, I. J. Antibiot. 1999, 52, 134. 
 (5) Sinha, S.; Srivastava, R.; De, C. E.; Singh, R. K. Nucleos. Nucleot. Nucl. 
2004, 23, 1815. 
 (6) (a) Houston, D. R.; Synstad, B.; Eijsink, V. G. H.; Stark, M. J. R.; Eggleston, I. 
M.; van Aalten, D. M. F. J. Med. Chem. 2004, 47, 5713;  (b) Asano, N. Glycobiology 2003, 
13, 93R;  (c) Byun, H.-G.; Zhang, H.; Mochizuki, M.; Adachi, K.; Shizuri, Y.; Lee, W.-J.; 
Kim, S.-K. J. Antibiot. 2003, 56, 102. 
 (7) (a) Fdhila, F.; Vazquez, V.; Sanchez, J. L.; Riguera, R. J. Nat. Prod. 2003, 66, 
1299;  (b) Kanokmedhakul, S.; Kanokmedhakul, K.; Phonkerd, N.; Soytong, K.; Kongsaeree, 
      
 
234 
 
P.; Suksamrarn, A. Planta Med. 2002, 68, 834;  (c) Sugie, Y.; Hirai, H.; Inagaki, T.; 
Ishiguro, M.; Kim, Y. J.; Kojima, Y.; Sakakibara, T.; Sakemi, S.; Sugiura, A.; Suzuki, Y.; 
Brennan, L.; Duignan, J.; Huang, L. H.; Sutcliffe, J.; Kojima, N. J. Antibiot. 2001, 54, 911; 
 (d) Abraham, W.-R. Drug Des. Rev. 2005, 2, 13;  (e) De, K. T. R.; Iglewski, B. H. 
Infect. Immun. 2000, 68, 4839;  (f) Kozlovsky, A. G.; Zhelifonova, V. P.; Adanin, V. M.; 
Antipova, T. V.; Ozerskaya, S. M.; Ivanushkina, N. E.; Grafe, U. Appl. Biochem. Microbiol. 
2003, 39, 393. 
 (8) (a) Kwon, O. S.; Park, S. H.; Yun, B.-S.; Pyun, Y. R.; Kim, C.-J. J. Antibiot. 
2000, 53, 954;  (b) Song, M. K.; Hwang, I. K.; Rosenthal, M. J.; Harris, D. M.; 
Yamaguchi, D. T.; Yip, I.; Go, V. L. W. Exp. Biol. Med. (Maywood, NJ, U. S.) 2003, 228, 
1338;  (c) Hwang, I. K.; Go, V. L. W.; Harris, D. M.; Yip, I.; Kang, K. W.; Song, M. K. 
Diabetes Obes. Metab. 2003, 5, 317. 
 (9) Kilian, G.; Jamie, H.; Brauns, S. C. A.; Dyason, K.; Milne, P. J. Pharmazie 
2005, 60, 305. 
 (10) Imamura, M.; Prasad, C. Peptides 2003, 24, 445. 
 (11) Lopez-Rodriguez, M. L.; Morcillo, M. J.; Fernandez, E.; Porras, E.; Orensanz, 
L.; Beneytez, M. E.; Manzanares, J.; Fuentes, J. A. J. Med. Chem. 2001, 44, 186. 
 (12) (a) Wyatt, P. G.; Allen, M. J.; Borthwick, A. D.; Davies, D. E.; Exall, A. M.; 
Hatley, R. J. D.; Irving, W. R.; Livermore, D. G.; Miller, N. D.; Nerozzi, F.; Sollis, S. L.; 
Szardenings, A. K. Bioorg. Med. Chem. Lett. 2005, 15, 2579;  (b) Brooks, D. P.; Glaxo 
Group Limited, UK . 2005, WO2005000311A1, 99. 
 (13) Witiak, D. T.; Wei, Y. Prog. Drug Res. 1990, 35, 249. 
 (14) Huang, R.; Zhou, X.; Xu, T.; Yang, X.; Liu, Y. Chem. Biodiversity 2010, 7, 
2809. 
 (15) (a) Miller, K. A.; Tsukamoto, S.; Williams, R. M. Nat. Chem. 2009, 1, 63;  (b) 
Miller, K. A.; Figueroa, M.; Valente, M. W. N.; Greshock, T. J.; Mata, R.; Williams, R. M. 
      
 
235 
 
Bioorg. Med. Chem. Lett. 2008, 18, 6479;  (c) Williams, R. M. Chem. Pharm. Bull. 2002, 50, 
711. 
 (16) Birch, A. J.; Wright, J. J. J. Chem. Soc., Chem. Commun. 1969, 13, 644. 
 (17) Coetzer, J. Acta Crystallogr. 1974, B30, 2254. 
 (18) Paterson, R. R. M.; Simmonds, M. J. S.; Kemmelmeier, C.; Blaney, W. M. 
Mycol. Res. 1990, 94, 538. 
 (19) (a) Birch, A. J.; Wright, J. J. Tetrahedron 1970, 26, 2329;  (b) Birch, A. J.; 
Russell, R. A. Tetrahedron 1972, 28, 2999. 
 (20) Yamazaki, M.; Okuyama, E.; Kobayashi, M.; Inoue, H. Tetrahedron Lett. 1981, 
22, 135. 
 (21) (a) Ondeyka, J. G.; Goegelman, R. T.; Schaeffer, J. M.; Kelemen, L.; Zitano, 
L. J. Antibiot. 1990, 43, 1375;  (b) Liesch, J. M.; Wichmann, C. F. J. Antibiot. 1990, 43, 
1380;  (c) Blanchflower, S. E.; Banks, R. M.; Everett, J. R.; Manger, B. R.; Reading, C. J. 
Antibiot. 1991, 44, 492. 
 (22) Blanchflower, S. E.; Banks, R. M.; Everett, J. R.; Reading, C. J. Antibiot. 1993, 
46, 1355. 
 (23) Banks, R. M.; Blanchflower, S. E.; Everett, J. R.; Manfer, B. R.; Reading, C. J. 
J. Antibiot. 1997, 50, 840. 
 (24) Whyte, A. C.; Gloer, J. B.; Wicklow, D. T.; Dowd, P. F. J. Nat. Prod. 1996, 59, 
1093. 
 (25) (a) Polonsky, J.; Merrien, M. A.; Prangé, T.; Pascard, C. J. Chem. Soc., 
Chem. Commun. 1980, 12, 601;  (b) Prangé, T.; Billion, M. A.; Vuilhorgne, M.; Pascard, 
C.; Polonsky, J.; Moreau, S. Tetrahedron Lett. 1981, 22, 1977. 
 (26) Qian-Cutrone, J.; Haung, S.; Shu, Y. Z.; Vyas, D.; Fairchild, C.; Menendez, A.; 
Krampitz, K.; Dalterio, R.; Klohr, S. E.; Gao, Q. J. Am. Chem. Soc. 2002, 124, 14556. 
 (27) Tsukamoto, S.; Kato, H.; Samizo, M.; Nojiri, Y.; Onuki, H.; Hirota, H.; Ohta, T. 
J. Nat. Prod. 2008, 71, 2064. 
      
 
236 
 
 (28) Hayashi, H.; Nishimoto, Y.; Nozaki, H. Tetrahedron Lett. 1997, 38, 5655. 
 (29) Hayashi, H.; Nishimoto, Y.; Akiyama, K.; Nozaki, H. Biosci. Biotech. Bioch. 
2000, 64, 111. 
 (30) Fenical, W.; Jensen, P. R.; Cheng, X. C.; U.S. Patent: 2000, 6,066,635  
 (31) Qian-Cutrone, J.; Krampitz, K. D.; Shu, Y. Z.; Chang, L. P. U.S. Patent 2001, 
6, 291. 
 (32) Greshock, T. J.; Grubbs, A. W.; Jiao, P.; Wicklow, D. T.; Gloer, J. B.; Williams, 
R. M. Angew. Chem., Int. Ed. 2008, 47, 3573. 
 (33) Fuchser, J. Ph.D. Dissertation, University of Gottingen 1995. 
 (34) (a) Martínez-Luis, S.; Rodríguez, R.; Acevedo, L.; González, M. C.; Lira-
Rocha, A.; Mata, R. Tetrahedron 2006, 62, 1817;       i    oa,       l  a   n  on  l  , 
M.; Mata, R. Nat. Prod. Res. 2008, 22, 709. 
 (35) (a) Porter, A. E. A.; Sammes, P. G. J. Chem. Soc. 1970, 1103;  (b) Baldas, 
J.; Birch, A. J.; Russell, R. A. J. Chem. Soc., Perkin Trans. 1 1974, 50. 
 (36) Steyn, P. S. Tetrahedron 1973, 29, 107. 
 (37) Williams, R. M.; Kwast, E.; Coffman, H.; Glinka, T. J. Am. Chem. Soc. 1989, 
111, 3064. 
 (38) Sanz-Cervera, J. F.; Glinka, T.; Williams, R. M. Tetrahedron 1993, 49, 8471. 
 (39) Ding, Y.; Wet, J. R. d.; Cavalcoli, J.; Li, S.; Greshock, T. J.; Miller, K. A.; 
Finefield, J. M.; Sunderhaus, J. D.; McAfoos, T. J.; Tsukamoto, S.; Williams, R. M.; Sherman, 
D. H. J. Am. Chem. Soc. 2010, 132, 12733. 
 (40) Kato, H.; Yoshida, T.; Tokue, T.; Nojiri, Y.; Hirota, H.; Ohta, T.; Williams, R. 
M.; Tsukamoto, S. Angew. Chem., Int. Ed. 2007, 46, 2254. 
 (41) Tsukamoto, S.; Kawabata, T.; Kato, H.; Greshock, T. J.; Hirota, H.; Ohta, T.; 
Williams, R. M. Org. Lett. 2009, 11, 1297. 
 (42) Finefield, J. M.; Kato, H.; Greshock, T. J.; Sherman, D. H.; Tsukamoto, S.; 
Williams, R. M. Org. Lett. 2011, 13, 3802. 
      
 
237 
 
 (43) Finefield, J. M.; Greshock, T. J.; Sherman, D. H.; Tsukamoto, S.; Williams, R. 
M. Tetrahedron Lett. 2011, 52, 1987. 
 (44) Tsukamoto, S.; Kato, H.; Greshock, T. J.; Hirota, H.; Ohta, T.; Williams, R. M. 
J. Am. Chem. Soc. 2009, 131, 3834. 
 (45) (a) Nussbaum, F. Angew. Chem., Int. Ed. 2003, 42, 3068;  (b) Myers, A. G.; 
Herzon, S. B. J. Am. Chem. Soc. 2003, 125, 12080. 
 (46) Herzon, S. B.; Myers, A. G. J. Am. Chem. Soc. 2005, 127, 5342. 
 (47) Baran, P. S.; Guerrero, C. A.; Hafensteiner, B. D.; Ambhaikar, N. B. Angew. 
Chem., Int. Ed. 2005, 44, 3892. 
 (48) (a) Somei, M. Heterocycles 1999, 50, 1157;  (b) Masanori, S. In Adv. 
Heterocycl. Chem.; Academic Press: 2002; Vol. 82, p 101. 
 (49) Wulff, J. E.; Herzon, S. B.; Siegrist, R.; Myers, A. G. J. Am. Chem. Soc. 2007, 
129, 4898. 
 (50) Myers, A. G.; Wulff, J. E.; Siegrist, R.; Nising, C. F.; Chan, K. P.; President 
and Fellows of Harvard College, USA . 2009, WO2009020768A1, p 227. 
 (51) Grisendi, S.; Mecucci, C.; Falini, B.; Pandolfi, P. P. Nat. Rev. Cancer. 2006, 6, 
493. 
 (52) (a) Trost, B. M. Pure Appl. Chem. 1988, 60, 1615;  (b) Stambuli, J. P.; 
Silverman, S. M.; Schwörer, U. J. Am. Chem. Soc. 2006, 128, 13328. 
 (53) Trost, B. M.; Cramer, N.; Bernsmann, H. J. Am. Chem. Soc. 2007, 129, 3086. 
 (54) (a) Gassman, P. G.; van Bergen, T. J. J. Am. Chem. Soc. 1974, 96, 5508; 
 (b) Gassman, P. G.; Gruetzmacher, G.; van Bergen, T. J. J. Am. Chem. Soc. 1974, 
96, 5512. 
 (55) Trost, B. M.; Mignani, S. M.; Nanninga, T. N. J. Am. Chem. Soc. 1986, 108, 
6051. 
 (56) Greshock, T. J.; Grubbs, A. W.; Williams, R. M. Tetrahedron 2007, 63, 6124. 
 (57) Sanz-Cervera, J. F.; Williams, R. M. J. Am. Chem. Soc. 2002, 124, 2556. 
      
 
238 
 
 (58) (a) Stocking, E. M.; Sanz-Cervera, J. F.; Unkefer, C. J.; Williams, R. M. 
Tetrahedron 2001, 57, 5303;  (b) Titouani, S. L.; Lavergne, J. P.; Vaillefont, P.; Jaquier, R. 
Tetrahedron 1980, 36, 2961. 
 (59) (a) Frebault, F. C.; Simpkins, N. S. Tetrahedron 2010, 66, 6585;  (b) 
Frebault, F. C.; Simpkins, N. S.; Fenwick, A. J. Am. Chem. Soc. 2009, 131, 4214. 
 (60) Baldwin, J. E. J. Chem. Soc., Chem. Commun. 1976, 734. 
 (61) (a) Fleming, I. Frontier Orbitals and Organic Chemical Reactions; John Wiley 
and Sons Ltd., 1976;  (b) Fukui, K. Acc. Chem. Res. 1971, 4, 57;  (c) Kirby, A. J.; Editor 
Stereoelectronic Effects; Oxford Univ Press, 1996;  (d) Fossey, J.; Lefort, D.; Sorba, J. Free 
Radicals in Organic Chemistry; Wiley, 1995. 
 (62) (a) Beckwith, A. L. J.; Schiesser, C. H. Tetrahedron 1985, 41, 3925;  (b) 
Beckwith, A. L. J.; Lawrence, T. J. Chem. Soc., Perkin Trans. 2 1979, 1535;  (c) 
Beckwith, A. L. J.; Phillipou, G.; Serelis, A. K. Tetrahedron Lett. 1981, 22, 2811;  (d) 
Athelstan L.J, B. Tetrahedron 1981, 37, 3073. 
 (63) (a) Bürgi, H. B.; Dunitz, J. D.; Shefter, E. J. Am. Chem Soc. 1973, 95, 5065; 
 (b) Bürgi, H. B.; Dunitz, J. D. Acc. Chem. Res. 1983, 16, 153;  (c) Bürgi, H. B.; 
Dunitz, J. D.; Lehn, J. M.; Wipff, G. Tetrahedron 1974, 30, 1563;  (d) Arnaud, R.; Douady, 
J.; Subra, R. Nouv. J. Chim. 1981, 5, 181;  (e) Nagase, S.; Kern, C. W. J. Am. Chem Soc. 
1980, 102, 4513;  (f) Houk, K. N.; Paddon-Row, M. N.; Spellmeyer, D. C.; Rondan, N. G.; 
Nagase, S. J. Org. Chem 1986, 51, 2874. 
 (64) (a) Rajanbabu, T. V. Acc. Chem. Res. 1991, 24, 139;  (b) Kirschning, A. 
Angew. Chem., Int. Ed. 2010, 49, 2971. 
 (65) Giese, B. Radicals in Organic Synthesis: Formation of Carbon-Carbon Bonds; 
Pergamon Press, 1986. 
 (66) Houk, K. N. J. Am. Chem Soc. 1973, 95, 4092. 
 (67) (a) Julia, M.; Maumy, M. Bull. Soc. Chim. Fr. 1969, 2427;  (b) Julia, M.; 
Maumy, M.; Mion, L. Bull. Soc. Chim. Fr. 1967, 2641. 
      
 
239 
 
 (68) Julia, M.; Mansour, B.; Mansuy, D. Tetrahedron Lett. 1976, 17, 3443. 
 (69) (a) Beckwith, A. L. J.; Blair, I. A.; Phillipou, G. Tetrahedron Lett. 1974, 15, 
2251;  (b) Beckwith, A.; Gream, G.; Struble, D. Aust. J. Chem. 1972, 25, 1081;  (c) Julia, 
M.; Descoins, C.; Baillarge, M.; Jacquet, B.; Uguen, D.; Groeger, F. A. Tetrahedron 1975, 31, 
1737. 
 (70) Park, S. U.; Chung, S. K.; Newcomb, M. J. Am. Chem. Soc. 1986, 108, 240. 
 (71) (a) Wilt, J. W. J. Am. Chem. Soc. 1981, 103, 5251;  (b) Chatgilialoglu, C.; 
Woynar, H.; Ingold, K. U.; Davies, A. G. J. Chem. Soc. Perkin Trans 2 1983;  (c) Wilt, J. 
W. Tetrahedron 1985, 41, 3979. 
 (72) (a) Bachi, M. D.; Frolow, F.; Hoornaert, C. J. Org. Chem. 1983, 48, 1841;  (b) 
Burnett, D. A.; Choi, J. K.; Hart, D. J.; Tsai, Y. M. J. Am. Chem. Soc. 1984, 106, 8201. 
 (73) (a) Curran, D. P.; Shen, W. J. Am. Chem. Soc. 1993, 115, 6051;  (b) Curran, 
D. P.; Kim, D.; Ziegler, C. Tetrahedron Lett. 1991, 47, 6189;  (c) Curran, D. P.; Kim, D.; 
Liu, H. T.; Shen, W. J. Am. Chem. Soc. 1988, 110, 5900. 
 (74) Lathbury, D. C.; Parsons, P. J.; Pinto, I. J. Chem. Soc., Chem. Commun. 
1988, 81. 
 (75) (a) Heiba, E. A. I.; Dessau, R. M. J. Am. Chem. Soc. 1967, 89, 3772;  (b) 
Broka, C. A.; Reichert, D. E. C. Tetrahedron Lett. 1987, 28, 1503;  (c) Miyata, O.; Naito, T. 
Acad. Sci. Paris, Chem. 2001, 4, 401;  (d) Kyoko, N.; Koichiro, O.; Kiitiro, U. Bull. 
Chem. Soc. Jpn. 1987, 60, 3465;  (e) Bosch, E.; Bachi, M. D. J. Org. Chem. 1993, 58, 
5581;  (f) Alcaide, B.; Rodriguez-Campos, I. M.; Rodriguez-Lopez, J.; Rodriguez-Vicente, A. 
J. Org. Chem. 1999, 64, 5377;  (g) Wille, U.; Jargstorff, C. Eur. J. Org. Chem. 2003, 16, 
3173;  (h) Wille, U. Tetrahedron Lett. 2002, 43, 1239;  (i) Wille, U. J. Am. Chem. Soc. 
2002, 124, 14;  (j) Wille, U.; Lietzau, L. Tetrahedron 1999, 55, 10119;  (k) Wille, 
U.; Plath, C. Liebigs Ann. 1997, 111;  (l) Renaud, P.; Beaufils, F.; Feray, L.; Schenk, 
K. Angew. Chem., Int. Ed. 2003, 42, 4230;  (m) Beaufils, F.; Dénès, F.; Renaud, P. Org. 
Lett. 2004, 6, 2563;  (n) Dénès, F.; Beaufils, F.; Renaud, P. Org. Lett. 2007, 9, 4375;  (o) 
      
 
240 
 
Beaufils, F.; Dénès, F.; Becattini, B.; Renaud, P.; Schenk, K. Adv. Synth. Catal. 2005, 347, 
1587. 
 (76) Escoubet, S.; Gastaldi, S.; Vanthuyne, N.; Gil, G.; Siri, D.; Bertrand, M. P. J. 
Org. Chem. 2006, 71, 7288. 
 (77) Baran, P. S.; Guerrero, C. A.; Ambhaikar, N. B.; Hafensteiner, B. D. Angew. 
Chem., Int. Ed. 2005, 44, 606. 
 (78) (a) Greshock, T. J.; Grubbs, A. W.; Tsukamoto, S.; Williams, R. M. Angew. 
Chem., Int. Ed. 2007, 46, 2262;  (b) Artman, G. D.; Grubbs, A. W.; Williams, R. M. J. Am. 
Chem. Soc. 2007, 129, 6336;  (c) Greshock, T. J.; Williams, R. M. Org. Lett. 2007, 9, 
4255. 
 (79) Baran, P. S.; Hafensteiner, B. D.; Ambhaikar, N. B.; Guerrero, C. A.; 
Gallagher, J. D. J. Am. Chem. Soc. 2006, 128, 8678. 
 (80) Williams, R. M.; Glinka, T.; Kwast, E.; Coffman, H.; Stille, J. K. J. Am. Chem. 
Soc. 1990, 112, 808. 
 (81) Hafensteiner, B. D.; Escribano, M.; Petricci, E.; Baran, P. S. Bioorg. Med. 
Chem. Lett. 2009, 19, 3808. 
 (82) Williams, R. M.; Sanz-Cervera, J. F.; Sancenón, F.; Marco, J. A.; Halligan, K. 
J. Am. Chem. Soc. 1998, 120, 1090. 
 (83) Williams, R. M.; Glinka, T.; Kwast, E. J. Am. Chem. Soc. 1988, 110, 5927. 
 (84) (a) Pichowicz, M.; Simpkins, N. S.; Blake, A. J.; Wilson, C. Tetrahedron Lett. 
2006, 47, 8413;  (b) Pichowicz, M.; Simpkins, N. S.; Blake, A. J.; Wilson, C. 
Tetrahedron 2008, 64, 3713. 
 (85) Hara, T.; Durell, S. R.; Myers, M. C.; Appella, D. H. J. Am. Chem. Soc. 2006, 
128, 1995. 
 (86) Ellis, D. A.; Wolkenberg, S. E.; Boger, D. L. J. Am. Chem. Soc. 2001, 123, 
9299. 
 (87) Escolano, C. Angew. Chem., Int. Ed. 2005, 44, 7670. 
      
 
241 
 
 (88) Fagan, P. J.; Hauptman, E.; Shapiro, R.; Casalnuovo, A. J. Am. Chem. Soc. 
2000, 122, 5043. 
 (89) (a) Tlili, A.; Xia, N.; Monnier, F.; Taillefer, M. Angew. Chem., Int. Ed. 2009, 48, 
8725;  (b) Zhao, D.; Wu, N.; Zhang, S.; Xi, P.; Su, X.; Lan, J.; You, J. Angew. Chem., Int. Ed. 
2009, 48, 8729;  (c) Altman, R. A.; Shafir, A.; Choi, A.; Lichtor, P. A.; Buchwald, S. L. J. 
Org. Chem. 2008, 73, 284. 
 (90) (a) Torraca, K. E.; Huang, X.; Parrish, C. A.; Buchwald, S. L. J. Am. Chem. 
Soc. 2001, 123, 10770;  (b) Vorogushin, A. V.; Huang, X.; Buchwald, S. L. J. Am. Chem. 
Soc. 2005, 127, 8146. 
 (91) Aranyos, A.; Old, D. W.; Kiyomori, A.; Wolfe, J. P.; Sadighi, J. P.; Buchwald, 
S. L. J. Am. Chem. Soc. 1999, 121, 4369. 
 (92) (a) Othman, R. B.; Bousquet, T.; Othman, M.; Dalla, V. Org. Lett. 2005, 7, 
5335;  (b) Zhang, L.; Kozmin, S. A. J. Am. Chem. Soc. 2004, 126, 10204;  (c) 
Tranchant, M. J.; Moine, C.; Othman, R. B.; Bousquet, T.; Othman, M.; Dalla, V. Tetrahedron 
Lett. 2006, 47, 4477. 
 (93) Othman, R. B.; Affani, R.; Tranchant, M. J.; Antoniotti, S.; Dalla, V.; Duñach, 
E. Angew. Chem., Int. Ed. 2010, 49, 776. 
 (94) Concellon, J. M.; Rodriguez-Solla, H.; Bardales, E.; Huerta, M. Eur. J. Org. 
Chem. 2003, 1775. 
 (95) Fabre, J. L.; Farge, D.; James, C.; Lavé, D. Tetrahedron Lett. 1985, 26, 5447. 
 (96) Stocking, E. M.; Sanz-Cervera, J. F.; Williams, R. M. J. Am. Chem. Soc. 2000, 
122, 1675. 
 (97) Miller, K. A.; Welch, T. R.; Greshock, T. J.; Ding, Y.; Sherman, D. H.; Williams, 
R. M. J. Org. Chem. 2008, 73, 3116. 
 (98) Domingo, L. R.; Zaragoza, R. J.; Williams, R. M. J. Org. Chem. 2003, 68, 
2895. 
 (99) Jin, S.; Wessig, P.; Liebscher, J. J. Org. Chem. 2001, 66, 3984. 
      
 
242 
 
 (100) Adams, L. A.; Valente, M. W. N.; Williams, R. M. Tetrahedron 2006, 62, 5195. 
 (101) Williams, R. M.; Maruyama, L. K. J. Org. Chem. 1987, 52, 4044. 
 (102) Williams, R. M.; Cao, J.; Tsujishima, H.; Cox, R. J. J. Am. Chem. Soc. 2003, 
125, 12172. 
 (103) Cushing, T. D.; Sanz-Cervera, J. F.; Williams, R. M. J. Am. Chem. Soc. 1993, 
115, 9323. 
 (104) Davies, S. G.; Christopher Garner, A.; Ouzman, J. V. A.; Roberts, P. M.; 
Smith, A. D.; Snow, E. J.; Thomson, J. E.; Tamayo, J. A.; Vickers, R. J. Org. Biomol. Chem. 
2007, 5, 2138. 
 (105) (a) Davies, S. G.; Rodriguez-Solla, H.; Tamayo, J. A.; Garner, A. C.; Smith, A. 
D. Chem. Commun. 2004, 2502;  (b) Bull, S. D.; Davies, S. G.; Garner, A. C.; Parkes, A. 
L.; Roberts, P. M.; Sellers, T. G. R.; Smith, A. D.; Tamayo, J. A.; Thomson, J. E.; Vickers, R. 
J. New J. Chem. 2007, 31, 486;  (c) Bull, S. D.; Davies, S. G.; Epstein, S. W.; Garner, A. 
C.; Mujtaba, N.; Roberts, P. M.; Savory, E. D.; Smith, A. D.; Tamayo, J. A.; Watkin, D. J. 
Tetrahedron 2006, 62, 7911;  (d) Bull, S. D.; Davies, S. G.; O'Shea, M. D. J. Chem. Soc., 
Perkin Trans. 1 1998, 3657. 
 (106) (a) Groaning, M. D.; Meyers, A. I. Tetrahedron 2000, 56, 9843;  (b) 
Seebach, D.; Maetzke, T.; Petter, W.; Kloetzer, B.; Plattner, D. A. J. Am. Chem. Soc. 1991, 
113, 1781. 
 (107) Seebach, D.; Boes, M.; Naef, R.; Schweizer, W. B. J. Am. Chem. Soc. 1983, 
105, 5390. 
 (108) (a) Benson, O.; Demirdji, S. H.; Haltiwanger, R. C.; Koch, T. H. J. Am. Chem. 
Soc. 1991, 113, 8879;  (b) Bordwell, F. G.; Lynch, T. Y. J. Am. Chem. Soc. 1989, 111, 
7558;  (c) Pasto, D. J. J. Am. Chem. Soc. 1988, 110, 8164;  (d) Viehe, H. G.; 
Janousek, Z.; Merenyi, R.; Stella, L. Acc. Chem. Res. 1985, 18, 148;  (e) Benson, S. W.; 
Egger, K. W.; Golden, D. M. J. Am. Chem. Soc. 1965, 87, 468. 
 (109) Blanksby, S. J.; Ellison, G. B. Acc. Chem. Res. 2003, 36, 255. 
      
 
243 
 
 (110) (a) Harrowven, D. C.; Stenning, K. J.; Whiting, S.; Thompson, T.; Walton, R. 
Org. Biomol. Chem. 2011, 9;  (b) Flanagan, S. R.; Harrowven, D. C.; Bradley, M. Tet. Lett. 
2003, 44, 1795;  (c) Li, H.; Boonnak, N.; Padwa, A. J. Org. Chem. 2011, 76, 9488;  (d) 
Paleo, E.; Osornio, Y. M.; Miranda, L. D. Org. Biomol. Chem. 2011, 9;  (e) Tucker, J. W.; 
Narayanam, J. M. R.; Krabbe, S. W.; Stephenson, C. R. J. Org. Lett. 2009, 12, 368;  (f) 
Gribble, G. W.; Fraser, H. L.; Badenock, J. C. Chem. Commun. 2001;  (g) Bennasar, M. 
L.; Roca, T.; Griera, R.; Bosch, J. J. Org. Chem. 2001, 66, 7547;  (h) Miranda, L. D.; Cruz-
Almanza, R.; Pavón, M.; Romero, Y.; Muchowski, J. M. Tet. Lett. 2000, 41, 10181;  (i) 
Tsuge, O.; Hatta, T.; Tsuchiyama, H. Chem. Lett. 1998, 27, 155;  (j) Zhang, W.; Pugh, G. 
Tet. Lett. 1999, 40, 7591;  (k) Ziegler, F. E.; Belema, M. J. Org. Chem. 1997, 62, 1083; 
 (l) J. Moody, C.; L. Norton, C. J. Chem. Soc. Perkin Trans 1 1997;  (m) Caddick, S.; 
Aboutayab, K.; Jenkins, K.; West, R. I. J. Chem. Soc. Perkin Trans 1 1996;  (n) Yang, 
C. C.; Chang, H. T.; Fang, J. M. J. Org. Chem. 1993, 58, 3100;  (o) Byers, J. H.; Kosterlitz, 
J. A.; Steinberg, P. L.  
C.R. Acad. Sci., Ser. IIc: Chem. 2001, 4, 471. 
 (111) Chern, C.-Y.; Huang, Y.-P.; Kan, W. M. Tetrahedron Lett. 2003, 44, 1039. 
 (112) Ueki, T.; Kinoshita, T. Org. Biomol. Chem. 2005, 3, 295. 
 (113) Meng, W.-H.; Wu, T.-J.; Zhang, H.-K.; Huang, P.-Q. Tetrahedron: Asymmetry 
2004, 15, 3899. 
 (114) (a) Braslau, R.; Burrill, L. C.; Siano, M.; Naik, N.; Howden, R. K.; Mahal, L. K. 
Macromolecules 1997, 30, 6445;  (b) Langer, T.; Illich, M.; Helmchen, G. Synlett 1996, 
1137;  (c) Porter, N. A.; Su, Q.; Harp, J. J.; Rosenstein, I. J.; McPhail, A. T. Tetrahedron Lett. 
1993, 34, 4457;  (d) Porter, N. A.; Rosenstein, I. J. Tetrahedron Lett. 1993, 34, 7865; 
 (e) Rathke, M. W.; Lindert, A. J. Am. Chem. Soc. 1971, 93, 4605;  (f) Cohen, T.; 
McNamara, K.; Kuzemko, M. A.; Ramig, K.; Landi, J. J.; Jr, n. Tetrahedron 1993, 49, 7931; 
 (g) Chung, S. K.; Dunn, L. B. J. Org. Chem. 1983, 48, 1125;  (h) Frazier, R. H.; 
      
 
244 
 
Harlow, R. L. J. Org. Chem. 1980, 45, 5408;  (i) Alvarez-Ibarra, C.; Csákÿ, A. G.; 
Colmenero, B.; Quiroga, M. L. J. Org. Chem. 1997, 62, 2478. 
 (115) Kaiser, E. M. J. Am. Chem. Soc. 1967, 89, 3659. 
 (116) (a) Schmittel, M.; Burghart, A.; Werner, H.; Laubender, M.; Söllner, R. J. Org. 
Chem. 1999, 64, 3077;  (b) Ryter, K.; Livinghouse, T. J. Am. Chem. Soc. 1998, 120, 
2658;  (c) Hirao, T.; Fujii, T.; Ohshiro, Y. Tetrahedron 1994, 50, 10207;  (d) Paolobelli, A. 
B.; Latini, D.; Ruzziconi, R. Tetrahedron Lett. 1993, 34, 721;  (e) Fujii, T.; Hirao, T.; 
Ohshiro, Y. Tetrahedron Lett. 1992, 33, 5823;  (f) Baciocchi, E.; Casu, A.; Ruzziconi, R. 
Tetrahedron Lett. 1989, 30, 3707;  (g) Ito, Y.; Konoike, T.; Saegusa, T. J. Am. Chem. Soc. 
1975, 97, 649. 
 (117) (a) Kise, N.; Kumada, K.; Terao, Y.; Ueda, N. Tetrahedron 1998, 54, 2697; 
 (b) Inaba, S.-i.; Ojima, I. Tetrahedron Lett. 1977, 18, 2009. 
 (118) Kohno, Y.; Narasaka, K. Bull. Chem. Soc. Jpn. 1995, 68, 322. 
 (119) P. W. R. Harris; M. A. Brimble; V. J. Muir; M. Y. H. Lai; N. S. Trotter; Callis, D. 
J. Tetrahedron 2005, 61, 10018. 
 (120) (a) For examples of this type of reaction using ammonia and other amines, s. 
T. B., C. Hounsou and B. P. Deprez Bioorg. Med. Chem. Lett. 2007, 17, 789;  (b) G. N. 
Maw; C. M. N. Allerton; E. Gbekor; Million, W. A. Bioorg. Med. Chem. Lett. 2003, 13, 1425. 
 (121) Artman, G. D.; Grubbs, A. W.; Williams, R. M. J. Am. Chem. Soc. 2007, 129, 
6336. 
 (122) Nelson, L. A. K.; Shaw, A. C.; Abrams, S. R. Tetrahedron 1991, 47, 3259. 
 (123) Gribble, G. W.; Lord, P. D.; Skotnicki, K.; Dietz, S. E.; Eaton, J. T.; Johnson, J. 
J. Am. Chem. Soc. 1974, 96, 7812. 
 (124) Cushing, T. D.; Sanz-Cervera, J. F.; Williams, R. M. J. Am. Chem. Soc. 1996, 
118, 557. 
 (125) (a) Snider, B. B. Tetrahedron 2009, 65, 10738;  (b) Snider, B. B.; 
Armanetti, L.; Baggio, R. Tetrahedron Lett. 1993, 34, 1701;  (c) Kates, S. A.; 
      
 
245 
 
Dombroski, M. A.; Snider, B. B. J. Org. Chem. 1990, 55, 2427;  (d) Snider, B. B.; 
Buckman, B. O. Tetrahedron 1989, 45, 6969;  (e) Snider, B. B.; Mohan, R.; Kates, S. A. 
Tetrahedron Lett. 1987, 28, 841. 
 (126) For expected titration results see: http://istcgroup.com/pdf/Pure%20. 
 (127) (a) Jana, G. K.; Sinha, S. Tetrahedron Lett. 2010, 51, 1994;  (b) 
Coogan, M. P.; Stanton, L. S.; Walther, T. J. Organomet. Chem. 2003, 677, 125. 
 (128) Frebault, F.; Simpkins, N. S.; Fenwick, A. J. Am. Chem. Soc. 2009, 131, 4214. 
 (129) Montagne, C.; Fournet, G.; Joseph, B. Synthesis 2005, 136. 
 
 
 
 
